

CHRISTIAN MAXIMILLIAN SCHMIDT, MD, PHD, MBA, FACS

CURRICULUM VITAE

DATE: January 2, 2022

ADDRESS: Indiana University School of Medicine
Professor of Surgery, Biochemistry and Molecular Biology
545 Barnhill Dr., EH 129
Indianapolis, IN 46202
(317) 948-8358
(317) 278-4897 (Fax)
maxschmi@iupui.edu

EDUCATION:

1984 - 1988	University of Chicago, The College, Chicago, IL	BA
1988 - 1992	University of Chicago, Graduate School of Business, Chicago, IL	MBA
1988 - 1992	University of Chicago, Pritzker School of Medicine, Chicago, IL	MD
1992 - 1995	Johns Hopkins Hospital, Baltimore, MD, Residency/Internship	
1998	Georgetown University, Washington DC,	PhD
1999-2000	Johns Hopkins Hospital, Baltimore, MD, Senior /Chief Resident	

FURTHER EDUCATION:

1998	Royal College of Surgeons Department of Surgery, Beaumont Hospital, Dublin, Ireland	Registrar
2000- 2001	Johns Hopkins Hospital Hepato-Pancreaticobiliary/Alimentary Tract Surgery Faculty Fellowship (Director: John Cameron, MD) Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD	Fellowship

APPOINTMENTS:

ACADEMIC: TEACHING

2002 – present	Associate Faculty , Indiana University Graduate School, Bloomington, IN
2007- 2012	Director of Education for Research , Department of Surgery, Indiana University School of Medicine, Indianapolis, IN

- 2007- present **Director of Surgical Research Clerkship**, Indiana University School of Medicine, Indianapolis, IN
- 2011- present **Director of Surgical Research Honors Program**, Indiana University School of Medicine, Indianapolis, IN
- 2015- present **Vice Chairman, Academic Affairs**, Department of Surgery
Indiana University School Medicine, Indianapolis, IN

ACADEMIC: RESEARCH

- 2001 - 2008 **Assistant Professor of Biochemistry and Molecular Biology**
Department of Biochemistry and Molecular Biology
Indiana University Medical Center, Indianapolis, IN
- 2008 - 2012 **Associate Professor of Biochemistry and Molecular Biology with tenure**
Department of Biochemistry and Molecular Biology
Indiana University Medical Center, Indianapolis, IN
- 2006 - 2012 **Assistant Program Director for Research**,
Department of Surgery
Indiana University School of Medicine, Indianapolis, IN
- 2012- present **Professor of Biochemistry and Molecular Biology**
Department of Biochemistry and Molecular Biology
Indiana University Medical Center, Indianapolis, IN
- 2012 – present **Founder, B9, LLC**

ACADEMIC: SERVICE

- 2000 - 2001 **Instructor/Assistant Chief of Staff**, Johns Hopkins Hospital
Department of Surgery, Baltimore, MD
- 2001 - 2008 **Assistant Professor of Surgery**, Department of Surgery
Indiana University School Medicine, Indianapolis, IN
- 2008 - 2012 **Associate Professor of Surgery with tenure**, Department of Surgery
Indiana University School Medicine, Indianapolis, IN
- 2012- present **Professor of Surgery**, Department of Surgery
Indiana University School Medicine, Indianapolis, IN
- 2012 - 2017 **Director**, Pancreaticobiliary Robotic Program
Indiana University Health University Hospital, Indianapolis, IN
- 2012 - present **Director**, Pancreatic Cyst and Cancer Early Detection Center
Indiana University Health University Hospital, Indianapolis, IN
- 2016 – 2019 **Chief of Surgery**, Department of Surgery
Indiana University Health University Hospital, Indianapolis, IN

2019 – present **Medical Director of Perioperative & Surgical Services**, Adult Academic Health Center
(University Hospital & Methodist Hospital)
Indiana University Health, Indianapolis, IN

NON-ACADEMIC

2001 - present Attending Surgeon, University Hospital, Indianapolis, IN
2001 - 2009 Staff Surgeon, Richard L. Roudebush VA Medical Center, Indianapolis, IN
2001 - present Attending Surgeon, Methodist Hospital, Indianapolis, IN
Ad Hoc Staff Surgeon, Wishard Hospital, Indianapolis, IN
2006 - 2008 Attending Surgeon, IU North Hospital, Carmel, IN
2011-2013 Attending Surgeon, IU West Hospital, Avon, IN

CONSULTING

2011 – 2014 Redpath Integrated Pathology, Inc, Consultant, Scientific Advisory Board Member
2011 – 2014 Asuragen, Inc, Consultant, Scientific Advisory Board Member
2013- 2015 Mauna Kea Technologies, Inc Consultant
2015- 2016 Interpace Diagnostics, Chair, Pancreatic Scientific Advisory Board

LICENSURE, CERTIFICATION, SPECIALTY BOARD STATUS:

Maryland Medical License (inactive)	#D0056014
Indiana Medical License (active)	#01054664
Diplomat National Board of Medical Examiners	#07/1993
General Surgery Board Certification (active)	#05730 – 4-2003; Recertified 12-2013 (exp 7-2024)
Advanced Trauma Life Support (ATLS)	1992, 1998, 2013 (ID 129737 exp 12-12-21)
Advanced Cardiac Life Support (ACLS)	1991

PROFESSIONAL ORGANIZATION MEMBERSHIPS:

1992 - present Johns Hopkins Medical and Surgical Association, member

1992 - present National Pancreas Foundation, member

1992 - present University of Chicago Surgical Society, member

1992 - present American Association for Cancer Research, member

1992 - present Eastern Cooperative Oncology Group, member

1992 - 2001 American Medical Association, member

1995 - 2006 Federation of American Societies for Experimental Biology, member

1995 -2006 American Physiological Society, member

1995 - present American College of Surgeons

- 1995 – Candidate
- 2002 – Associate fellow
- 2004 – Fellow

1996 - present Society for Surgery of the Alimentary Tract, member

2001 - 2003 American Association for the Advancement of Science, member

2002 - present Association for Academic Surgery, member

2001- present Indiana State Medical Association, member

2001 - present Indianapolis Medical Society, member

2001 - present Old Hands Society, member

2001 - present Indiana State Chapter, American College of Surgeons

- 2001 – Associate Fellow
- 2004- present – Fellow

2001 - present Indiana University Cancer Center

- 2001 – 2015 Associate Member
- 2016 - present – Full Member

2001 - 2008 American Association for the Study of Liver Disease, member

2002 - present American Hepato-Pancreatic-Biliary Association, member

2003 - present International Hepato-Pancreato-Biliary Association, member

2003 - present American College of Surgeons Oncology Group, member

2004 - present Midwest Surgical Association, member

2004 - present Western Surgical Association, member

2005 - present Society of University Surgeons, member
2005 - present Central Surgical Association (CSA), member
2008 - present Surgical Biology Club II, member
2010- present Society of Clinical Surgery, member
2014 - present American Surgical Association, member

PROFESSIONAL HONORS AND AWARDS:

TEACHING

Indiana University - IU Trustee Teaching Award Nominee, 2006-7; 2009-10

Indiana University - IU Faculty Teaching Award Nominee (1 of ~25), 2006-7

Association for Academic Surgery- Career Development Scholarship Award 2009

Department of Surgery, Indiana University School of Medicine- Medical Student Teaching Award 2020

RESEARCH

American College of Surgery, (Maryland Chapter) Baltimore, MD, Resident Research Award, September 1992

Baltimore Academy of Surgery, Baltimore, MD, Resident Research Award, 1994

Georgetown University, Washington DC, Twelfth Annual Research Days, 1998

Winner (Post-doctorate Division), Twelfth Annual Research Days Poster Competition,
Second place (Post-doctorate Division) Twelfth Annual Research Days Oral Competition

Society of Experimental Biology and Medicine, Washington DC, Second place, Student Research Forum,
March 1998

John Hopkins Hospital, Department of Surgery, Winner, Zuidema Basic Science Research Competition,
June 1998

American Association for Cancer Research, Winner of AACR-PanCAN Career Development Award in
Pancreatic Cancer Research, November 2002

Central Surgical Association Foundation Award, Winner March 2002

Richard L. Roudebush, VA Medical Center, Winner, VA Young Investigator Award, 2005

SERVICE

University of Chicago, Pritzker School of Medicine, Chicago, IL, Departmental Award for Outstanding
Performance in Surgery, 1992

Johns Hopkins University, School of Medicine, Baltimore, MD, Medical Student Society, Best House-Staff
Award, April 1994

Society of Surgery of the Alimentary Tract, Poster of Distinction, 2002

Society of Surgery of the Alimentary Tract, Poster of Distinction x2, 2005

American's Top Surgeons, 2006

Society of Surgery of the Alimentary Tract, Poster of Distinction, 2006

Central Surgical Association – Best New Member paper, 2007

Indiana University- Patient Satisfaction Award- top 10% of >500 physicians on Regenstrief Institute report on patient satisfaction 2007-8

Indiana University- Patient Satisfaction Award- top 10% of >500 physicians on Regenstrief Institute report on patient satisfaction 2008-9

Indiana University- Patient Satisfaction Award- top 10% of >500 physicians on Regenstrief Institute report on patient satisfaction 2009-10

Indiana University- Patient Satisfaction Award- top 10% of >500 physicians on Regenstrief Institute report on patient satisfaction 2010-11

Strathmore's Who's Who Worldwide- 2011

America's Top Surgeons- 2011

Patient Satisfaction 3S Surgical Unit- 6-2011 “recognized as outstanding/going above and beyond”

Top Doctors- 2012, 2020-2021- On the 2012 cover of Indianapolis Monthly Magazine

Indiana University- Stoplight report- top 10% of >500 physicians IU Health patient satisfaction 2012-13 (highest statistically significant score in general surgery division of 60 faculty)

Healthcare Heroes- 2013- Finalist for Pancreatic Cyst and Cancer Early Detection Center, Indianapolis Business Journal

Indiana University- Stoplight report- top 10% of >500 physicians IU Health patient satisfaction 2013-14 (highest statistically significant score in general surgery division of 60 faculty)

Indiana University- Stoplight report- top 10% of >500 physicians IU Health patient satisfaction 2014-15 (highest statistically significant score in general surgery division of 60 faculty)

Alpha Omega Alpha, Medical Honor Society, Inductee 2020

TEACHING:

TEACHING ASSIGNMENTS

COURSES (IU SCHOOL OF MEDICINE)

7/2001 – present

Surgical Research Program Elective #93SG780

FORUMS/SEMINARS

7/1999-6/2000 Chief Resident's Surgical Clerkship Conference, (*Bi-weekly*),
Johns Hopkins School of Medicine, Baltimore, MD

7/2000-9/2000 ACS Surgical Skills Conference, (*Weekly*)
Johns Hopkins School of Medicine, Baltimore, MD

7/2000-6/2001 ACS Surgical Clerkship Conference, (*Bi-Weekly*)
Johns Hopkins School of Medicine, Baltimore, MD

7/2001-present Lab Research Forum (*Weekly*)
Indiana University School of Medicine, Indianapolis, IN

5/2005 – 5/2006 Director, Department of Surgery Combined Labs Meeting (*Monthly*)
Indiana University School of Medicine, Indianapolis, IN

CLINICAL TEACHING

7/2001 – 12/2009 Richard L. Roudebush Surgical Service, service attending 2/12 months.
Responsible for inpatient service and consults. Supervised chief resident, junior resident and intern. Bedside teaching, intraoperative teaching, patient management.
Richard L. Roudebush Surgical Clinic, service attending 2/12 months.
Responsible for outpatient service and consults. Supervised chief resident, junior resident and intern. Bedside teaching, bedside procedure teaching, patient management.

7/2001 – present University Hospital Surgical Service, service/private attending 12/12 months.
Responsible for inpatient service and consults. Supervise chief resident, junior resident and intern. Bedside teaching, intraoperative teaching, patient management.
University Hospital Surgical Clinic, service/private attending 12/12 months.
Responsible for outpatient service and consults. Supervise chief resident, junior resident and intern. Bedside teaching, bedside procedure teaching, patient management.

7/2005 – present Hepatopancreatobiliary Fellowship Attending, 12 months. Supervise fellow.
Bedside teaching, intraoperative teaching, patient management.

7/2006 - 2019 University Hospital Pancreatitis and Urgent HPB Service, 2/12 months.
Responsible for inpatient service and consults. Supervise fellow, chief resident, junior resident and intern. Bedside teaching, patient management.

7/2011 – 2013 IU West Hospital Surgical Service, service/private attending 12/12 months.
Responsible for inpatient service and consults. Supervise junior resident. Bedside teaching, intraoperative teaching, patient management.
IU West Hospital Surgical Clinic, 12/12 months. Responsible for outpatient service and consults. Supervise junior resident. Bedside teaching, bedside procedure teaching, patient management.

7/2015 – 2019 IUH Methodist, Emergency General Surgery Service attending 1/12 months.
Responsible for inpatient service and consults. Supervise senior and junior residents. Bedside teaching, intraoperative teaching, patient management.

7/2019 – present

Methodist Hospital Surgical Service, service/private attending 12/12 months. Responsible for inpatient service and consults. Supervise chief resident, junior resident and intern. Bedside teaching, intraoperative teaching, patient management.

Methodist Hospital Surgical Clinic, service/private attending 12/12 months. Responsible for outpatient service and consults. Supervise chief resident, junior resident and intern. Bedside teaching, bedside procedure teaching, patient management.

MENTORING

7/2001-present

Teaching/mentorship of national/international faculty, clinical/research fellows, residents, post-doctoral, medical, college and high school students in my laboratory (*See below*)

○ 7/01-present

Michele Yip-Schneider, PhD, Post-Doc, Assistant Scientist, Associate Scientist

- Publications: Multiple
- Awards: Poster of Distinction DDW 2002
- Grants: Multiple
 - American Cancer Society Grant 2003-2004
 - Biomedical Resources Grant, 2005
 - Immunohistochemistry Core Pilot Grant, 2005
 - Biomedical Resources Grant, 2006
 - LARC Pilot Grant, 2007-09

○ 7/01-03

Chad Wiesenauer, MD, Resident

- Publications: Multiple
- Awards
 - American College of Surgeons Research Award, Indiana Chapter, 2002
 - JK Berman Essay Award, 2002
 - Willis D. Gatch General Surgery Research Award, 2003
 - JK Berman Essay Award, 2003
 - JK Berman Essay Award, 2004

○ 10/01-1/02

Heidi Martin, Master's Student, Butler University, Indianapolis, IN

○ 11//01-8/04

Yufang Wang, MS, Student

- Publications: Multiple

○ 5/02-8/02

Faith Albertin, Undergraduate Student

5/03-8/03

○ 5/02-9/02

Atit Patel, PharmD Student

○ 6/02

Jerry Fleisch, Volunteer Faculty

○ 7/02 -6/05

John Sandoval, MD Surgical Resident

- Publications: Multiple

○ 10/02-1/03

Min Wu, Post-Doc, Assistant Scientist

○ 1/03-2/03

Jaritzabel Roman, Biochem/Molecular Biology Student

○ 10/02-6/03

Karl Bilimoria, Medical Student

- Publications: Multiple
- Awards: Multiple
- Grants: Multiple

○ 10/02-6/30/03

Joel Baumgardner, Medical Student

- Publications: Multiple

- 4/03-4/04 Emilie Powell, Medical Student
 - Publications: Multiple
- 5/03-8/03 Matt Ralstin, Medical Student
 - 6/04 - 6/15/05 Multiple Publications
 - Awards
 - SSAT Program, Poster of Distinction Award, 2005
 - Grants
 - Walther Oncology Scholarship, 2005-2006
 - NIH M01 RR00759, Clinical Research Fellowship, 6/2004 to 6/2005
- 6/03-12/04 Patrick Klein, PhD, Post Doctoral
 - Publications: Multiple
 - 2005 – Assistant Professor promotion
- 7/03-7/04 Jennifer Choi, MD, Surgical Resident
 - Publications: Multiple
- 7/03-7/04 Earl Gage, MD, Surgical Resident
 - AACR-AstraZeneca Scholar-in-Training Award, 2004
 - Publications: Multiple
 - Awards
 - AACR-AstraZeneca Scholar-in-Training Award, 2004
- 5/04-8/04 Amer Zeni, Medical Student
 - Grants
 - NIH T35 Fellowship Recipient
- 6/04-8/04 Kasi McCune, Medical Student
 - Publications: Multiple
- 6/04-8/04 Jesus Matos, Medical Student
 - Publications: Multiple
- 7/04-6/06 Matthew Hennig, Surgical Resident
 - Publications: Multiple
 - Awards
 - Willis D. Gatch, MD Award, American College of Surgeons, Indiana Chapter, 2006
 - JK Berman Best General Surgery Paper, 2006
 - Poster of Distinction, SSAT , 2005, 2006
- 10/04-1/05 Alexander Menze, Medical Student
- 6/05 - 8/05 Julie Mohamed, Medical Student
- 6/05 - 8/05 Amanda Norris, Medical Student
- 7/05 – 6/07 Sabrina Wentz, Post-Doc Fellow
 - Publications: Multiple
- 7/05 - 8/05 Jason Kennard, Medical Student
 - Publications: Multiple
- 7/05 - 8/05 Jennifer Dixon, Medical Student
 - Publications: Multiple
- 7/05 – 6/06 Bryan K. Holcomb, Surgical Resident
 - Publications: Multiple
 - Awards
 - Niarchos Foundation Scholarship, 2005
 - Carl H. McCaskey, MD Award, American College of Surgeons, Indiana Chapter, 2006
- 5/06 – 8/06 Victor Njoku, Medical Student
 - Grants
 - Recipient of NIH T35 Fellowship
- 8/05-1/06 Courtney Doyle, Medical Student
- 5/06 - 7/06 Stephen Noble, Medical Student

- 6/2006 Reid Vegeler, Medical Student
 - Publications: Multiple
- 8/06-9/06 Josh Waters, Medical Student
 - Publications: Multiple
- 8/06-10/06 Patrick White, Medical Student
 - Publications: Multiple
- 10/06-12/06 Jason Denbo, Medical Student
- 10/06-12/06 Jeff Glant, Medical Student
 - Publications: Multiple
- 11/06 -12/06 Lilian Azih, Medical Student
- 12/06-1/07 Dominique Dempth, Medical Student
- 6/07 – present Joal Beane, Medical Student (summer, 3-4 months additional), resident
 - Publications: Multiple
- 6/08 – present Ryan Dumas, Medical Student
 - Publications: Multiple
 - William and Fern Groves Hardiman Research Scholarship \$1500
- 7/07 – 6/09 Jesus Matos, Resident (see also above as medical student)
 - Publications: Multiple
 - Awards
 - IN ACS Best Paper 2008
 - Grants
 - NIH Cancer Biology Training Grant (NIH T32 CA111198)
- 7/08 – 6/10 Courtney Doyle, Resident (see also above as medical student)
 - Publications: Multiple
 - Awards
 - JK Berman Best Clinical Research Paper, 2009
- 10/08 – 3/09 Olivier Turrini, Faculty Fellow from Marseilles, France
 - Publications: Multiple
- 7/09 – 6/11 Josh Waters, Resident (see also above as medical student)
 - Publications: Multiple
 - Awards
 - JK Berman Best Oncologic Research Paper, 2010
- 7/09 – 6/10 Juan Saavedra, Faculty Fellow from Mexico City, Mexico
 - Publications: Multiple
 - Grants
 - IHPBA Warren Fellowship
- 10/09 – 3/10 Shadi Aboudi, Resident Fellow from Damascus, Syria
 - Publications: multiple
- 3/10 – Jeff Glant, Post-Doctoral Fellow (see also above as medical student)
 - Publications: multiple
- 07/10 – 06/11 Daniel DiRenzo, Graduate Student
 - Publications: Multiple
 - Grants
 - CTSI predoctoral grant (Co-Mentor with Steve Konieczny)
- 06/10 – 07/10 Christy Cauley, Medical Student
 - Publications: single
- 07/10 – 08/10 Jacob Miller, Medical Student
 - Publications: single
- 07/10 – 08/10 Abby Mills, Undergraduate Student
 - Publications: single
- 07/10 – 06/11 Juliana Meyer, Faculty Fellow
 - Publications: multiple
- 10/11 – 2013 Se-Joon Lee, Faculty Fellow
 - Publications: multiple

- 9/12 – 2013 Kristina Shaffer, Medical student
 - Publications: multiple
- 9/12 – 2013 Emily Sturm, Medical student
 - Publications: multiple
- 9/12 – present Christian Schmidt II, High School student
 - Publications: multiple
- 11/12 – 2013 Morgan Barron, Medical student
 - Publications: multiple
- 2012 - present Alexandra Roch, Faculty Fellow
 - Publications: multiple
 - Grants: multiple
- 2013 – 2014 Ariel Gallanosa, Graduate student
 - Publications: pending
- 2013 – 2014 Harjut Singh, Medical student
 - Publications: single
- 2013 – present Eugene Ceppa, Faculty
 - Publications: multiple
- 2014 – 2015 Elliot Adams, Medical student
 - Publications: pending
- 2014 – 2015 Dan Fer, Medical student
 - Publications: pending
- 2014 – present Rose Carr, PGY2
 - Publications: multiple
- 2014 – present Neil Sharma, Faculty (outside IU)
 - Publications: pending
- 2015 – present Carlo Rosati, Resident (IU)
 - Publications: one
 - Served as Clinical Mentor
- 2015 – present James Butler, Resident (IU)
 - Publications: multiple
 - Grants: AAS/AASF Grant 2015
 - Served on his PhD Committee
 - Served as Clinical Mentor
- 2015 – present Kate Bigelow, undergraduate IU
 - Publications: multiple
- 2015 – present Karthik Ramanathan, Resident (IU)
 - Presentations: AHPBA 2017
 - Publications: pending
- 2015 – present Mazhar Soufi, Resident (NY)
 - Publications: multiple
- 2016 – present Brandon Kiel, MS (IU)
 - Publications: pending
- 2017 – present Rachel Simpson, Resident (IU)
 - Publications: multiple
 - MSA: Best Resident Paper 2018
- 2017 – present Nathan Cokerill, MS (IU)
 - Publications: 1
- 2017 – present Katelyn Flick, Resident (IU)
 - Publications: multiple
- 2018 – present Christine Wang, Resident (IU)
 - Served as Clinical/Career Mentor
- 2018 Mitch Fennerty, MS (IU)
 - Served as Research Mentor
 - Publications: multiple

- 2019 – present Amir Hajrasouliha, MD Ophtho Faculty (IU)
 - Served as Faculty Academic Mentor
- 2019 – present Rachel Kim, MD Resident (IU)
 - Served as Faculty Academic Mentor
 - Served as Research Mentor
 - Publications: multiple
- 2021 – present Dietrich Brown (Central Christian Academy)
 - 21st Century Scholar Mentor

TEACHING ADMINISTRATION AND CURRICULUM DEVELOPMENT

2015- 2017 **PhD Committee Member** for James Butler, Indiana University School of Medicine, Indianapolis, IN

PROFESSIONAL DEVELOPMENT

2014 – present **Surgery Leadership Series**, Department of Surgery, Indianapolis, IN

2017 – 2018 **Effective Surgical Educator Series**, Department of Surgery, Indianapolis, IN

2020 – 2021 Surgical Educator Series, Department of Surgery, Indianapolis, IN

2020 – 2021 **Leaders Growing Leaders**, Department of Surgery, Indianapolis, IN

2021 **DEI: Black Men in White Coats**, IUSM, Indianapolis, IN

2021 **DEI: Surgery Grand Rounds** (Dr. DuyKhanh Pham Ceppa), Department of Surgery, IUSM, Indianapolis, IN

GRANTS/FELLOWSHIPS IN TEACHING

6/04 - 8/04 **NIH (T35) Summer Research Fellowship, (Mentee: Amer Zeni)**, “The Role of p53 in P-glycoprotein Mediated MEK Inhibitor Resistance, \$5,000, Mentor

8/04 – 7/05 **NIH (M01 RR00750) Clinical Research Fellowship, (Mentee: Matthew C. Ralstin)** “A Biomarker Study of COX-2-Inhibitors in Patients with IPMN,” \$25,000, Mentor

5/05 - 8/05 **NIH (T35)** “The Role of ETOH Growth Signaling in Hepatocellular Carcinoma,” \$5,000, Mentor

12/08 – 7/09 **NIH (T32CA111198) Cancer Biology Training Grant**, “The Role of NF-kB in Pancreatic Cancer”, \$80,000, Mentor (Mentee- Jesus Matos)

1/10 – 1/11 **IHPBA Warren Fellowship**, “Targeting NF-kB in Pancreatic Cancer”, \$20,000, Mentor (Mentee- Juan Saavedra)

- 7/10 – 6/11 **CTSI Pre-doctoral Fellowship**, “Understanding the molecular events that lead up to the development of pancreatic ductal adenocarcinoma (PDA), \$24,000, Co-Mentor with Steve Konieczny (Mentee- Daniel DiRenzo)
- 2015 – 2016 **AAS/AASF Research Fellowship Award (Mentee: James Butler) PI/Co-mentor Butler/Schmidt** “Improving Transgene Expression on Porcine Endothelium Through Identification of Endogenous Promoters: A Strategy to Drive Human Complement Regulatory Proteins” \$20,000

INVITED PRESENTATIONS: TEACHING

LOCAL

1. **Schmidt CM:** “*Building a Teaching Portfolio*”, Effective Surgical Educator Series, Department of Surgery, IU School of Medicine, Indianapolis, IN February 21, 2018

REGIONAL

2. **Schmidt CM:** *American Health Care Quality/Cost: the Role of Sub-Specialization*. Invited speaker, US Healthcare Administration 380-50 Butler Course, October 2, 2017.
3. **Schmidt CM:** “*History and Evolution of Physicians, Hospitals and Healthcare Management Systems*”, Invited speaker, US Healthcare Administration 380-50 Butler Course, February 26, 2018
4. **Schmidt CM:** *Pancreatic Cancer Early Detection: Hope in an Otherwise Hopeless Condition*, Invited speaker, Planned Giving, May 3, 2018
5. **Schmidt CM & Kristen Kelly:** “*IU Health AAHC ERAS*”, Invited speaker, ICPS Executive Workgroup, September 10, 2019
6. **Schmidt CM:** “*Health Administration: The Good, the Bad, and the Ugly*”, Invited speaker, US Healthcare Administration 380-50 Butler Course, October 17, 2019
7. **Schmidt CM:** “*Health Administration: Physician Incentives and Patient Advocacy*”, Invited speaker, US Healthcare Administration 380-50 Butler Course, February 24, 2020
8. **Schmidt CM:** “*Academic & Private Practice in an era of Healthcare Management Systems*”, Invited speaker, US Healthcare Administration 380-50 Butler Course, November 2, 2020
9. **Schmidt CM:** “*Health Care Management, an Academic Surgeon’s Perspective*” Invited speaker, US Healthcare Administration 380-50 Butler Course, March 15, 2021

NATIONAL

10. **Schmidt CM:** “*Is there value in obtaining additional degrees: MS, MPH, PhD, MBA?*”, AAS Career Development Course, Chicago, IL, October 10, 2009.

INTERNATIONAL

11. **Schmidt CM:** “*Life-work balance in academic surgery: Is this possible?*” Inaugural Australasian Fundamentals of Research and Career Development Course, Brisbane, Australia, May 5, 2009.
12. **Schmidt CM:** *Choosing a Mentor: Key to Academic Success*. Inaugural French Fundamentals of Surgical Research Course, Paris, Fr, October 7, 2011.
13. **Schmidt CM:** *Writing a Successful Grant*. Inaugural French Fundamentals of Surgical Research Course, Paris, Fr, October 7, 2011.

RESEARCH/CREATIVE ACTIVITY:

GRANTS/FELLOWSHIPS: RESEARCH

COMPLETED

- 1987 **Business Fellowship and Full Tuition Scholarship**, University of Chicago, Graduate School of Business, Chicago, IL
- 1988 **Richter Fellowship Grant for Student Research**, University of Chicago, Chicago, IL
- 11/01 - 7/05 **Walther Oncology Institute Grant** (Salary Compensation for Technical Assistance), \$140,000, Principal Investigator
- 7/01 - 6/02 **American Cancer Society (IRG-84-002-18)**, “The Role of Growth and Survival Pathways in Mediating the Effects of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Pancreatic Cancer Cells, \$19,400, Principal Investigator
- 7/02 - 6/03 **Central Surgical Association Grant**, “The Role of COX-2 in Human and Experimental Pancreatic Tumorigenesis, \$10,000, Principal Investigator
- 1/02 - 12/03 **Clarian Values Fund for Research (VFR-121)**, “Hepatocellular Carcinoma, Pathogenesis and Chemotherapeutics,” \$100,000, Principal Investigator
- 7/03 - 6/05 **Merit Review Award (Health Services Research and Development)**, “Health Related Quality of Life in VA Patients with Intestinal Stomas,” \$312,650, Co-Principal Investigator
- 7/03 - 6/05 **AACR-PanCAN Career Development Grant in Pancreatic Cancer Research**, “Chemopreventive Role of Cyclooxygenase Inhibitors in Pancreatic Tumorigenesis,” \$100,000, Principal Investigator
- 12/03 - 11/05 **NIH (P50 AA07611-16-20)** “The Role of Ethanol to MAPK Signaling in the Pathogenesis of Hepatocellular Carcinoma,” \$70,000, Principal Investigator
- 5/03- 12/07 **Pharmacia Inc.**, “A Phase II Trial of Celecoxib in Patients with IPMN-IU, \$105,000, Principal Investigator (investigator initiated clinical trial)
- 7/04 -6/06 **Indiana University Cancer Center**, “Proteomic Profiles in Patients with IPMN Treated with COX-2 Inhibitors, \$10,500, Principal Investigator
- 7/1/05- 6/1/07 **VA Young Investigator Award**, “The Mechanism of Nuclear Factor kB-Mediated Gemcitabine Resistance in Pancreatic Carcinoma,” \$25,000, Principal Investigator.
- 7/05 – 6/07 **Genetech and Indiana Cancer Center**, “Pilot Study Using Neoadjuvant Chemoradiotherapy and Tarceva™ (EGFR-Tyrosine Kinase Inhibitor) For Potentially Resectable Pancreatic Cancer,”\$76,678, Co-Principal Investigator
- 01/06 – 12/06 **Collaborative Biomedical Research Grant, Indiana University**, “Establishing the Importance of Mist1 in Human Pancreatic Ductal Adenocarcinoma,” \$50,000, Co-Principal Investigator

- 01/06 - 12/06 **GI Pilot Study, Indiana University Cancer Center**, “Studies of a Unique Pancreatic Cancer Mouse Model with Disruption of TGF- β Function,” \$40,000, Co-Principal Investigator
- 01/06 - 12/06 **GI Pilot Study, Indiana University Cancer Center**, “Discovery of 14-3-3 σ Inhibitors for Better Treatment of Pancreatic Cancers Using Chemoinformatics/virtual Screening,” \$27,000, Co-Principal Investigator
- 10/06 – 9/08 **Clinical Trial, Bayer**, “A Pilot Study of Gemcitabine and Novel Raf Kinase – Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 and Radiotherapy in Patients with Locally Advanced Unresectable Pancreatic Adenocarcinoma,” \$143,750, Co-Principal Investigator
- 09/06-08/08 **NIH (1 R03 CA 112629-01A1)**, “A Biomarker Study of COX-2 Inhibitors in IPMN,” \$151,500, Principal Investigator
- 9/06 - 08/09 **ACS RSG-06-267-01-CCE (American Cancer Society)** , “Targeting NF-kB in Pancreatic Cancer,” \$540,000, Principal Investigator
- 3/08 – 12/11 **NIH (1R21AA016360-01A2)**, “Mechanism of Alcohol/Alcoholism-induced Liver Neoplasia”, \$416,625, Principal Investigator
- 7/10 – 12/12 **Lustgarten Foundation Early Detection Grant**, Schmidt (Co-PI), Early Detection of Pancreatic Cancer. The goal of this project is characterize early serum and pancreas fluid biomarkers to detect pancreatic cancer. This is a multi-institutional collaboration with the lead scientist, Bert Vogelstein, at Johns Hopkins. \$170,000
- 10/10 – 3/12 **Indiana Clinical and Translational Sciences Institute**, Schmidt (Co-PI), Dietary and Genetic Etiology of Pancreatic Cancer: A Pilot Epidemiologic Study in Indianapolis, Dietary, lifestyle and genetic factors related to energy imbalance and insulin resistance in pancreatic cancer etiology in a pilot case-control study (\$20,610)
- 5/12 – 4/13 **Asuragen, Inc**, Schmidt (PI), MiRNA profiling of pancreatic cysts to determine malignant potential, a confirmatory study. \$40,000
- 3/12 - 2014 **NIH R01HS019818** (PI- Paul Dexter) Agency for Healthcare Research and Quality; Pilot Project- Schmidt, Co-PI (on Pilot) Early detection of pancreatic cancer through rigorous screening of at risk individuals using informatics and natural language processing
- 3/12- 2014 **NIH TR000006** (PI- Anantha Shekhar) CTSA grant (National Center for Advancing Translational Sciences); Pilot Project- Schmidt, Co-PI (on pilot) Early detection of pancreatic cancer through rigorous screening of at risk individuals using informatics and natural language processing
- 1/12 – 12/14 **IU Health/IUSCC Signature Center Grant**, Schmidt (Co-PI), establishment of core facility for mouse models of pancreatic adenocarcinoma. \$300,000 (3 yr matching \$150K/\$150K grant)
- 12/12 – 11/16 **Lustgarten Foundation Early Detection Grant**, Schmidt (Co-PI), Early Detection of Pancreatic Cancer. The goal of this project is characterizing early serum and pancreas fluid biomarkers to detect pancreatic cancer. This is a multi-

institutional collaboration with the lead scientist, Bert Vogelstein, at Johns Hopkins. \$360,000

12/14 – 11/16

Lustgarten Foundation Early Detection Grant, Schmidt (PI), Cyst fluid VEGF in Pancreatic Cyst Diagnosis. The goal of this project is characterizing pancreas fluid VEGF as a diagnostic test for serous cystic neoplasms. \$30,000

10/1/16 – 9/30/18

NIH R21 CA209366 Schmidt/Zhang (PI/PI)
Role of serum insulin resistance markers in prediction of IPMN malignancy
Goal: insulin resistance markers in IPMN malignant progression.
\$203,906

11/19/2019 – 11/19/2020

IU Simon Cancer Center P30 Support Grant (P30CA082709) (Near Miss Internal Grant) Schmidt and Zhang – co-PIs (on internal grant)
“Longitudinal Proteomic and Metabolomic Predictors of Pancreatic Cyst Malignant Progression and Early-Stage Pancreatic Cancer
\$46,200

10/1/15 – 9/30/21

NIH U01CA196403-01 Maitra/Schmidt (PI/ Largest Site PI/Co-Investigator) Imaging and Molecular Correlates of Progression in Cystic Neoplasms of the Pancreas
Goal: to use molecular and imaging correlates to predict diagnosis and malignant potential of pancreatic cystic neoplasms.
\$78,000/yr

ACTIVE

5/1/16 – 4/30/22

NIH 1U01CA200468-01 (EDRN) Maitra/Schmidt (PI/ Largest Site PI/Co-Investigator) A Clinical Validation Center for Early Detection of Pancreatic Cancer
Goal: Validate diagnostic biomarkers for pancreatic cancer early detection.
\$100,000+/yr

5/1/21 – 4/30/26

NIH U01 CA239522-01 Schmidt/Zhang (PI/PI) Longitudinal Proteomic and Metabolomic Predictors of Pancreatic Cyst Malignant Progression and Early Stage Pancreatic Cancer
Goal: Collect longitudinal samples in patients, using them as their own control, to discover proteomic and metabolomics predictors of pancreatic cyst malignant progression and early-stage pancreatic cancer detection.
\$3,961,757.00

PENDING

2021

DOD (Role: Co-I) submitted

2022

NIH Spore (Role: Co-I) pending submission

INVITED PRESENTATIONS: RESEARCH

LOCAL

1. Schmidt CM: *The Use of Radiolabeled Immunoconjugates in the Detection of Recurrent and Metastatic Colorectal Cancer*, Forty-sixth Annual Scientific Session of the Pritzker School of Medicine, University of Chicago May 1992.
2. Schmidt CM, Block, Michelassi, Ryan, Cooper: *Indium 111 Labeled B72.3 Murine Monoclonal Antibody as a Diagnostic Imaging Agent in the Management of Patients with Colorectal Adenocarcinoma*, Annual Report of Cancer Research at the University of Chicago, 1992-93.
3. Schmidt CM: *Simple Radiographic Evaluation of Ileal-Anal Pouch Volume Correlates with Bowel Function*, Baltimore Academy of Surgery May 1994.
4. Schmidt CM: *Differential Guanine Nucleotide Proteins in Human Hepatocellular Carcinoma Growth*, Seminar, Georgetown University Medical Center, June 1996.
5. Schmidt CM: *The Role of Adenylyl Cyclase Linked Guanine Nucleotide Proteins in Human Hepatocellular Carcinoma Growth*, Seminar, Department of Surgery, Georgetown University Medical Center, Baltimore, MD, September 1997.
6. Schmidt CM: *The Role of Gi-and Gs-Protein-Linked MAPK Signaling in Human Hepatocellular Carcinoma Growth*, Seminar, Department of Physiology and Biophysics, Georgetown University Medical Center, Baltimore, MD, October 1997.
7. Schmidt CM: *Inhibitory Guanine Nucleotide Proteins Regulates Human Hepatocellular Carcinoma Growth via a MAPK Pathway*, Student Research Days at Georgetown University Medical Center, Baltimore, MD, February 1998.
8. Schmidt CM: *The Role of Gi-Gs and Gq/11-Protein Linked MAPK Signaling in Human Hepatocellular Carcinoma Growth*, Seminar, Department of Physiology and Biophysics, Georgetown University Medical Center, Baltimore, MD, April 1998.
9. Schmidt CM: *Alpha Subunit of Inhibitory Guanine Nucleotide Proteins Regulates Human Hepatocellular Carcinoma Growth via a MAPK Pathway*, SEBM Student Research Competition, oral presentation, Georgetown University, March 1998.
10. Schmidt CM: *The Role of Gi-and Gs-Protein-Linked MAPK Signaling in Human Hepatocellular Carcinoma Growth*, Zuidema Competition, Johns Hopkins Hospital, oral presentation, June 1998.
11. Schmidt CM: *Preoperative colonic and Ileal Histopathology Predicts Risk of Pouchitis after Ileo-anal Pull Through Operation*, John Hopkins Hospital, Lafelle Seminar, March 1999.
12. Schmidt CM: *Preoperative Colonic and Ileal Histopathology Predicts Risk of Pouchitis after Ileo-anal Pull Through Operation*, Johns Hopkins Hospital, Fazio Seminar, April 1999.
13. Schmidt CM: *The Role of MAPK Signaling in the Regulation of Hepatocellular Carcinoma*, Walther Oncology Seminar, Indianapolis, IN, March 1, 2002.
14. Schmidt CM: *Bench Perspectives of a Clinician on Hepatocellular Carcinoma*, Indiana University Cancer Center Grand Rounds, March 15, 2002.
15. Schmidt CM: *Indiana University Hepatocellular Carcinoma Treatment Algorithm*, GI Oncology Research Forum, Indiana University Medical School, Department of Surgery, July 25, 2002.
16. Schmidt CM: *IPMN Trial*, GI Oncology Research Forum, Indiana University Medical School, Department of Surgery, August 29, 2002.
17. Schmidt CM: *Hepatocellular Carcinoma: A Surgeon's Bench Perspective*, Indiana University Surgery Grand Rounds, December 4, 2002.
18. Wiesenauer C, Schmidt CM, Yip-Schneider M, Wang Y, Madura J, Grosfeld J: *MEK Regulation in Hepatocellular Carcinoma*, Surgical Forum 2002.
19. Schmidt CM: *Combined Treatment with COX-2 Inhibitors and MEK Inhibitors in Hepatocellular Carcinoma*, Walther Retreat, Indiana University Medical School, Poster-presentation, August 2003.

20. Schmidt CM: *NFkB in Pancreatic Cancer*, Walther Retreat, Indiana University Medical School, Poster-presentation, August 2003.
21. Schmidt CM: *The Role of COX-2 in Human and Hamster Pancreatic Tumorigenesis*, Indiana University Cancer Center, Experimental Therapeutics Section, August 19, 2003.
22. Schmidt CM: *Schmidt Lab Research Directions*, Indiana University Medical School, Walther Oncology Seminar, October 10, 2003.
23. Wiesenauer CA, Schmidt CM: *Preoperative Predictors of Malignancy in Pancreatic IPMN's – The Indiana University Experience*, 24th Annual JK Berman Essay Program and Bruce White Lecture, Indiana University Medical School, Department of Surgery, June 11, 2004.
24. Gage EA, Schmidt CM: *NF-kB and Cyclooxygenase-2 Inhibitors Provide Synergistic Inhibition of Hepatocellular Carcinoma Cellular Proliferation Possibly Through Modulation of IKBa*, 24th Annual JK Berman Essay Program and Bruce White Lecture, Indiana University Medical School, Department of Surgery, June 11, 2004.
25. Choi J, Schmidt CM: *Predictors of Pancreaticoenteric Anastomotic Leak or Fistula and Effect on Patient Outcomes Following Pancreaticoduodenectomy*, 24th Annual JK Berman Essay Program and Bruce White Lecture, Indiana University Medical School, Department of Surgery, June 11, 2004.
26. Schmidt CM: *IPMNs, "The Polyps of Pancreatic Cancer:" Research Directions at Indiana University*, Indiana University Medical School, July 28, 2004.
27. Schmidt CM: EDT Program Meeting, *"GI Cancer Research Program Development,"* Indiana University School of Medicine, Experimental Developmental Therapeutics Committee, March 15, 2005.
28. Schmidt CM: *IU Surgical Research Development: Dr. Grosfeld's Vision, Current Status and a Few Tales from the Lab*, Academic Symposium: First Grosfeld Lectureship, Indianapolis, IN, June 3, 2005.
29. Schmidt CM: *Nuclear Factor-kB Mediated Gemcitabine Resistance in Pancreatic Cancer: A Work in Progress*, VAMC Research Seminar, September 8, 2005
30. Henning M, Schmidt CM: *Targeting MEK with PD325901 Inhibits Hepatocellular Carcinoma Growth in Multiple Models (Schmidt CM – Mentor)*, Walther Oncology, Indiana University School of Medicine, Indianapolis, IN, June 2, 2006.
31. Wentz S, Schmidt CM: *Sulindac Decreases N-nitrosobis (2-oxypropyl)amine-induced cholangiocarcinoma in hamsters (Schmidt CM – Mentor)*, Walther Oncology, Indiana University School of Medicine, Indianapolis, IN, June 2, 2006.
32. Henning M, Schmidt CM: *Targeting MEK with PD325901 Inhibits Hepatocellular Carcinoma Growth in vivo (Schmidt CM – Mentor)*, JK Berman Essay Presentations, Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, June 23, 2006.
33. Holcomb B, Schmidt CM: *NF-kB Regulation of Pancreatic Cancer*. JK Berman Essay Presentations, Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, June 23, 2006.
34. Safar B, Schmidt CM: *Diagnostic Evaluation, Preoperative Staging and Post-operative Surveillance of Patients with Intraductal Papillary Mucinous Neoplasms by Magnetic Resonance Cholangiopancreatography, (Schmidt CM – Mentor)*, JK Berman Essay Presentations, Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, June 23, 2006.

REGIONAL

35. Schmidt CM: *Detection of Recurrent and Metastatic Colorectal Cancer with Immune Scintigraphy-Comparison with CT*, Central Chapter Society of Nuclear Medicine March 1992.
36. Schmidt CM: *Increased Expression of Mitogen Activated Protein Kinase Pathway in Rat and Human Hepatocellular Carcinoma*, ASBMB, poster presentation April 1996.
37. Wiesenauer C, Schmidt CM: *Preoperative Predictors of Malignancy in Pancreatic IPMN's*, American College of Surgeons, Hilton Head, South Carolina, June 5, 2003.

38. Schmidt CM: *Liver Cancer Overview and Research Directions*, Indiana American College of Surgeons, Hilton Head, South Carolina, June 6, 2003.
39. Gage EA, Schmidt CM: *Characterization of a Novel MEK Inhibitor (PD181461) Which Inhibits Human Hepatocellular Carcinoma Growth in Vitro and in Vivo*, Indiana American College of Surgeons Forum, April 2004.
40. Choi J, Schmidt CM: *Doxorubicin's Effect on MEK-ERK Signaling Predicts its Efficacy in Hepatocellular Carcinoma*, Indiana American College of Surgeons Forum, April 2004.
41. Henning M, Schmidt CM: *Effects of Ethanol on TGF α , MEK Activity and Proliferation in Hepatocellular Carcinoma (Oral Presentation)*, Am College of Surgeons, Indiana Chapter, Indianapolis, IN, May 2005.
42. Eppstein A, Schmidt CM: *Differential Sensitivity of Chemoresistant Neuroblastoma Subtypes to MAPK-Targeted Treatment Correlates with ERK, p53 Expression and Signaling Response to U0126 (oral presentation)* Am College of Surgeons, Indiana Chapter, Indianapolis, IN, May 2005.
43. Henning M, Schmidt CM: *Targeting MEK with PD325901 Inhibits Hepatocellular Carcinoma Growth in Multiple Models (Schmidt CM – Mentor)*, Indiana American College of Surgeons Annual Meeting, Sanibel Island, FL, May 16, 2006.
44. Holcomb B, Schmidt CM: *Role of NF- κ B in Pancreatic Cancer*. Indiana American College of Surgeons Annual Meeting, Sanibel Island, FL, May 16, 2006.

NATIONAL

45. Trippi, Schmidt CM, Enos, Valentine, Tavel: *Doppler Assessment of Left Ventricular Inflow during Exercise Induced Ischemia*, American Heart Association 60th Scientific Session November 1987.
46. Block, Michelassi, Schmidt CM: *The Clinical Trials of Radiolabeled Immunoconjugates for the Detection of Colorectal, Ovarian and Prostate Carcinoma*, Forty-First Annual Meeting of the Society of Pelvic Surgeons, November 1992; 35.
47. Schmidt CM: *Novel Radiographic Evaluation of Ileal-Anal Pouch Volume Correlates with Bowel Function*, SSAT May 1994.
48. Schmidt CM: *Increased Expression of Guanine Nucleotide Regulatory Protein (G-Protein) G11 in Hepatocellular Carcinoma (HCC)*, AASLD, poster presentation November 1996.
49. Schmidt CM: *Increased Expression of Guanine Nucleotide Regulatory Proteins Gq α /G11 in Hepatocellular Carcinoma*, FASEB Oral Presentation, December 1996.
50. Schmidt CM: *Alterations in Guanine Nucleotide Regulatory Proteins in Human Hepatocellular Carcinoma*, AACR, poster presentation April 1997.
51. Schmidt CM: *Functionally Significant Gi-Protein Linked MAPK Pathway in Primary Human Hepatocellular Carcinoma*, AASLD, poster presentation, November 1997.
52. Schmidt CM: *Preoperative Colonic and Ileal Histopathology Predicts Risk of Pouchitis after Ileo-anal Pull Through Operation*, Southern Surgical Association, oral presentation, November 1997.
53. Schmidt CM: *Functionally Significant Gq α -Linked MAPK Pathway in Experimental Hepatocellular Carcinoma*, FASEB, poster presentation, April 1998.
54. Schmidt CM: *Inhibitory Guanine Nucleotide Proteins Regulate Human Hepatocellular Carcinoma Growth via a MAPK Pathway*, DDW, poster presentation, May 1998.
55. Schmidt CM: *The Role of Adenylyl Cyclase Linked MAPK Signaling in the Regulation of Human Hepatocellular Carcinoma Growth*, American College of Surgeons, Surgical Forum, oral presentation, October 1998.
56. Schmidt CM: *G-Protein Stimulated Mitogenesis in Human Hepatocellular Carcinoma*, AASLD, poster presentation, November 1998.
57. Schmidt CM, Talamini MA, Kaufman HK, Moesinger RJ, Bayless TM: *Laparoscopic Surgery for Crohn's Disease: Reasons for Conversion*, DDW, May 2000.
58. Schmidt CM: *Hepatocellular Carcinoma Trial Designs*, ECOG, June 9, 2002.
59. Schmidt CM: *Preoperative Predictors of Malignancy in Pancreatic IPMNs*. Western Surgical Association, November 18, 2002.
60. Wiesenauer C, Schmidt CM: *Chemotherapy with MEK Inhibitors, PD098059 and U0126, in Human HCC: Multiple Mechanisms of Tumor Kill in Vitro*, Poster Presentation DDW 2002.

61. Yip-Schneider M, Schmidt CM: *Inhibition of Akt Signal Transduction Pathway Complements the Response of Pancreatic Carcinoma Cells to Sulindac*, Poster Presentation DDW 2002.
62. Schmidt CM: *The Role of COX-2 in Human and Experimental Pancreatic Tumorigenesis*, Central Surgical Association, March 22, 2003.
63. Schmidt CM: *The Role of COX-2 in Hepatocellular Carcinoma*, Indiana University Medical School, Department of Surgery Surgical Research Forum, April 16, 2003.
64. Schmidt CM: *Novel Combination of COX-2 and MEK Inhibitors in Human Hepatocellular Carcinoma Provides Synergistic Increase in Apoptosis*, SSAT at DDW, May 21, 2003.
65. Madura JA, Schmidt CM: *Enucleation of Branch-type IPMN's*, Midwest Surgical Association, Galena, IL, August 7, 2003.
66. Schmidt CM: *The Role of COX-2 in Human and Hamster Pancreatic Tumorigenesis*, PanCAN Meeting, Beverly Hills, CA, November 7, 2003
67. Schmidt CM: *Pancreaticoduodenectomy: A Twenty Year Experience in 516 Patients*, Western Surgical Conference, Tucson, AZ, November 12, 2003.
68. Choi J, Schmidt CM: *Doxorubicin's Effect on MEK-ERK Signaling Predicts its Efficacy in Hepatocellular Carcinoma*, Society of University Surgeons, 2004.
69. Gage E, Schmidt CM: *Characterization of a Novel MEK Inhibitor (PD181461) Which Inhibits Human Hepatocellular Carcinoma in Vitro and in Vivo*, American Association for Cancer Research's Annual Meeting, Orlando, Florida, March 27 – March 31, 2004.
70. Yip-Schneider MT, Schmidt CM: *The Role of Cyclooxygenase-2 in Hamster and Human Pancreatic Tumorigenesis*, American Association for Cancer Research's Annual Meeting, Orlando, Florida, March 27 – March 31, 2004.
71. Klein PJ, Schmidt CM: *The Role of Protein Phosphatase 1 in Human Hepatocellular Carcinoma*, American Association for Studies of Liver Diseases/Digestive Diseases Weekly, New Orleans, LA, May 15 to May 20, 2004.
72. Gage EA, Schmidt CM: *NF- κ B and Cyclooxygenase-2 Inhibitors Provide Synergistic Inhibition of Hepatocellular Carcinoma Cellular Proliferation Possibly Through Modulation of IKBa*, SSAT/Digestive Diseases Weekly, New Orleans, LA, May 15 to May 20, 2004.
73. Baldwin CM, Wendel C, Mohler MJ, Grant M, Rawl S, Ko C, Rosenfeld K, Schmidt CM, Krouse RS: *Influence of Ostomy Type on Fatigue and Quality of Sleep in Military Veterans*, Associated Professional Sleep Societies 19th Meeting, June 18-23, Denver, CO, 2005.
74. Eppstein A, Schmidt CM: *Differences in MAP kinase signaling responses to MEK inhibition in three distinct neuroblastoma cell types (poster presentation)*, AACR Meeting, Anaheim, CA, April, 2005.
75. Yip-Schneider MT, Schmidt CM: *Suppression of human pancreatic tumor growth in vivo by sulindac and a novel analog of parthenolide with improved bioavailability (poster presentation)*, AACR Meeting, Anaheim, CA, April, 2005.
76. Klein P, Schmidt CM: *Human hepatocellular carcinoma exhibits resistance to small molecule MEK inhibition that is independent of P53, HBx and P-glycoprotein expression (poster presentation)*, AACR Meeting, Anaheim, CA, April, 2005.
77. Ralstin M, Schmidt CM: *NF- κ B and COX-2 inhibitors provide complementary growth inhibition in human hepatocellular carcinoma through apoptosis and cyclinD1 mediated G0/G1 arrest (poster presentation)*. DDW Meeting, SSAT Poster of Distinction, Chicago, IL, May, 2005.
78. Hennig M, Schmidt CM: *Chronic ethanol exposure may promote MEK-ERK dependent growth in human hepatocellular carcinoma (HCC) (oral presentation on SSAT Plenary)* DDW Meeting, Chicago, IL, May 2005.
79. Eppstein A, Schmidt CM: *Differential Signaling Response of Neuroblastoma to MEK Activity Inhibitor Treatment Predicts Resistance to MAP Kinase Based Treatment Strategies*, Am. Pediatric Surgical Association Meeting, Tucson AZ, May 2005.
80. Eppstein A, Schmidt CM: *Differential Sensitivity of Chemoresistant Neuroblastoma Subtypes to MAPK-Targeted Treatment Correlates with ERK, p53 Expression and Signaling Response to U0126, (Scientific Poster)* APSA 36th Annual Meeting, Phoenix, AZ, May 29 – June 1, 2005.

81. Wentz S, Schmidt CM: *Sulindac Decreases N-nitrosobis (2-oxypropyl)amine-induced cholangiocarcinoma in hamsters (Schmidt CM – Mentor)*, AACR (poster) 2006.
82. Henning M, Schmidt CM: *Targeting MEK with PD325901 Inhibits Hepatocellular Carcinoma Growth in TGF-+ Transgenic Mice” Poster of Distinction*, SSAT 47th Annual Meeting, Los Angeles CA, May 20-24, 2006.
83. Holcomb B, Schmidt CM: *NF-kB Targeting in Pancreatic Cancer Promotes the Antiproliferative Effects of Gemcitabine*, SSAT 47th Annual Meeting, Los Angeles CA, May 20-24, 2006.
84. Schmidt CM: *Health-Related Quality of Life in Veterans with Colorectal Cancer*, Association of VA Surgeons 20th Annual Surgical Symposium, Cincinnati, OH May 7-9, 2006.
85. Vegeler R, Schmidt CM: *“Effect of LC-1, A Novel Nuclear Factor-KappaB (NF-kB) Inhibitor, and Celecoxiv, A COX-2 Inhibitor, in a N-Nitrosobis(2-oxopropyl)amine(BOP) Model of Lung Cancer,”* Academic Surgery Congress, 2007.
86. Holcomb BA, Schmidt CM: *“Tumor Genetics and Signaling Response to Gemcitabine Correlate with Treatment Effect of Gemcitabine-based Molecular Targeting Strategies,”* AHPBA, Las Vegas, NV, April 2007.
87. Wentz SC, Schmidt CM: *MEK Targeting is effective chemoprevention of HCC in TGFalpha transgenic mice*. SSAT Plenary Annual Meeting, 2007.
88. Schmidt CM. *PGE₂ in pancreatic cyst fluid differentiates IPMN from mucinous cystadenoma and may predict degree of IPMN dysplasia*. SSAT/DDW Plenary Annual Meeting, 2007.
89. Schmidt CM, Klein PJ, Wentz SC, Hennig M, Yip-Schneider MT, Matos-Bramblia JM, Froehlich JC, *“Novel Model of Alcohol-induced Hepatocellular Carcinoma (HCC),”* RSA Annual Meeting, Chicago, IL, July 2007.
90. Schmidt CM: *“Flourinated NF-kB inhibitors for pancreatic cancer therapy”* American Chemical Society Winter Fluorine Conference, January 12, 2009
91. Schmidt CM, Wu H, Dumas RP, Agaram N, Feliciano DV, Yip-Schneider MT. *VEGF-A, A Novel and Highly Accurate Pancreatic Fluid Biomarker for Serous Pancreatic Cysts*. SSA Proceedings, 2013.
92. Waters, JA, Schmidt CM et al. *Targeted NF-kB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts*. CSA 2015.
93. Carr RA, Yip-Schneider MT, Dolejs SC, Schmidt CM. *Pancreatic cyst fluid vascular endothelial growth factor: highly accurate in combination with carcinoembryonic antigen for serous cystic neoplasm diagnosis*. WSA 2016
94. M Yip-Schneider, R Carr, H Wu, CM Schmidt. *Prostaglandin E2: a pancreatic fluid biomarker of IPMN dysplasia*. AHPBA 2017.
95. Carr RA, Yip-Schneider MT, Dolejs S, Hancock BA, Wu H, Radovich M, Schmidt CM. *Pancreatic cyst fluid VEGF-A and CEA: a highly accurate test for the diagnosis of serous cystic neoplasm*. Panc Club 2017
96. Carr RA, Yip-Schneider, et al Schmidt CM. *Pancreatic Cyst Fluid Glucose: Rapid, Inexpensive, and Accurate Diagnosis of Mucinous Pancreatic Cysts*. Oral Plenary Presentation. CSA/MSA 2017
97. Yip-Schneider MT, Carr RA, Wu H, Fan H, Liu Z, Korc M, **Schmidt CM**, Zhang J. *Circulating Leptin: Potential Predictor of IPMN Malignant Risk*. WSA 2017
98. Simpson RE, Yip-Schneider MT, Wu H, Fan H, Liu Z, Korc M, Zhang J, **Schmidt CM**. *Circulating Thrombospondin-2 enhances prediction of malignant intraductal papillary mucinous neoplasm*. MSA, July 2018 (Best Resident Paper)
99. Sims EK et al, **Schmidt CM** et al *Pro-insulin Secretion is a Persistent Feature of Type I Diabetes (T1D)*. Servier-IGIS Symposium 2019

INTERNATIONAL

100. Klein PJ, Schmidt CM: *Human Hepatocellular Carcinoma Cells Exhibit Resistance to MEK Inhibition by U0126*, International Hepato-Pancreatic-Biliary Association, Washington DC, June 2 to June 6, 2004.
101. Choi J, Schmidt CM: *Predictors of Pancreaticoenteric Anastomotic Leak or Fistula and Effect on Patient Outcomes Following Pancreaticoduodenectomy*, International Hepato-Pancreatic-Biliary Association, Washington DC, June 2 to June 6, 2004.
102. Hekmatyar SK, Schmidt CM, Babsky A, Wu H, Wentz S, Hennig ME, Miller MA, Sebolt-Leopold, JS, Bansal N: *“Monitoring of Liver Tumor Response to Treatment by MRI,”* Joint Annual Meeting ISMRM-ESMRMB, Berlin, Germany, May 19-25, 2007.

SERVICE

UNIVERSITY SERVICE

DEPARTMENT

2001-present (missed 2020)	Surgery Resident Mock Oral Boards Examiner Department of Surgery, IU School of Medicine, Indianapolis, IN
2001-present (missed 2020)	Surgery Skills Lab Instructor Department of Surgery, IU School of Medicine, Indianapolis, IN
2001-2012	Prospective Surgery Resident Interviewer Department of Surgery, IU School of Medicine, Indianapolis, IN
7/2001-2003	Active participant, Department of Surgery Chair Search Department of Surgery, IU School of Medicine, Indianapolis, IN
12/2002 – 6/2012	Founder/Director, Department of Surgery Research Forum Department of Surgery, IU School of Medicine, Indianapolis, IN
7/2002 – present	Founder/Director, Indiana University Pancreas Tissue Fluid Bank Department of Surgery, IU School of Medicine, Indianapolis, IN
7/2004 – 6/2013	Co-Director, JK Berman/Bruce White Lectureship Program Department of Surgery, IU School of Medicine, Indianapolis, IN
5/2005 – 5/2006	Director, Department of Surgery Lab Meeting Department of Surgery, IU School of Medicine, Indianapolis, IN
3/2006 – 2011	Member, Research Committee Department of Surgery, IU School of Medicine, Indianapolis, IN
7/2014 – present (missed 2020)	Professor Rounds (when formalized) Department of Surgery, IU School of Medicine, Indianapolis, IN
7/2015 – present	Member, HPB Section Committee (monthly) Department of Surgery, IU School of Medicine, Indianapolis, IN
7/2015 – present	Member, HPB Section Research Committee (monthly) Department of Surgery, IU School of Medicine, Indianapolis, IN
7/2015 – present	Member, Surgical Council (monthly, bi-monthly)

Department of Surgery, IU School of Medicine, Indianapolis, IN

2015 – present Chair, Department of Surgery Promotion and Tenure Committee, Department of Surgery, Indiana University School of Medicine, Indianapolis, IN

7/2016 – present Member, Clinical Operations Council (2016-2018 monthly-> 2019 quarterly)
Department of Surgery, IU School of Medicine, Indianapolis, IN

2016 – present HPB Surgery Resident Mock Oral Boards Examiner
Department of Surgery, IU School of Medicine, Indianapolis, IN

2017 – 2019 General Surgery Steering Committee (monthly) – ad hoc member
Department of Surgery, IU School of Medicine, Indianapolis, IN

2018 – 2019 Surgery Resident Mock Oral Boards Author (Pancreatic Questions)
Department of Surgery, IU School of Medicine, Indianapolis, IN

2020 – present Member, DEI Promotions & Tenure Task Force, IUSM, Indianapolis, IN

2020 – present Executive Steering Committee, Professional Development | Diversity | Wellness
Department of Surgery, IU School of Medicine, Indianapolis, IN

2021- present Executive Committee / Task Force to Improve OR and Clinic Efficiency (Chair-
Dr. Selzer)
Department of Surgery, IU School of Medicine, Indianapolis, IN

SCHOOL

2017 – present Member, IU School of Medicine Promotion and Tenure Committee, Indiana
University School of Medicine, Indianapolis, IN

2017 – present Member, IU School of Medicine Lecturers & Clinical Rank Faculty Promotions
Committee, Indiana University School of Medicine, Indianapolis, IN

CAMPUS

2001 - 2007 Walther Oncology, Principal Investigator

2001 - 2007 Hoosier Oncology Group, member

2001-2008 Surgical Representative, Richard L. Roudebush VA Hospital
Indiana University School of Medicine, Indianapolis, IN

12/2002- present College Mentors for Kids (a mentoring organization which pairs college students
with “at risk” elementary school aged children in structured activities centered
around community service, arts and culture and higher education. The
organization started as “Blooming Kids” in Bloomington, IN and has evolved
into College Mentors for Kids, a Regional/National organization mentoring
thousands of children annually)

- 2002-present Mentor, **IUPUI** Chapter

- 2002-2005 *Chair, Board of Trustees, Indianapolis, IN
 - 2002-2008 Trustee, College Mentors for Kids, Indianapolis, IN
 - 2008-present Benefactor, MidWest/National Initiative
- *under my leadership, annual budget went from \$200K to \$1.2M

2003 Member, ACOS Search/Screen Committee
Richard L. Roudebush VA Hospital, Indianapolis, IN

7/2003 - 2011 Member, Institutional Review Board (IRB-04)
IUPUI, Indianapolis, IN

3/2004 – 12/2008 Quality Control Coordinator, Tumor Registry
Richard L. Roudebush VA Hospital, Indianapolis, IN

5/2007 – 2016 Reviewer, IUPUI Research Support Funds Grant Committee
IUPUI, Indianapolis, IN

2018 – 2019 Member, IUPUI Faculty Promotions & Tenure Committee, IUPUI, Indianapolis,
IN

UNIVERSITY

2001-2016 Associate Member, IU Cancer Center (IUCC)

7/2001-2011 Member, IU Cancer Center (IUCC) Experimental Therapeutics Committee
Indiana University, Indianapolis, IN

4/2002 - 2005 Director, GI Oncology Research Forum
Co-Director, IUCC GI Cancer Research Program Development
Indiana University, Indianapolis, IN

12/2002 – 11/2010 Member, Pancreas Research Group
Indiana University, Indianapolis, IN

5/2003 - 2006 Member, Task Force on Improving Promotion and Tenure Committee,
Indiana University, Indianapolis, IN

4/2005 – 7/2007 Member, IUCC Hepatobiliary Research Subgroup
Indiana University, Indianapolis, IN

2005 – 2006 Member, IUCC Molecular Carcinogenesis Committee
Indiana University, Indianapolis, IN

2011 – 2017 Member, IU Simon Cancer Center (IUSCC) Tumor Microenvironment and
Metastasis Committee
Indiana University, Indianapolis, IN

7/2017 – present Member, IU Simon Cancer Center (IUSCC) Prevention and Control Committee
Indiana University, Indianapolis, IN

2017 – present Full Member, IU Simon Cancer Center (IUCC)
Indiana University, Indianapolis, IN

MEDICAL CENTER SERVICE

2011 – 2017	Robotic Operating Room Sub-Committee IU School of Medicine, Indianapolis, IN
2016 – 2019	OR Committee (monthly), IU Health University Hospital, Indianapolis, IN Member 2016-2018 Chair 2019
2016 – 2019	Critical Care Quality (monthly), IU Health University Hospital, Indianapolis, IN
2016 – 2018	VSST Steering Committee HPB Surgery (weekly), IU Health University Hospital, Indianapolis, IN
2016 – 2019	All Hands (monthly), IU Health Academic Health Center (University and Methodist Hospitals), Indianapolis, IN
2016 – 2019	Program Planning Workshop (monthly), IU Health Academic Health Center (University and Methodist Hospitals), Indianapolis, IN
2016 – 2018	Perioperative Administrative Council (monthly), IU Health System, Indianapolis, IN
2016 – present	Physician Leadership Council (monthly), IU Health Academic Health Center (University and Methodist Hospitals), Indianapolis, IN
2017 – present	Quality Data Meeting (monthly), IU Health Academic Health Center (University and Methodist Hospitals), Indianapolis, IN
2017 – 2018	RIE (HPB Surgery) Executive Sponsor (daily, weekly), IU Health University Hospital, Indianapolis, IN
2017 – 2018	Surgical Site Infection Working Group (monthly), IU Health Academic Health Center (University and Methodist Hospitals), Indianapolis, IN
2017 – present	Quality & Safety Steering Committee (monthly), IU Health Academic Health Center (University and Methodist Hospitals), Indianapolis, IN
2017– 2019	Uplift Executive Steering Committee, IU Health AHC, Indianapolis, IN
2019	Chair, OR Committee (monthly) IUH Methodist Hospital, Indianapolis, IN
2019– 2020	VSST Perioperative (weekly) IUH AAHC, Indianapolis, IN
2019– present	Chair, Triad Perioperative Committee (weekly) IUH AAHC, Indianapolis, IN
2019– present	Member, Perioperative Leadership Committee (monthly) IUH AAHC, Indianapolis, IN

2019– present	Chair, AAHC OR Committee (quarterly) IUH AAHC, Indianapolis, IN
2019– 2020	Chair, Methodist OR Cabinet (monthly) IUH Methodist Hospital, Indianapolis, IN
2019– 2020	Chair, University OR Cabinet (monthly) IUH University Hospital, Indianapolis, IN
2019– present	Chair, AAHC OR Cabinet [weekly (during COVID19 era), monthly, quarterly] IUH AAHC, Indianapolis, IN
2019– present	Co-Chair (Co-Chair, Kristen Kelley, RN), Surgical Quality/Safety Leadership Council (monthly)- less active in COVID19 era IUH AAHC, Indianapolis, IN
2019– 2020	Member, AAHC of Future (Deloitte Consultants) (monthly) IUH AAHC, Indianapolis, IN
2019– 2020	Member, AAHC of Future (Price Waterhouse Consultants) (monthly) IUH AAHC, Indianapolis, IN
2020– 2021	Member, AAHC of Future (Innova Consultants) (monthly) IUH AAHC, Indianapolis, IN
2020– present	Member, Med/Tech Physician Advisory Committee (weekly)- advises System Med/Tech Committee during COVID19 IUH AAHC, Indianapolis, IN

PROFESSIONAL SERVICE

LOCAL

1994 - 1995	<i>Co-Chairman Re-engineering Project, “Clinical Process and Care Model Redesign Committee, Johns Hopkins Hospital, Baltimore, MD</i>
1994 - 1995	<i>Member, “Steering Committee, Incentive Committee, Clinical Process Design Team,” Johns Hopkins Hospital, Baltimore, MD</i>
1994 - 1996	<i>House Staff Society Council, Representative Johns Hopkins Hospital, Baltimore, MD</i>
1995 - 1996	<i>House Staff Society Council, Treasurer Johns Hopkins Hospital, Baltimore, MD</i>

REGIONAL

2001 - present	Indiana State Chapter, American College of Surgeons <ul style="list-style-type: none"> • 2002-2009- Moderator, Presenter Indiana State Chapter, ACS Meetings • 2010- 2013 – Councilor
----------------	---

NATIONAL Editorial Board Membership

2008 – present Associate Editor, Journal of Future Medicinal Chemistry

Journal Reviewer

2002 – present Surgery
2002 – present Journal of Surgical Research
2002 – present Journal of Pharmacology and Experimental Therapeutics
2003 – present Journal of the National Cancer Institute
2004 – present Pancreatology
2005 – present Journal of Pediatric Surgery
2005 – present Annals of Surgery
2006 – present Journal of the American College of Surgeons
2006 – present Cancer Research
2010 - present World Journal of Surgery
2010 – present American Journal of Surgery

NIH Study Section Reviewer/Membership

2007 – 2008 NIDDK Digestive Disease Development Centers
Review (2007/10 Council ZDK1 GRB-G 01 1)

2011 NIH DSMB Study Section Ad Hoc Reviewer

Surgical Association/Society Leadership Positions

1996 - present Society for Surgery of the Alimentary Tract

- 2006 Program Committee (Ad Hoc)
- 2001-present Moderator and/or Presenter Annual Meeting SSAT/DDW
- 2009-2014- Research Committee

2001 - present Association for Academic Surgery

- 2001 – present- Attendance, Presenter at Annual AAS or ASC Meeting
- 2003, 2004, 2007-2010 Moderator at Annual AAS or ASC Meeting
- 2002 – present - Reviewer, AAS’s Journal of Surgical Research
- 2002 – 2004 - AAS Committee on Issues
- 2006 – 2007 - AAS Program Committee
- 2006 – 2010 - AAS Awards/Fellowships Committee
- 2008 – 2010- Chair, AAS Fund Raising Task Force (Fall Courses)
- 2007 – 2010 - AAS Institutional Representative
- 2007 – 2011 - AAS Nominating Committee
- 2007 – 2010 - AAS Executive Council
- 2007 – 2010 - AAS/SUS Core Committee Academic Surgical Congress
- 2007 – 2010 - Co-Chair, ASC Fund Raising Task Force
- 2007 – 2010 - Chair, AAS Audit Committee
- 2007 – 2010 - AAS Treasurer
- 2009 – 2010 - AAS-SUS Conflict of Interest Committee

2007 - present Association for Academic Surgery Foundation

- 2007 – 2011 - Board, Trustee
- 2007 – 2011 - Donor at Patron Level
- 2010 - 2011 Secretary-Treasurer

- 2011 – 2014 President, Chairman of BOD
*under my leadership, corpus went from \$30K to near \$1M

2006 - present

Central Surgical Association (CSA)

- 2006-2009 - Foundation Investment Committee
- 2009-2012 - Program Committee
- 2015-16 Nominating Committee
- 2016 – 19 Councilor
- 2018 Moderator, Quick Shots
- 2018 Moderator, Debate
- 2019 – 2022 Treasurer, Chair Audit Committee

2006 - 2007

Western Surgical Association (WSA)

- 2006-2007 Auditor, Treasurer's Committee
- 2018 – 2019 Auditor, Treasurer's Committee
- 2019- Discussant (multiple prior years, but did not keep track)
- 2019- Council Member
- 2019- Chair, Publications Committee
- 2020-2025 Secretary

2007 - present

Society of University Surgeons (SUS)

- 2007-2009- SUS Social and Legislative Committee
- 2010- SUS Treasurer Candidate
- 2010-2012- SUS Council (ad hoc)

2009

American Chemical Society

- 2009 Moderator, Winter Fluorine Conference, St Pete, FL

2010 - present

Midwest Surgical Association (MSA)

- 2010-2013 Councilor
- 2019 Chair, Program Committee
- 2019 Executive Council
- 2019 MSA Moderator
- 2020 Member, Program Committee
- 2020-2021 Chair, Audit Committee

2011- present

American Board of Surgery

- 2011 BOD Candidate
- 2012 Associate Examiner

2015 - present

Americas Hepatopancreaticobiliary Association

- 2015 International Relations Committee
- 2018 Discussant (multiple prior years, but did not keep track)

Company Start-ups

2011 – present

B9, LLC Incorporated (This company was founded on the mission to establish benign (“B9”) biomarkers for patients. This is a novel platform since most biomarker companies look for biomarkers of disease conditions. The company is part of the IURTC SpinUp program at IU. The company has received internal funding to support nationalization of 2 biomarker patents. In addition, the

company has submitted 2 internal grants and 1 NIH small business grant to date to support its initiatives.

- 2011- present

Founder, Chairman BOD

INTERNATIONAL

Surgical Association/Society Leadership Positions

2002 - present

Association for Academic Surgery

- 2009 – 2010 - AAS/Royal Australasian College of Surgeons Course Task Force
- 2009 – 2011 – Co-Director, Inaugural AAS/French Association of Surgery/French Academie of Surgery Course
- 2009 – present - Chairman, AAS/French Course Task Force
- 2012 - 2013 Member, AAS/German Course Task Force

2003 - present

International Hepato-Pancreato-Biliary Association

- 2009-2010 - IHPBA Program Committee (ad hoc)

2009- present

International Consensus Committee for Treatment of IPMN and MCN, member

- 2010- Speaker at IAP/JPS Joint Meeting, Fukuoka, Japan
- 2016- Guidelines Update

2020- present

Verona EBM IPMN Committee, member

- 2020- Speaker at Meeting, Verona, Italy (Virtual)
- 2020- IU Trial Selected- Dilated MPD in IPMN following Whipple

Patents

8-31-09

Materials and Methods for the Differential Diagnosis of Pancreatic Lesions
(09116)U.S.Provisional Patent Application 61/237,346;
Our Ref: 9995-0128

5-3-10

Use of Novel Alpha-methylene-gamm butyrolactones (AMGBL) to Inhibit Cancer (10059) U.S.Provisional Patent Application

PATIENT CARE/CLINICAL SERVICE *(Some areas duplicated in part from above for clarity)*

2001 - present

Programmatic Development and Directorship, IU Health Pancreatic Cyst and Cancer Early Detection Center (IU Health Pancreatic Cyst and Cancer Early Detection Center (PCC-EDC) mission is to prevent pancreatic cancer through rigorous identification, tracking and treatment of patients "at risk" for pancreatic cancer through a multidisciplinary screening clinic, registry, community outreach, education and research discovery. There are at present 4 components to Center:

- **IU Health Pancreatic Cyst and Cancer Early Detection Clinic (PCC)**- this is a multidisciplinary clinic of care providers from multiple Departments and disciplines that screens >1000 patients annually, largest such clinic in US & possibly the World

- **IU-Regenstrief Pancreatic Cyst Registry (PCR)**- uses novel informatic and natural language processing approach to identify patients “at risk” for pancreatic cancer in Indiana. Plans are to use this patented statewide program I co-developed to establish a National Pancreatic Cancer Prevention Program
 - **IU Pancreatic Tissue Fluid Bank (PTB)**- one of the most robust pancreatic disease specific tissue bank in the US which has supported multiple research projects and discoveries locally and nationally
 - **IU Pancreatic Cyst Biomarker Discovery Lab (PCL)**- performs research directed at early detection and treatment of pancreatic cancer
- In addition to the 4 components of the Center, there is a robust **Community Outreach** which involves production of a **website** which launched in 7/2011 www.pancyst.org . It also involves my involvement with the following **Indiana organizations** (Bigelow- Brand Charity Advisory Board, Pancreatic Cancer Action Network, Lustgarten Foundation, Gaston Indiana Initiative for Pancreatic Cancer Research) as Board Member, Educator, Speaker and Participant. The Pancreatic Cyst and Cancer Early Detection Center was featured on Channel 13 in 2011, Channel 6 in 2013 and Channel 8 in 2014.

7/2001 – 12/2009	Richard L. Roudebush Surgical Service, service attending 12/12 months. Responsible for inpatient service and consults. Richard L. Roudebush Surgical Clinic, service attending 12/12 months. Responsible for outpatient service and consults.
7/2001 – present	University Hospital Surgical Service, service/private attending 12/12 months. Responsible for inpatient service and consults. University Hospital Surgical Clinic, service/private attending 12/12 months. Responsible for outpatient service and consults.
7/2005 – present	Pancreaticobiliary Fellowship Attending, 12 months.
7/2006 - present	University Hospital Pancreatitis and Urgent HPB Service, 2/12 months. Responsible for inpatient service and consults.
2006 - present	Programmatic Development and Directorship, Pancreaticobiliary Robotics. This involves pioneering robotic approaches to operations, teaching residents, fellows, IU/outside faculty and giving invited talks/presentations. The program has grown to include 3 general surgery faculty. The program now seeks a dedicated fellow to support robotics and other minimally invasive pancreaticobiliary surgery. Internationally, IU was one of the first centers to initiate robotic techniques in pancreaticobiliary surgery. Nationally, IU currently is one of 5 centers in the US performing a high volume of robotic pancreaticobiliary surgery. Regionally, IU was recently designated as a center to begin using single incision robotic technology in service of our patients. For this development, I was recently featured on Channel 13 (video available on request).
7/2011 – 2013	IU West Hospital Surgical Service, service/private attending 12/12 months. Responsible for inpatient service and consults. IU West Hospital Surgical Clinic, 12/12 months. Responsible for outpatient service and consults.
7/2011- present	Pancreatic Cyst and Cancer Early Detection Center, Website Designer/Developer. This website was designed and developed by me to support the Pancreatic Cyst and Cancer Early Detection Center. The mission is to raise awareness and hope of early detection and prevention of pancreatic

cancer through research, education and treatment. It is also the mission of the Center's website to facilitate the establishment of a network of other such programs throughout the US in order to promote early detection and prevention of pancreatic cancer in patients who are identified as "at risk". At present, the website is supported solely through community funds. Industry funding has been pledged.

GRANTS/FELLOWSHIPS: SERVICE

ACTIVE

7/01 – present

Pancreatic Cyst and Cancer Early Detection Fund (Individual donations to the Pancreatic Cyst and Cancer Early Detection Center. Recent, pledged, and projected funding shown below)

2011	\$32,000
2012	\$78,000
2013	\$92,000
2014	\$150,000
2015	\$65,000
2016	\$70,000
2017	\$77,748
2018	\$139,322.66 (includes \$60K from Dr. Spitzberg)

INVITED PRESENTATIONS: SERVICE

LOCAL

- Schmidt CM: *Infectious Colitis: A Surgical Perspective*, Johns Hopkins Hospital, Resident Conference, September 2000.
- Schmidt CM: *Pathophysiology and Management of GI Bleeding*, Johns Hopkins Hospital, Resident Conference, September 2000.
- Schmidt CM: *Indications for Colostomy in Penetrating Abdominal Trauma*, Johns Hopkins Hospital, Trauma Conference, August 2000.
- Schmidt CM: *Liver Trauma: Therapeutic Options*, Johns Hopkins Hospital, Trauma Conference, March 2001.
- Schmidt CM: *Burns: Current Management and Controversies*, Johns Hopkins Hospital, Trauma Conference, May 2001.
- Schmidt CM: *"IPMN" at IU Gastrointestinal Oncology: The Multidisciplinary Approach*, Indiana University Gastrointestinal Oncology, September 16, 2005.
- Schmidt CM: *"IPMN's: The IU Experience,"*, Surgical Grand Rounds, Indiana University School of Medicine, January 31, 2007
- Schmidt CM: *IU Pancreas Tissue Fluid Bank- form and function.* Pancreas Research Group/IUCC, November 2008.
- Schmidt CM: *"Pancreatic IPMN: Biomarkers of Malignancy and Oncologic Indications for Resection"*, Wisconsin Surgical Travelers Program, Indianapolis, IN, May 5, 2008.
- Schmidt CM: *IPMN: Surgical Management.* Indianapolis, IN, June 22, 2011.
- Schmidt CM: *IPMN: Clinical and Molecular Risk Stratification.* Detroit, IN, Sept 1, 2011.
- Schmidt CM: *Pancreatic Cysts: Management in a Molecular Era.* Naperville, IL Mar 1, 2012.
- Schmidt CM: *IPMN- Evolving Treatment Strategies.* Springfield, IL March 8, 2012
- Schmidt CM: *IPMN: A New Frontier in Management.* Evansville, IN April 12, 2012.
- Schmidt CM: *IPMN-Integration of Molecular Profiling in Oncologic Risk Stratification.* Grand Rounds, IU Department of Surgery, IUSOM, May 1 2013.

16. Schmidt CM: Pancreatic Cysts: Surgery or not? IU Department of Surgery Inaugural General Surgery Post-Graduate Course, October 18, 2015.
17. Schmidt CM: Pancreatic Cysts and Cancer Early Detection Center. Cancer Summit, IU Health, April 17, 2015.
18. Schmidt CM: Pancreatic Cysts and Cancer Early Detection. IU Department of Surgery Grand Rounds, January 6, 2016
19. Schmidt CM: Pancreatic Cysts: the Basics. GI Grand Rounds, April 20, 2018
20. Schmidt CM: AAHC of Future. Surgery Grand Rounds, March 10, 2021

REGIONAL

21. Schmidt CM: *Hepatocellular Carcinoma: Treatment Advances*, Union Hospital, Terre Haute, IN, November 28, 2005.
22. Matos JM, Schmidt CM. Novel Model of Alcohol/alcoholism-induced Hepatocellular Carcinoma. Indiana American College of Surgeons Annual Meeting, Indianapolis, IN, April 25, 2008.
23. Schmidt CM: *"IPMN: Current management, controversies and barriers/opportunities to progress"*, U. Washington, Seattle, WA, May 15, 2008.
24. Schmidt CM: *"Can we prevent pancreatic cancer through rigorous surveillance of pancreatic cysts?"* Elkhart General Hospital Grand Rounds, November 19, 2008
25. Schmidt CM: *"Can we prevent pancreatic cancer through rigorous surveillance of pancreatic cysts: Current treatment and research directions?"* Bloomington Hospital Grand Rounds, February, 2009
26. Schmidt CM: *"Can we prevent pancreatic cancer through rigorous surveillance of pancreatic cysts: How much work-up is necessary?"* Ball Memorial Hospital Grand Rounds, April, 2009
27. Schmidt CM: *"Pancreatic cysts: How much work-up is necessary?"* Bluffton Regional Medical Center, Grand Rounds, Bluffton, IN, September, 2009
28. Schmidt CM: *"Pancreatic Cancer, Diagnosis and Treatment"*, Indiana Cancer Registrars Association Fall Education Conference, Plainfield, IN, November 13, 2009.
29. Schmidt CM: *"Robotic-assisted Pancreatic Surgery"*, Indiana Chapter American College of Surgeons, April 30, 2010
30. Schmidt CM: Robotic Pancreaticoduodenectomy. Indiana American College of Surgeons, April 29, 2011.
31. Schmidt CM: Robotics in General Surgery, March 25, 2014

NATIONAL

32. Schmidt CM: Invited Speaker to National/International Radio Program on *"Medical Treatment Advances,"* Pancreatic Cancer Action Network, Beverly Hills, CA, November 11 – November 14, 2004.
33. Schmidt CM: *"Total Pancreatectomy (RO Resection) Improves Survival Over Total Pancreatectomy in Isolated Neck Margin Positive Pancreatic Adenocarcinoma,"* Central Surgical Association, Chicago, IL March 8-10, 2007.
34. Baker MS, DeWitt JM, Kognkam P, Leblanc JK, Cramer HM, Howard TJ, Schmidt CM, Lillemoe KD, Pitt HA, *"Cystic Pancreatic Neuroendocrine Tumors: A Rare Entity?"* American Hepato-Schmidt CM: *"Intraductal Papillary Mucinous Neoplasms (IPMN): Factors Predicting Malignancy,"* ASA Plenary Annual Meeting, 2007.
35. Waters JA, Schmidt CM: *"CT vs. MRCP: Optimal Classification of IPMN Type and Extent,"* AHPBA, Las Vegas, NV, April 2007.
36. Zyromski NJ, Nakeeb A, Schmidt CM, Pitt HA, Lillemoe KD, Howard TJ: *"Unusual Early and Late Complications of Pancreaticoduodenectomy: Recognition is Paramount to Diagnosis,"* Poster Session, American Hepato-Pancreato-Biliary Association Annual Meeting, Las Vegas, NV, April 19-22, 2007.

37. Howard TJ, Cohen SM, Zyromski NJ, Nakeeb A, Schmidt CM, Pitt HA, Lillemoe KD: "Persistent Pancreatic Fistula Following Necrosectomy: *Long-Term Patency of Pancreaticojejunostomy is Superior to Fistulojejunostomy*," Washington DC, SSAT Annual Meeting, May 19-23, 2007.
38. Schmidt CM, Wiesenauer CA, Sitzmann JV: "*Long Term Effects on Diet after Proctocolectomy for Ulcerative Colitis*," Midwest Surgical Association, August, 2007.
39. Yancey K, Pitt HA, Wang M, Yip-Schneider MT, Sherman S, Lillemoe KD, Goggins M, Schmidt CM. "*Proteome of Normal Pancreatic Juice*". American Pancreatic Association, 2007.
40. Y Zhukov, TJ Howard, A Nakeeb, HA Pitt, KD Lillemoe, L McHenry, EL Fogel, CM Schmidt, NJ Zyromski. "*Resistant Organisms Predict Poor Outcome in Necrotizing Pancreatitis: A Plea to do no Harm*". American Pancreatic Association, 2007.
41. Lavu H, Knuth JL, Baker MS, Zyromski NJ, Schmidt CM, Nakeeb A, Howard TJ. "*Middle pancreatectomy is a technique readily incorporated into a pancreatic surgeons clinical practice*". AHPBA, 2008.
42. Brugge WR, Collier K, McGreevy K, Schmidt CM, DeWitt JD. "*Ethanol pancreatic injection of cysts: Results of a prospective, multicenter, randomized, double blinded study*". ASGE/DDW 2007.
43. Matos JM, Schmidt CM. A pilot study of perillyl alcohol in pancreatic cancer. ASC 2008.
44. Matos JM, Schmidt CM. Proteomic profiles of human hepatocellular carcinoma and adjacent non-malignant liver. ASC 2008.
45. Kooby, Gillespie, Bentrem, Nakeeb, Schmidt, Merchant, Parikh, Martin, Scoggins, Ahmad, Kim, Park, Staley, Byrd-Sellers, Wood, Hawkins. Multicenter Analysis of 667 Left Pancreatectomies: Should the Laparoscopic Approach Become Standard? American Surgical 2008.
46. A Nakeeb, A Prather, HA Pitt, A Mathur, CM Schmidt, NJ Zyromski, JA Madura, TJ Howard, KD Lillemoe. Distal Pancreatectomy in the modern era: Evolution of a procedure. Pancreas Club 2008.
47. Schmidt CM, Bilimoria KY. Predictors of Survival in 865 Patients with Acinar Cell Carcinoma of the Pancreas: Survival after Surgery compared to Ductal Adenocarcinoma. SSAT Plenary Annual Meeting 2008.
48. Matos JM, Schmidt CM. Pancreatic Acinar Cell Carcinoma: a Multi-institutional study. SSAT/DDW 2008.
49. Y Zhukov, TJ Howard, L McHenry, EL Fogel, A Nakeeb, HA Pitt, KD Lillemoe, CM Schmidt, NJ Zyromski. Yeast infection in patients with necrotizing pancreatitis may cause a rise in morbidity and mortality. SSAT/DDW, 2008.
50. Pittman J, Rawl S, Grant M, Ko C, Schmidt CM, Wendel C, Krouse R. Demographic and Clinical Factors related to Ostomy Complications and Quality of Life in Veterans with an Ostomy. WOCN Society 40th Annual Conference (June 21-25th, 2008).
51. Lopes JM, Zyromski NJ, Zhukov, Attila N, Pitt HA, Lillemoe KD, Schmidt CM, Howard TJ. Pancreatitis DVT incidence. SSAT/DDW 2008.
52. Kennedy EP, Yeo CY, Schmidt CM. Clinical Significance and Natural History of Microinvasive Pancreatic Adenocarcinomas Associated with Resected Intraductal Papillary Mucinous Neoplasms: A Multi-Institutional Experience. SSAT/DDW 2008.
53. Schmidt CM: "*IPMN*", National Pancreas Foundation Fellows Symposium, Bloomingdale, IL, April 14, 2008.
54. Schmidt CM: "*IPMN: the polyp of pancreatic cancer*" Sound Medicine Radio Broadcast, September? 2008.
55. Schmidt CM: "*IPMN: How much work-up is necessary?*" American College of Surgeons, October 13, 2008.
56. Doyle CJ, Yip-Schneider MT, Schmidt CM. Pancreatic fluid TGF- α expression in intraductal papillary mucinous neoplasms and other cystic lesions of the pancreas. ASC 2009.
57. Matos JM, Grutzmann R, Schmidt CM. Solid Pseudopapillary Neoplasms: a multi-institutional experience. ASC 2009.
58. Weber SM, Schmidt CM et al. Laparoscopic versus open left pancreatectomy: can preoperative factors indicate the safer technique? SSO 2009.

59. Cho CS, Kooby DA, Schmidt M, Nakeeb A, Bentrem D, Merchant N, Parikh AA, Martin RC III, Scoggins CR, Ahmad S, Kim HJ, Hamilton N, Hawkins W, Weber SM.. Laparoscopic versus open left pancreatectomy: can preoperative factors indicate the safer technique? Pancreas Club 2009.
60. Schmidt CM. SELDI-TOF mass spectroscopy of serum predicts hepatocellular carcinoma in patients prior to liver transplantation. SSAT/DDW 2009.
61. Al-Azzawi, Hayder H.1; Bermes, Angela M.1; Kuhlenschmidt, Heidi1; Howard, Thomas J.1; Wiebke, Eric A.1; Pitt, Henry A.1; Nakeeb, Attila1; Schmidt, C. Max1; Lillemoe, Keith D.1; Zyromski, Nicholas J.1 Colectomy in necrotizing pancreatitis portends a complex clinical course. Submitted for SSAT 2009.
62. Schmidt CM, Turrini O. Should high serum CA 19-9 levels preclude surgery in patients with resectable pancreatic head adenocarcinoma? SSAT/DDW 2009.
63. Schmidt CM: *“Resection of IPMN should be based on symptoms, cytology and cross-sectional imaging”* ASGE/DDW, May 2009.
64. Al-Haddad M, Schmidt CM et al. The Role of Pancreatic Cyst Fluid DNA Analysis in Patients' Management: Are we there yet? ASCGE/DDW Chicago, IL, June 3, 2009.
65. Turrini O, Schmidt CM. A novel risk assessment tool may predict survival benefit of elderly patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma. ACoS 2009.
66. Cho CS, Kooby DA, Schmidt M, Nakeeb A, Bentrem D, Merchant N, Parikh AA, Martin RC III, Scoggins CR, Ahmad S, Kim HJ, Hamilton N, Hawkins W, Weber SM. Laparoscopic versus open left pancreatectomy: can preoperative factors indicate the safer technique? ACoS 2009.
67. Schmidt CM. Impact of hospital volume, surgeon volume, and surgeon experience on outcomes of pancreaticoduodenectomy. Western Surgical Association, November, 10, 2009
68. Sandrasegaran K, Akisik FM, Rydberg M, Patel AA, Cramer HM, Agaram NP, Schmidt CM. The usefulness of diffusion-weighted imaging in characterization of cystic pancreatic lesions. RSNA 2009.
69. Akisik MF, Aisen AM, Sandrasegaran K, Schmidt CM, Jennings SG, Sherman S, Rydberg M. Growth rates and behavior over time of pathologically proven pancreatic side branch IPMN. RSNA 2009.
70. Kleyman S, Cardenes H, Howard T, Yu M, Burns M, Schmidt CM, Loehrer PJ, Helft P, Nakeeb A, Lillemoe KD, Chiorean EG. Is Adjuvant Gemcitabine-based Chemoradiation (GRT) Superior to Gemcitabine Alone for Resected Pancreatic Adenocarcinoma? The Indiana University Experience. ASCO 2010.
71. Pitt HA Kilbane EM, Nakeeb A, Howard TJ, Schmidt CM, Maluccio MM, Zyromski NJ, House MG, Lillemoe KD. Reducing surgical site infections in hepato-pancreato-biliary surgery. ACS-NSQIP 2010.
72. Saavedra JRA, Schmidt CM. The Role of Robotic-assisted Approach to Distal Pancreatectomy. ASC 2010
73. Doyle C, Schmidt CM. Adenosquamous carcinoma of the pancreas: a multi-institutional study. ASC 2010.
74. Doyle C, Schmidt CM. HAD Rat: A Model for Ethanol-Induced Hepatocellular Carcinoma. ASC 2010.
75. Waters JA, Schmidt CM. Increased Hepatocellular Dysplasia in Alcohol Preferring P Rat model. ASC 2010.
76. Ziegler KM, Nakeeb A, Pitt HA, Schmidt CM, Bishop SN, Moreno J, Matos JM, Zyromski NJ, House MG, Madura JA, Howard TJ, Lillemoe KD. Pancreatic Surgery: Evolution at a High Volume Center. CSA 2010.
77. Waters JA, Schmidt CM. Robotic Distal Pancreatectomy: Cost-effective? CSA 2010.
78. Schmidt CM: *“Introduction: Necrotizing Pancreatitis: Novel Minimally Invasive Strategies”*, DDW-SSAT, State of the Art Conference, May 3, 2010.

79. Al-Haddad MA, DeWitt JM, Sherman S, Schmidt CM, Juliar BE, Stuart JS, LeBlanc JK. Diagnostic accuracy of pancreatic cyst fluid tumor markers obtained by EUS-guided sampling. AGA-DDW 2010.
80. Schmidt CM, Turrini O. Preservation of Replaced or Accessory Right Hepatic Artery during Pancreaticoduodenectomy for Pancreatic Adenocarcinoma: Impact on Margin Status and Survival. SSAT-DDW, 2010.
81. Parikh P, Waters JA, Pitt HA, Aguilar-Saavedra JR, Cardenes H, Chiorean EG, Helft PR, Schmidt CM, Nakeeb A, Lillemoe KD. Ampullary carcinoma: Adjuvant chemoradiation improves survival in node-positive patients. SSAT-DDW, 2010.
82. Ball CG, Correa-Gallego C, Howard TJ, Zyromski NJ, House M, Pitt HA, Nakeeb A, Schmidt CM, Lillemoe KD. Radiation dose from CT in patients with necrotizing pancreatitis: How much is too much? SSAT-DDW, 2010.
83. Waters JA, Schmidt CM. Survival of Invasive Intraductal Papillary Mucinous Neoplasm (IPMN) and Pancreatic Adenocarcinoma Following Resection: A Multi-institutional Comparison According to AJCC Stage. ACoS, 2010.
84. Pitt HA, Kilbane EM, Nakeeb A, Howard TJ, Schmidt CM, Maluccio, Zyromski NJ, House MG, Lillemoe KD. Reducing Surgical Site Infections in Hepato-Pancreato-Biliary Surgery. ACoS 2010.
85. Horner DJ, Wendel CS, Coons SJ, Rawl SM, Grant M, Schmidt CM, Ko CY, Krouse RS. Positive Correlation of Employment and Psychological Quality of life for Veterans with Major Abdominal Surgery. AVAS 2010.
86. White PB, Wu H, Yip-Schneider MT, Schmidt CM, Ziegler ZM, Pitt HA, Swartz-Basile DA, Zyromski NJ. High-Fat Diet Hastens Mortality from Pancreatic Adenocarcinoma in Kras/Cre/p53 Mice. APA 2010.
87. Friedlin J, Schmidt CM et al. Comparing Methods for Identifying Pancreatic Cancer Patients Using Electronic Data Sources. AMIA Nov 15, 2010.
88. Chafic E, Hajj IE, DeWitt J, Sherman S, Imperiale TF, LeBlanc J, McHenry L, Schmidt CM, Al-Haddad MA. Comparison of Preoperative Cytopathology, Tumor Markers and Molecular Analysis for the Diagnosis of Mucinous Pancreatic Cysts in Patients Undergoing Surgical Resection. ACG 2010 (received the presidential award for best poster).
89. Beane JD, Nakeeb A, Pitt HA, Ziegler KM, Schmidt CM, Zyromski NJ, Howard TJ, Lillemoe KD. Splenic Preserving Distal Pancreatectomy: With or Without Vessel Preservation? Southern Surgical Association, 2010.
90. Aboudi S, Waters JA, Aguilar-Saavedra JR, Schmidt CM. Routine Closed Suction Drainage Of Pancreatic Resection In The Setting Of A Soft Pancreas: Is It Necessary? ASC 2011.
91. Meyer JE, Miller JR, Waters JA, Al-Haddad M, DeWitt J, Sherman S, Lillemoe KD, Schmidt CM. Outcome of Pancreatic Remnant Following Segmental Pancreatectomy for Non-Invasive Intraductal Papillary Mucinous Neoplasm (IPMN) American Hepato-Pancreato-Biliary Association, 2011.
92. JA Glant, JA Waters, MG House, NJ Zyromski, AJ Nakeeb, HA Pitt, KD Lillemoe, CM Schmidt. Does the Interval from Imaging to Operation affect the Rate of Occult Metastases Encountered During Operation for Pancreatic Adenocarcinoma? Central Surgical Association 2011.
93. Al-Haddad M, Schmidt CM et al. Preoperative Endoscopic Tissue Sampling of Intraductal Papillary Mucinous Neoplasms (IPMNs) with Mural Nodules (MNs). DDW 2011 (poster)
94. Miller JR, Meyer J, Waters JA, Al-Haddad M, DeWitt J, Sherman S, Lillemoe KD, Schmidt CM. Outcome of the Pancreatic Remnant Following Segmental Pancreatectomy for Non-Invasive IPMN. Indiana American College of Surgeons, April 29, 2011. Received Medical Student Scholarship Award
95. Cauley CE, Waters J, Dumas R, Meyer J, Al-Haddad M, DeWitt J, Sherman S, Lillemoe KD, Schmidt CM. Outcomes of Primary Surveillance for Intraductal Papillary Mucinous Neoplasm. Indiana American College of Surgeons, April 29, 2011. Received Medical Student Scholarship Award

96. JA Glant, CM Schmidt. Does the Interval from Imaging to Operation affect the Rate of Occult Metastases Encountered During Operation for Pancreatic Adenocarcinoma? Central Surgical Association 2011.
97. Miller JR, Schmidt CM Outcome of Pancreatic Remnant Following Segmental Pancreatectomy for Non-Invasive Intraductal Papillary Mucinous Neoplasm (IPMN) American Hepato-Pancreato-Biliary Association, 2011.
98. Cauley CE, Schmidt CM. Outcomes of Primary Surveillance for Intraductal Papillary Mucinous Neoplasm. SSAT Plenary, May 10, 2011.
99. Cauley CE, Schmidt CM. Outcomes of Primary Surveillance for Intraductal Papillary Mucinous Neoplasm. Best of DDW Plenary., May 10, 2011.
100. Al-Haddad M, Schmidt CM.. Preoperative Endoscopic Tissue Sampling of Intraductal Papillary Mucinous Neoplasms (IPMNs) with Mural Nodules (MNs). AGA/DDW 2011
101. Schmidt CM: IPMNs: Guides to Surgical Management- Past and Future. Pancreasfest, Pittsburgh PA July 28, 2011
102. Schmidt CM: IPMN: Guides to Management- Past and Future. New York Society Gastroenterology, Dec 15, 2011.
103. Ceppa EP, House MG, Pitt HA, Kilbane EM, Janitz S, Nakeeb A, Howard TJ, Schmidt CM, Maluccio MA, Zyromski NJ, Lillemoe KD.. Reducing Surgical Site Infections in Hepato-Pancreato-biliary Surgery. AHPBA 2012.
104. Ceppa EP, McCurdy RM, Kilbane M, Nakeeb A, Howard TJ, Schmidt CM, Zyromski NJ, Lillemoe KD, Pitt HA, House MG.. Does Pancreatic Stump Closure Method Influence Distal Pancreatectomy Fistula Rate. SSAT/DDW, San Diego, CA, May 21 2012.
105. Leung W, Coté GA, Tan D, Waters JA, Schmidt CM, Sherman S, Lehman GA, Fogel E, Watkins J, McHenry L, House MG. Self-expandable metallic stents do not impact on the frequency of complications related to preoperative biliary drainage or subsequent pancreatoduodenectomy. SSAT/DDW, San Diego, CA, May 21 2012
106. Schmidt CM: Is surgical intervention for cystic neoplasms being overutilized? Surgical Intervention. SSAT, San Diego, CA, May 20, 2012
107. Luz LP, Chang MC, DeWitt JM, Schmidt CM, Sherman S, LeBlanc K, Al-Haddad MA. Impact of tumor markers on compliance with current consensus guidelines for the resection of cystic pancreatic tumors. AGA/DDW, San Diego, CA, May 21, 2012
108. Al-Haddad MA, Schmidt CM, Korc M, Lang L, Skaar T. MiRNA can identify IPMN with advanced dysplasia. AGA/DDW, San Diego, CA, May 21, 2012
109. Klochan CM, Al-Haddad MA, DeWitt JM, LeBlanc JK, Cote GA, Sherman S, McHenry L, Schmidt CM, Stuart JS. Cost analysis of molecular (DNA) markers of suspected mucinous pancreatic cysts (MPC), AGA/DDW, San Diego, May 22, 2012
110. Ferries IK, House MG, Hayward TZ, Schmidt CM, Zyromski NJ, Nakeeb A, Lillemoe KD, Howard TJ, Pitt HA. Parenteral nutrition after pancreaticoduodenectomy: Who needs it?, SSAT/DDW, San Diego, May 22, 2012.
111. DeWitt JM, Al-Haddad M, Sherman S, LeBlanc J, Schmidt CM, Finkelstein S. Alterations in Cross-sectional Imaging and Cyst Fluid Genetics Following Endoscopic Ultrasound Guided Pancreatic Cyst Ablation with Ethanol and Paclitaxel. ACG 2012
112. Schmidt CM. MiRNA in biofluids: pancreatic cyst fluid. Association of Molecular Pathology Meetings, Long Beach, CA, Oct 24, 2012.
113. Lee SJ, Waters JA, Schmidt CM, Pitt HA, Zyromski NJ. Does acute pancreatitis change the natural history of IPMN? APA 2012.
114. Shaffer K, Schmidt CM et al. IPMN type but not grade of dysplasia is associated with smoking. AHPBA, 2013.
115. Schmidt CM. Genetics and Biology of IPMN/MCN. AHPBA, Feb 23, 2013.
116. Schmidt CM. Enucleation for benign pancreatic lesions- Pro. AHPBA, Feb 23, 2013.

117. Sturm E, Schmidt CM. Obesity increases malignant risk in patients with branch-duct IPMN. CSA, 2013.
118. Schmidt CM. Management of Pancreatic Cysts. Hartford Hospital, Pancreatic Cancer Symposium. Keynote Speaker March 8, 2013.
119. Barron M, Schmidt CM.. Does Preoperative Imaging Accurately Predict Main Duct Involvement in Intraductal Papillary Mucinous Neoplasm. SSAT 2013
120. Ceppa E, Schmidt CM et al. Impact of Pancreatoduodenectomy Complications on Adjuvant Therapy and Long-Term Outcomes for Pancreatic Adenocarcinoma. SSAT and, Pancreas Club, 2013
121. Chafic AE, Roch A, Schmidt CM, Al-Haddad MA, et al. Predictors of Malignancy in Branch Duct IPMN: How accurate are the 2012 International Consensus Guidelines? ACG, 2013.
122. Aggarwal A, Valsangkar N, Roch A, Chafic AE, DeWitt JM, Sherman S, LeBlanc J, McHenry L, Cote G, Imperiale TF, Schmidt CM, Al-Haddad MA. Recurrence after Surgical Resection of Branch Duct Intraductal Papillary Mucinous Neoplasms (BD-IPMNs). ACG, 2013.
123. Catalano M, Al-Haddad MA, Schmidt CM, Haddad N, Malhotra N, Mertz H, Siddiqui A, Kowalski T, Patel S, Martinez N, Lybik M, Mallat D, Karasik M, Golioto M, Linder J, Corcoran B, Ellsworth E, Jackson S, Finkelstein SD. Clinical validity of integrated molecular profiling in diagnosing pancreatic lesions: Results (N=492) of an outcomes based registry. ACG, 2013.
124. Al-Haddad MA, Schmidt CM, Catalano M, Haddad N, Malhotra N, Mertz H, Siddiqui A, Kowalski T, Patel S, Okoh E, Lybik M, Mallat D, Karasik M, Swales C, Linder J, Corcoran B, Ellsworth E, Jackson S, Finkelstein SD. The performance of second-line integrated molecular profiling compared to common, first-line testing risk features in diagnosing and predicting benign and malignant pancreatic lesions: Interim results from an outcome based registry in 422 patients. ACG, 2013.
125. Roch A, Schmidt CM. Non-operative management of main pancreatic duct involved intraductal papillary mucinous neoplasm may be indicated in select patients. WSA 2013.
126. Une prise en charge non chirurgicale des TIPMP du canal principal peut être raisonnablement offerte à des patients sélectionnés AM Roch, CM Schmidt . 115th meeting of the French Surgical Association, Paris, October 2nd 2013
127. Roch AM, Schmidt CM. Characterization of the Serum Proteome in patients with Malignant Intraductal Papillary Mucinous Neoplasm. ASC 2014.
128. Schmidt H, Kilbane EM, Turner AP, House MG, Zyromski NJ, Nakeeb A, Schmidt CM, Ceppa EP. Socioeconomic Status and Surgical Outcomes after Total Pancreatectomy. AHPBA 2014.
129. Ceppa E, Pitt H, Nakeeb A, Schmidt CM, Zyromski N, House M, Brand B, Weidert D, Lillemoe KD. Reducing readmissions following pancreatectomy: coordination of the care continuum. AHPBA 2014.
130. Roch A, Schmidt CM. International consensus guideline parameters carry unequal weight and are not cumulative in intraductal papillary mucinous neoplasm malignant risk prediction. AHPBA 2014.
131. Schmidt CM. MIS/Robotic Whipple-Viable Option in Today's Economic Climate-Pro. AHPBA 2014.
132. Schmidt CM. Robotic Pancreatectomy: SWOT, "Keys" to Success, Future Outlook. AHPBA 2014.
133. Roch A, Schmidt CM et al. Abnormal Serum Pancreatic Enzymes, but not Pancreatitis, are Associated with an Increased Risk of Malignancy in Patients with Intraductal Papillary Mucinous Neoplasms. CSA 2014.
134. Beane JD, House MG, Miller A, Nakeeb A, Schmidt CM, Ceppa E, Zyromski N, Feliciano DV, Pitt HA. Optimal management of delayed gastric emptying following pancreatectomy: an analysis of 1089 patients resected between 2007-2012. CSA 2014
135. Roch A, Schmidt CM. Intraductal Papillary Mucinous Neoplasm of the pancreas, one manifestation of a more systemic disease? Pancreas Club 2014
136. Butler, Schmidt CM, Zyromski et al. Is Antacid Therapy after Pancreatoduodenectomy Necessary? Contemporary Global Practice of Pancreatic Surgeons. SSAT 2014.
137. Schmidt HE, Schmidt CM, Ceppa E et al. Socioeconomic Status and Surgical Outcomes after Regional Pancreatectomy. SSAT 2014.

138. Schmidt CM. IU School of Medicine Video Interview. Vascular Endothelial Growth Factor, a Novel and Highly Accurate Pancreatic Fluid Biomarker for Serous Pancreatic Cysts, Indianapolis, IN 3-2014
139. Schmidt CM. WFYI Sound Medicine Radio broadcast interview “IU Health surgeon talks about new pancreatic cancer test” Indianapolis, IN 4-6-14
140. Roch A, Schmidt CM. Natural history of mixed type IPMN: Parameters predictive of progression. ASA, April 12, 2014.
141. Roch A, Schmidt CM. Extended distal pancreatectomy for pancreatic adenocarcinoma with splenic vein thrombosis and/or adjacent organ invasion. MSA, August 3, 2014.
142. Schmidt CM. IPMNs, If you don’t operate, then what. ACoS, October 28, 2014.
143. Roch A, Schmidt CM et al. Invasive mixed-type IPMN: Superior prognosis compared to invasive main-duct IPMN. CSA 2015.
144. Welsh M, Schmidt CM et al. Impact of margin status on survival in main duct involved IPMN. AHPBA 2015.
145. Springer S, Wang Y, Molin MD, Masica DL, Jiao Y, Kinde I, Blackford A, Raman SP, Wolfgang CL, Tomita T, Niknafs N, Douville C, Ptak J, Dobbyn L, Allen PJ, Klimstra DS, Schattner MA, Schmidt MC, Yip-Schneider M, Cummings OW, Brand RE, Zeh HJ, Singhi AD, Scarpa A, Salvia R, Malleo G, Zamboni G, Falconi M, Jang JY, Kim SW, Kwon W, Hong SM, Song KB, Kim SC, Swan N, Murphy J, Geoghegan J, Brugge W, Fernandez-Del Castillo C, Mino-Kenudson M, Schulick R, Edil BH, Adsay V, Paulino J, van Hooft J, Yachida S, Nara S, Hiraoka N, Yamao K, Hijioka S, van der Merwe S, Goggins M, Canto MI, Ahuja N, Hirose K, Makary M, Weiss MJ, Cameron J, Pittman M, Eshleman JR, Diaz LA Jr, Papadopoulos N, Kinzler KW, Karchin R, Hruban RH, Vogelstein B, Lennon AM: A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts. United European Gastroenterology Week (UEGW), Barcelona, October 2015 and American Pancreatic Association (APA), San Diego, CA, November 2015.
146. Roch A, Schmidt CM et al. Significance of portal vein invasion and extent of invasion in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma. SSAT 2015.
147. Roch A, Schmidt CM et al. Significance of portal vein invasion and extent of invasion in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma. Resident/Fellow SSAT 2015.
148. Roch A, Schmidt CM et al. IPMN of the pancreas, one manifestation of a more systemic disease. MidWest Surgical 2015.
149. Roch A, Schmidt CM et al. Multi-institutional study on the natural history of large-sized (>3cm) branch-duct IPMN. WSA 2015.
150. Butler J, Schmidt CM, Tector JA, et al. Silencing porcine carbohydrate genes significantly reduces human-anti-pig cytotoxicity profiles: an alternative to direct complement regulation. Short Oral at WSA 2015
151. Schmidt CM. Lesser omental space- an alternative approach to spleen-preserving robotic distal pancreatectomy. Video Presentation, WSA 2015.
152. Roch A, Ceppa EP, Tee MC, Marshall G, Morris-Stiff G, Alesidi A, Walsh M, Farnell M, Schmidt CM. Multi-institutional study on the natural history of large-sized (>3cm) branch-duct IPMN. Pancreas Club 2015.
153. Roch AM, House MG, Cioffi J, Ceppa EP, Zyromski NJ, Nakeeb A, Schmidt CM. Significance of portal vein invasion and extent of invasion in patients undergoing pancreatoduodenectomy for pancreatic adenocarcinoma. Pancreas Club 2016.
154. Springer S, Molin MD, Wang Y, Douville C, Masica DL, Blackford A, Wolfgang CL, Amini N, Allen PJ, Klimstra DS, Schattner MA, Schmidt MC, Yip-Schneider M, Cummings OW, Brugge WR, Brand RE, Zeh HJ, Singhi AD, Scarpa A, Salvia R, Malleo G, Zamboni G, Falconi M, Jang JY, Kim SW, Kwon W, Hong SM, Song KB, Kim SC, Swan N, Murphy J, Geoghegan J, Brugge W, Fernandez-Del Castillo C, Mino-Kenudson M, Schulick R, Edil BH, Adsay V, Paulino J, van Hooft J, Yachida S, Nara S, Hiraoka N, Yamao K, Hijioka S, van der Merwe S, Goggins M, Canto MI, Ahuja N, Hirose K, Makary M, Weiss MJ, Cameron J, Pittman M, Eshleman JR, Diaz LA Jr, Papadopoulos

- N, Hruban RH, Lennon AM: 597 Molecular Markers Help Define Cyst Type in the Pancreas: an International, Multicenter Study of Over 300 Cysts. Digestive Disease Week (DDW), San Diego, CA, May 2016 and United European Gastroenterology Week (UEGW), Vienna, Austria, October 2016.
155. Roch AM, Carr RA, Lancaster WP, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, Schmidt CM. Mucinous cystic neoplasm and branch duct IPMN of the pancreas: should we still treat them differently? SSA 2016
 156. R Carr, B Kiel, A Roch, E Ceppa, M House, N Zyromski, A Nakeeb, CM Schmidt. Association of pancreatic insufficiency with intraductal papillary mucinous neoplasm dysplasia. AHPBA 2017.
 157. C Schmidt II, AM Roch, RA Carr, P Bletsis, WP Lancaster, MG House, NJ Zyromski, A Nakeeb, EP Ceppa, CM Schmidt. Association of intraductal papillary mucinous neoplasm and pancreatic neuroendocrine tumors: myth or reality? AHPBA 2017.
 158. K Ramanathan, RA Carr, AM Roch, WP Lancaster, EP Ceppa, MG House, NJ Zyromski, A Nakeeb, CM Schmidt. Splenic involvement in pancreatic adenocarcinoma may carry significant clinical impact. AHPBA 2017.
 159. Roch AM, Bigelow K, Schmidt CM-II, Carr RA, Jester AL, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, Schmidt CM. Management of the undifferentiated solitary mucinous cystic lesion of the pancreas: a clinical dilemma. Panc Club 2017
 160. Roch AM, Carr RA, Lopes J, Ceppa EP, Yoder J, House MG, Nakeeb A, **Schmidt CM**, Zyromski NJ. Venous thromboembolism in necrotizing pancreatitis: an underappreciated risk. Panc Club 2017
 161. Carr RA, Roch AM, et al Schmidt CM. Cancer History: A Predictor of IPMN Subtype and Dysplastic Status? Top 5 Poster of Distinction. MSA 2017
 162. **Schmidt CM**. Evaluation and management of pancreatic cysts. ACoS 2017
 163. Simpson RE, Cockerill NJ, Yip-Schneider MT, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, Al-Haddad MA, **Schmidt CM**. DNA profile components predict malignant outcomes in select cases of intraductal papillary mucinous neoplasm with negative cytology. CSA March 2018
 164. Simpson R, Cockerill N, Yip-Schneider MT, Ceppa E, House MG, Zyromski NJ, Nakeeb A, Al-Haddad M, **Schmidt CM**. Clinical criteria for integrated molecular pathology in IPMN: less is more. AHPBA March 11, 2018.
 165. Butler J, Kays J, House MG, Nakeeb A, **Schmidt CM**, Ceppa EP, Zyromski NJ. Pancreaticoduodenectomy in the cirrhotic patient: predictors of outcome. AHPBA March, 2018
 166. Kelley KE, Fajardo AD, Strange NM, Harmon CA, Pawlecki K, Sieber M, Walke N, Fadel WF, Wooden WA, Sadowski J, Birdas TJ, Stevens LH, Rozycki GS, **Schmidt CM**. Impact of a Novel Preoperative Patient-centered Surgical Wellness Program. ASA April, 2018.
 167. Solis LM et al. Schmidt CM et al. Characterization of Immune Profiling of Pancreatic IPMN using Multiplex Immunofluorescence and Image Analysis Approaches. AACR, April 2018
 168. Springer S, Masica DL, Dal Molin M, Douville C, Thoburn CJ, Afsari B, Li L, Cohen JD, Thompson E, Allen PJ, Klimstra DS, Schattner MA, **Schmidt CM**, Yip-Schneider M, Simpson RE, Fernandez-Del Castillo C, Mino-Kenudson M, Brugge W, Brand RE, Singhi AD, Scarpa A, Lawlor R, Salvia R, Zamboni G, Hong SM, Hwang DW, Jang JY, Kwon W, Swan N, Geoghegan J, Falconi M, Crippa S, Doglioni C, Paulino J, Schulick RD, Edil BH, Park W, Yachida S, Hijioaka S, van Hooft J, He J, Weiss MJ, Burkhart R, Makary M, Canto MI, Goggins MG, Ptak J, Dobbyn L, Schaefer J, Sillman N, Popoli M, Klein AP, Tomasetti C, Karchin R, Papadopoulos N, Kinzler KW, Vogelstein B, Wolfgang CL, Hruban RH, Lennon AM. A multi-modality test to guide the management of patients with pancreatic cysts. DDW 2018
 169. Simpson RE, Ceppa EP, Wu HH, Akisik F, House MG, Zyromski NJ, Nakeeb A, Al-Haddad MA, DeWitt JM, Sherman S, **Schmidt CM**. The Dilemma of the Dilated Main Pancreatic Duct in the Distal Pancreatic Remnant After Proximal Pancreatectomy for IPMN. SSAT, May 2018
 170. Ponugoti P, et al. **Schmidt CM** et al. Gain and Loss of KRAS Mutations in Pancreatic Cyst Fluid During Prolonged Surveillance: a Natural History Study. ASGE, May 2018

171. Maatman T, et al. **Schmidt CM** et al. Necrosis Morphology does not Predict Success of Percutaneous Drain in Necrotizing Pancreatitis. SSAT, May 2018
172. Maatman T, et al. **Schmidt CM** et al. Leukocytosis after Distal Pancreatectomy and Splenectomy (DPS); a Marker of Major Complications? SSAT, May 2018
173. Simpson R, et al. **Schmidt CM** et al. Impact of Trainee Assistance on Outcomes Following Hepatectomy. SSAT, May 2018
174. Flick K, et al **Schmidt CM**. Pancreatic fluid interleukin-1B compliments prostaglandin E2 and serum CA19-9 in production of IPMN dysplasia. Oral Plenary WSA 2018.
175. Simpson RE, Fennerty ML, Colgate CL, Kilbane EM, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**. Post-Pancreatoduodenectomy Outcomes and Epidural Analgesia: A 5-Year Single Institution Experience. SSA Dec 2018
176. Birdas TJ, Rozycki GF, Dunnington GL, Stevens L, Liali V, **Schmidt CM**. "Show Me the Data": A Recipe for Quality Improvement Success in an Academic Surgical Department. SSA Dec 2018
177. Shahda S, et al. **Schmidt CM** et al. Neoadjuvant Therapy Duration and Outcome of Patients with Resectable PDAC. ASCO Jan 2019
178. Maatman T, et al Schmidt CM et al Zyromski NJ. Disconnected Pancreatic Duct Syndrome: Spectrum of Operative Management. ASC 2019.
179. Maatman T, et al Schmidt CM et al Zyromski NJ. Pancreatic Cancer Causing Necrotizing Pancreatitis: Not as Rare as you Think?. ASC 2019.
180. Maatman, et al. Schmidt CM et al. Does the Microbiology of Bactibilia Drive Postoperative Complications after Pancreatoduodenectomy. AHPBA Mar 2019.
181. Maatman, et al. Schmidt CM et al. Natural History of Disconnected Pancreatic Duct Syndrome and Necrotizing Pancreatitis: Which Operation and When? AHPBA Mar 2019.
182. Roch, et al. Schmidt CM et al. Drug Resistance in Infected Pancreatic Necrosis: Cause for Alarm. AHPBA Mar 2019.
183. Flick et al. Schmidt CM. "I will take glue with my stitches" A Comparison of skin Closure Techniques in Pancreaticoduodenectomy. AHPBA Mar 2019.
184. Roch A, et al. **Schmidt CM** et al. Can Mortality of Operative Pancreatic Debridement be Predicted Accurately? ACOS, Indiana Chapter April 2019
185. A Prospective Randomized Controlled Trial of Pancreatoduodenectomy with and without Post-anastomotic Intraperitoneal Antibiotic Irrigation. Maatman et al Schmidt CM et al House M. Trial Saline vs Irrigation. CSA 2019
186. Colon Involvement in Necrotizing Pancreatitis: Incidence, Risk Factors, and Outcomes. SSAT/DDW 2019
187. Simpson R, et al **Schmidt CM**. Low risk, low reward: a critical look at secretin-induced duodenal aspirate of pancreatic juice (SIDA). Poster SSAT/DDW 2019
188. Simpson R, et al **Schmidt CM**. DNA profiling of main pancreatic duct fluid: a worthwhile endeavor. Poster SSAT/DDW 2019
189. Flick K, et al, Schmidt CM et al, House MG. Can regional lymph node metastases from pancreatic cancer be predicted with cross-sectional imaging? Poster SSAT/DDW 2019
190. Roch et al **Schmidt CM** et al Zyromski NJ. the role and dangers of TPN after pancreatoduodenectomy. Poster SSAT/DDW 2019
191. Flick K, et al, Schmidt CM et al, House MG. Less is more when it comes to hepatobiliary scintigraphy for gall bladder dyskinesia: milkshakes save hundreds of dollars. Oral quick shot SSAT/DDW 2019
192. DePeralta D, Soufi M et al **Schmidt CM**. Novel preoperative patient-centered surgical wellness program impacts length of stay following pancreatectomy. Quick Shot Oral SSAT/DDW 2019
193. Vollmer C, Trudeau M, et al **Schmidt CM**, et al. Pancreatoduodenectomy following Roux-en-y gastric bypass: operative considerations and outcomes. Plenary SSAT/DDW 2019
194. Rahal M, et al, Schmidt CM et al Al-Haddad M. Serial EUS-guided FNA in pancreatic cystic neoplasms: a natural history study of Kras analysis in cyst fluid ASGE/DDW 2019

195. Rahal M, et al, Schmidt CM et al Al-Haddad M. Performance characteristics of DNA analysis in the evaluation of mucinous pancreatic cysts. ASGE/DDW 2019
196. Flick K, et al **Schmidt CM**. Pancreatic fluid interleukin-1B compliments prostaglandin E2 and serum CA19-9 in production of IPMN dysplasia. Panc Club 2019
197. Flick et al. **Schmidt CM**. “I will take glue with my stitches” A Comparison of skin Closure Techniques in Pancreaticoduodenectomy. Panc Club 2019
198. **Schmidt CM**. Evaluation and Management of Pancreatic Cysts. Am College of Surgeons 10-29-19
199. Simpson RE, Fennerty ML, Flick KF, Colgate CL, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**. Two open Whipples a day: Excessive or efficient. MSA 2019
200. Yip-Schneider MT, Soufi M, Carr RA, Flick KF, Wu H, Colgate CL, **Schmidt CM**. Performance of candidate urinary biomarkers for pancreatic cancer - Correlation with pancreatic cyst malignant progression? MSA 2019
201. Maatman TK, Westfall-Snyder JA, Nicolas ME, Yee EJ, Ceppa EP, House MG, Nakeeb A, **Schmidt CM**, Zyromski NJ, The Morbidity of C. Difficile in Necrotizing Pancreatitis. MSA 2019
202. Flick KF, Yip-Schneider MT, Sublette CM, Simpson RE, Colgate CL, Wu H, Soufi M, Dewitt JM, Mosley AL, Ceppa EP, Zhang J, **Schmidt CM**. A Quantitative Global Proteomics Approach Identifies Candidate Urinary Biomarkers That Correlate With Intraductal Papillary Mucinous Neoplasm Dysplasia. WSA 2019
203. Dirks RC, Burney HN, Anjanappa M, Sandusky GE, Hao Y, Liu Y, **Schmidt MC**, Nakshatri H. Breast Heterogeneity: Obstacles to Developing Universal Biomarkers of Breast Cancer Initiation and Progression. WSA 2019
204. Flick K, Sublette CM, Colgate CL, Yip-Schneider MT, Soufi M, Ceppa EP, Zyromski NJ, Nakeeb A, House MG, Schmidt CM: Impact of Social Determinants on Length of Stay Following Pancreaticoduodenectomy. Academic Surgical Congress, February 2020
205. Roch, A; Ceppa EP; **Schmidt CM** et al. Patients with deleterious germline mutations: a heterogeneous population for pancreatic cancer screening? AHPBA 2020- Steve Sotsky Award Recipient
206. Maatman TK, Westfall-Snyder JA, Ceppa EP, House MG, Nakeeb A, Nguyen TK, **Schmidt CM**, Zyromski NJ. Necrotizing Pancreatitis from Hypertriglyceridemia: More Severe Disease? AHPBA 2020
207. Maatman TK, McGuire SP, Lewellen KA, McGreevy KA, Ceppa EP, House MG, Nakeeb A, Nguyen TK, **Schmidt CM**, Zyromski NJ. Prospective Analysis of the Mechanisms Underlying Ineffective Deep Vein Thrombosis Prophylaxis in Necrotizing Pancreatitis. ACoS 2020
208. Flick K, **Schmidt CM** et al. Impact of mental health on surgical outcomes in pancreatectomy: an unrecognized social determinant of health. ACoS 2020.
209. Birdas T, Kelley K, **Schmidt CM** et al. Using a modified Delphi method to engage providers in ERAS deployment. ACoS 2020.
210. Flick KF, **Schmidt CM**, Colgate CL, Yip-Schneider MT, Sublette CM, Maatman TK, Soufi M, Ceppa EP, House MG, Zyromski NJ, Nakeeb A. Preoperative Nomogram Predicts Non-home Discharge in Patients Undergoing Pancreatoduodenectomy. AHPBA 2020.
211. Maatman TK, Ceppa EP, Fogel EL, Easler JJ, Gromski MA, House MG, Nakeeb A, **Schmidt CM**, Sherman S, Zyromski NJ. Biliary Stricture after Necrotizing Pancreatitis: An Underappreciated Challenge. SSAT 2020.
212. Maatman TK, Loncharich AJ, Flick KF, Simpson RE, Ceppa EP, Nakeeb A, Nguyen TK, **Schmidt CM**, Zyromski NJ, House MG. Transient Biliary Fistula After Pancreatoduodenectomy Increases Risk of Biliary Anastomotic Stricture. SSAT 2020.
213. Yee EJ, Al-Temimi MH, Flick KF, Kilbane EM, Nguyen TK, Zyromski NJ, **Schmidt CM**, Nakeeb A, House MG, Ceppa EP. Use of primary surgical drains in synchronous resection for colorectal liver metastases: a NSQIP analysis of current practice paradigm. SSAT 2020.

214. Soufi M, Al-Temimi M, Nguyen TK, House MG, Zyromski NJ, **Schmidt CM**, Nakeeb A, Ceppa EP. Friend or foe? Feeding tube placement at the time of pancreatoduodenectomy: propensity score case-matched analysis. SSAT 2020.
215. Maatman TK, McGuire SP, Lewellen KA, McGreevy KA, Ceppa EP, House MG, Nakeeb A, Nguyen TK, **Schmidt CM**, Zyromski NJ. Prospective Analysis of the Mechanisms Underlying Ineffective Deep Vein Thrombosis Prophylaxis in Necrotizing Pancreatitis. Pancreas Club 2020
216. Flick KF, Al-Temimi MH, Maatman TK, Sublette CM, Swensson JK, Nakeeb A, Ceppa EP, Nguyen TK, **Schmidt CM**, Zyromski NJ, Tann MA, House MG. Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After Pancreatoduodenectomy. Pancreas Club 2020.
217. Maatman TK, Loncharich AJ, Flick KF, Simpson RE, Ceppa EP, Nakeeb A, Nguyen TK, **Schmidt CM**, Zyromski NJ, House MG. Transient Biliary Fistula After Pancreatoduodenectomy Increases Risk of Biliary Anastomotic Stricture. Pancreas Club 2020.
218. Maatman TK, Westfall-Snyder JA, Ceppa EP, House MG, Nakeeb A, Nguyen TK, **Schmidt CM**, Zyromski NJ. Necrotizing Pancreatitis from Hypertriglyceridemia: More Severe Disease? Pancreas Club 2020
219. Maatman TK, McGreevy KA, Sood AJ, Ceppa EP, House MG, Nakeeb A, **Schmidt CM**, Nguyen TK, Zyromski NJ. Improved Outpatient Communication Decreases Unplanned Readmission in Necrotizing Pancreatitis. Pancreas Club 2020
220. Flick K, Sublette CM, Colgate CL, Yip-Schneider MT, Soufi M, Ceppa EP, Zyromski NJ, Nakeeb A, House MG, Schmidt CM: Impact of Social Determinants on Length of Stay Following Pancreaticoduodenectomy. Pancreas Club 2020
221. Maatman TK, Westfall-Snyder JA, Nicolas ME, Yee EJ, Ceppa EP, House MG, Nakeeb A, **Schmidt CM**, Zyromski NJ, The Morbidity of C. Difficile in Necrotizing Pancreatitis. Pancreas Club 2020
222. Flick KF, Soufi M, Yip-Schneider MT, Simpson RE, Colgate CL, Nguyen TK, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**. Routine Gastric Decompression after Pancreatoduodenectomy: Treating the Surgeon? ACOS 2020
223. McGuire SP, Maatman TK, Keller SL, Ceppa EP, House MG, Nakeeb A, Nguyen TK, **Schmidt CM**, Zyromski NJ. Early postoperative serum hyperamylasemia: Harbinger of morbidity hiding in plain sight? ASC 2021
224. Maatman TK, McGuire SP, Flick KF, Madison MK, Al-Haddad MA, Bick BL, Ceppa EP, DeWitt JM, Easler JJ, Fogel EL, Gromski MA, House MG, Lehman GA, Nakeeb A, **Schmidt CM**, Sherman S, Watkins JL, Zyromski NJ. Outcomes in Endoscopic and Operative Transgastric Pancreatic Debridement. ASA 2021
225. Schmidt CM. Pancreatic Cysts, When to Resect? SIU Surgery Grand Rounds, May 13, 2021.
226. Nguyen T, Kledzik M, Helft P, Ceppa E, Nakeeb A, Schmidt CM, Zyromski NJ, House M. Genetic Profiling of Goblet Cell Carcinoid of the Appendix Compared to Appendiceal Adenocarcinoma. CSA 2021.
227. Soufi M, Ceppa DP, Flick KF, Blackwell MM, Muraruc R, Nguyen T, Schmidt CM, Nakeeb A, House MG, Ceppa EP. Investigating the Incidence, Impact and Severity of Pulmonary Complications After Hepatectomy: A Single Institutional Experience. CSA 2021
228. McGuire S, Zyromski N et al **Schmidt CM**. Obesity Worsens Local and Systemic Complications of Necrotizing Pancreatitis and Prolongs Disease Course. SSAT 2021.
229. Allen S, Zyromski N et al **Schmidt CM**. Pancreatic Tail Volumetrics: A Novel Approach for Surgical Decision-Making in Disconnected Pancreatic Duct Syndrome. SSAT 2021.
230. Kone L, Pollini T, Brugge W, Fernandez-del Castillo C, Winter J, Yeo CJ, Hackert T, Buchler MW, Roggin K, Schmidt CM, Yip- Schneider MT, Salvia R, Bassi C, Chlipala G, and Maker AV: A novel microfluidic-based assay to determine high-risk pancreatic cysts for surgery utilizing pancreatic cyst fluid: An international multicenter study. AHPBA (August) 2021

231. Allen S, Soufi M, Allison H, Nguyen T, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**. Proximal versus distal resection in adenocarcinoma of the pancreatic neck: does it matter. AHPBA (August) 2021
232. Bajpai S, Zyromski NJ, McGuire S, et al **Schmidt CM**. Renal Failure in Necrotizing Pancreatitis: incidence, risk, and increased mortality. AHPBA (August) 2021
233. Zyromski NJ, McGuire S, et al **Schmidt CM**. Splanchnic Venous Thrombosis in Necrotizing Pancreatitis: Common, Heterogenous, and Deadly. AHPBA (August) 2021
234. Sans M, Stephens B, Rajapakshe K, Yip-Schneider MT, Schmidt CM, Hurd M, Fahrman J, Hanash S, Guerrero P, Maitra A: Investigating Molecular Underpinnings of Neoplastic Progression in Pancreatic Cysts using Spatial Transcriptomics. APA 2021
235. Soufi M, Ceppa EP et al Schmidt CM. Diuresis does make a difference in Major Hepatectomy. WSA 2021.
236. Kim RC, Roch AM, Ceppa EP, Nakeeb A, Schmidt CM, Zyromski NJ, House MG, Nguyen TK. Effect of the SARS-CoV-2 pandemic on the experience and outcomes of patients who underwent resection for pancreatic cancer at a high-volume tertiary care center. ACoS 2021
237. Sean P. McGuire, Thomas K. Maatman, et al. Eugene P. Ceppa, Michael G. House, Attila Nakeeb, Trang K. Nguyen, **Schmidt CM**, Nicholas J. Zyromski. Contemporary Intervention in Necrotizing Pancreatitis: Improved Understanding Changing Practice. ACoS 2021
238. Sean P. McGuire, Thomas K. Maatman, et al. Eugene P. Ceppa, Michael G. House, Attila Nakeeb, Trang K. Nguyen, **Schmidt CM**, Nicholas J. Zyromski. Primary vs. Salvage Operative Pancreatic Debridement: Discrete Interventions for Unique Populations. ACoS 2021
239. Roch AM, Allen S, Kim R, Ceppa EP, Nakeeb A, Schmidt CM, Zyromski NJ, Nguyen TK, House MG. Updated TNM Classification For Pancreatic Cancer: More Practical, But Room For Improvement. IHPBA 2022
240. McGuire S, Zyromski NJ. Operative Pancreas Debridement in 2021: Who and When. IHPBA 2022
241. Rachel C. Kim, MD, Alexandra M. Roch, MD, Sean McGuire, MD, Eugene P. Ceppa, MD, Trang K. Nguyen, MD, Nicholas J. Zyromski, MD, Attila Nakeeb, MD, Michael G. House, MD, C. Max Schmidt, MD, PhD, MBA. Pancreatic fistula after pancreatectomy – what else can we consider other than drain amylase in the early postoperative period? IHPBA 2022

INTERNATIONAL

242. Waters JA, Schmidt CM. Invasive IPMN: Adjuvant therapy and treatment of recurrence. IHPBA 2010
243. Turrini O, Schmidt CM.. Side-branch IPMN of the pancreatic head/uncinate: resection or enucleation? IHPBA 2010
244. Al-Haddad, M, Friedlin, J, Kesterson, J, Waters, JA, Aguilar-Saavedra, JR, Schmidt, CM. Natural language processing for the development of a clinical registry: a validation study in IPMN. IHPBA 2010.
245. Aguilar-Saavedra, JR, Waters, JA, Schmidt, CM. Natural language processing for the development of a clinical registry: a validation study in IPMN. IHPBA 2010.
246. Aguilar-Saavedra JR, Schmidt CM. Side-branch IPMN of the pancreatic head/uncinate: resection or enucleation? IHPBA 2010
247. Schmidt CM: *“Intraductal papillary mucinous neoplasm (IPMN): an atypical pancreatic ductal adenocarcinoma”*, Annual Pancreatic Cancer Symposium, September 25, 2009, Marseille, Fr
248. Schmidt CM: *“Robotic distal pancreatectomy: Superior outcomes? Cost effective?”*, International Hepato-Pancreatico- Biliary Association, Buenos Aires, Argentina, April 20, 2010.
249. Schmidt CM: *“A Debate: Branch Duct IPMN, the Case for Surgery”*, International Hepato-Pancreatico- Biliary Association, Buenos Aires, Argentina, April 21, 2010
250. Schmidt CM: *“IPMN vs MCN, other cysts: Role of Cyst Fluid Analysis.* Joint Meeting of IAP/JPS, Fukuoka, Japan, July 12 2010

251. Schmidt CM: *"IPMN Surveillance-How, How Often, Why?"* Joint Meeting of IAP/JPS, Fukuoka, Japan, July 12 2010
252. Ball C.G., Correa-Gallego JC, Howard TJ, Zyromski N, House MG, Pitt HA, Nakeeb A, **Schmidt CM** & Lillemoe KD. Damage control principles for hemorrhaging patients undergoing operative debridement for necrotizing pancreatitis. 9th Congress of the European-African Hepato-Pancreato-Biliary Association, Cape Town, South Africa, 2011.
253. Schmidt CM. IPMN: Guides to management: past, present, future. IHPBA, Paris, Fr 2012.
254. Augilar-Saavedra J, Schmidt CM. Molecular Targeted NF-kB Suppression Inhibits Gemcitabine Resistance in Human Pancreatic Tumor Cells In vitro and In vivo. IHPBA, Paris, Fr 2012.
255. Roch A, Schmidt CM. Automated pancreatic cyst screening using natural language processing:a new tool in pancreatic cancer early detection. IHPBA 2014
256. Mehrabi S, Schmidt CM et al. Identification of Patients with Family History of Pancreatic Cancer - Investigation of an NLP system Portability Med Info Meeting 2015

PUBLICATIONS

TEACHING: REFEREED

TEACHING: NON-REFEREED

Books

1. **Schmidt CM:** The Role of GI, Gs and Gq-protein linked MAPK Signaling in the Growth Regulation of Human and Experimental Hepatocellular Carcinoma, UMI Publishers, April 1998.

Book Chapters and Reviews

2. **Schmidt CM:** Informed Consent in The Johns Hopkins Manual of Common Surgical Procedures, Chen et al, editors, Williams and Wilkins 1996.
3. **Schmidt CM:** Lower GI Bleed, Lillemoe KD and Schulick RD (editors): New York, NY 2004; PocketMedicine.com.
4. Wiesenauer C, **Schmidt CM:** “Adrenal Gland,” in Surgery Review Illustrated, Editors; Tevar AD, Azuaje RE, Micon LT, McGraw-Hill Publishers 2004, Chapter 17; pp 423-427.
5. Wiesenauer C, **Schmidt CM:** “Stomach,” in Surgery Review Illustrated, Editors: Tevar AD, Azuaje RE, Micon LT, McGraw-Hill Publishers 2004, Chapter 22; pp 521-528.
6. Cardenes HR, Chiorean EG, DeWitt J, **Schmidt CM,** Loehrer PJ: Locally Advanced Pancreatic Cancer: Current Therapeutic Approach: The Oncologist, 2006; 11:612-623.
7. Waters J, **Schmidt CM:** IPMN- When to Resect? Adv Surg. 2008;42:87-108. Review.
8. **Schmidt CM,** Lillemoe K: “Infections in Hepatic, Biliary and Pancreatic Surgery,” in Surgery of the Liver, Biliary Tract and Pancreas, 4th Edition, Editors: Blumgart LH, DeMatteo RP, Chapman WC, et al, Elsevier Publishers 2007; Chapter 10; pp125-135.
9. Waters J, **Schmidt CM:** Lower GI Bleed, Lillemoe KD and Schulick RD (editors): New York, NY 2009; PocketMedicine.com
10. Waters J, **Schmidt CM:** Pancreatic Cystic Lesions, Lillemoe KD and Schulick RD (editors): New York, NY 2009; PocketMedicine.com.
11. **Schmidt CM,** Lillemoe KL. “Intraductal Papillary Mucinous Neoplasms of the Pancreas”. Current Surgical Therapy 2010.
12. Ball C, **Schmidt CM,** Lillemoe K: “Infections in Hepatic, Biliary and Pancreatic Surgery,” in Surgery of the Liver, Biliary Tract and Pancreas, 5th Edition, Editors: Blumgart LH, DeMatteo RP, Chapman WC, et al, Elsevier Publishers in press 2010-11.
13. **Schmidt CM:** “Reviewing the Literature/Developing a Hypothesis, Study Design” Success in Academic Surgery: Part 1, 1st Edition, Editors: Chen H, Kao L, Springer Science+Business Media, LLC 2011.
14. Waters JA, **Schmidt CM:** “Incidental Pancreatic Cyst” in Clinical Scenarios in General Surgery: 1st Edition, Editors: Sonnenday C, Dimick J. 2012

15. Brandon-Warner E, Schrum LW, **Schmidt CM**, McKillop IH. “Rodent Models of Alcoholic Liver Disease: Of Mice and Men. *Alcohol*. 2012 Dec;46(8):715-25.
16. **Schmidt CM**. Pancreatic cyst cytology: Optimization of cancer risk profiling. *Cancer Cytopathol*. 2013 Jan;121(1):2-3.
17. **Schmidt CM**, Gibbs H, Torbeck L, Dunnington G. The Business and Finance of Surgical Education. *Success in Academic Surgery: Part 2, 1st Edition*, Editors: Chen etc. Springer Science+Business Media, LLC 2013.
18. Parikh JA, **Schmidt CM**. Enucleation of Cystic Neoplasia. *Pancreatic Cancer, Cystic Neoplasms and Endocrine Tumors*. Wiley Blackwell Publisher 2014
19. Waters JA, **Schmidt CM**. Pancreatic Cysts including IPMN. *Handbook of Hepato-Pancreato-Biliary Surgery*. Editor: Nicholas J. Zyromski. Wolters Kluwer Publisher 2014.
20. Parikh JA, Ceppa E, **Schmidt CM**. Minimally Invasive and Robotic HJ. In Press 2015 Editor: Hughes
21. Roch A, **Schmidt CM**. Pancreatic Cyst. In Press 2016 Editors: Lillemoe, House
22. Carr R, **Schmidt CM**. Reviewing the Literature, Developing a Hypothesis, Study Design. In Press *Success in Academic Surgery: Part 1, 2nd Edition*, Editors: Chen H, Kao L, Springer Science+Business Media, LLC 2015-6 in press 2016
23. Carr R., **Schmidt CM**, Pitt HA. Surgical Treatment of Cystic Neoplasm. *The Pancreas, 3rd Edition*, Editors: Beger, Warshaw, Hruban, Buechler, Lerch, Neoptolemos, Shimosegawa, Whitcomb, Publisher NN, Development Editor – Medical Division, Wiley–Blackwell in press 2016.
24. Roch A, **Schmidt CM**. Management of Mixed-Type Intraductal Papillary Mucinous Neoplasm. *Adv Surg*. 2016 Sep;50(1):1-15. doi: 10.1016/j.yasu.2016.03.001. Epub 2016 Jul 9.
25. **Obeng-Gyasi S, Schmidt CM**. The Business and Finance of Surgical Education. *Success in Academic Surgery: Developing a Career in Surgical Education, 2nd Ed* (Editors: Pugh CM & Sippel RS) Springer Science+Business Media, LLC 2019
26. Ceppa E, **Schmidt CM**. Minimally Invasive Choledochojejunostomy. In Press 2021 Editor: Hughes

Audio-Visual Publications

27. Lillemoe K, **Schmidt CM**. Surgical Treatment of IPMN. *American College of Surgeons Cine-Clinics I Pancreatic (Disc 2)*, 2007.
28. **Schmidt CM**, Waters JA. Robotic Pancreaticoduodenectomy. *SAGES Scientific Session. Video Presentation*. 2011 (ID 34112)

RESEARCH/CREATIVE ACTIVITY: REFEREED

29. **Schmidt CM**, McKillop IH, Cahill PA, Sitzmann JV: Alterations in Guanine Nucleotide Regulatory Protein Expression and Activity in Human Hepatocellular Carcinoma, *Hepatology* 1997; 26:1189-1194.
30. **Schmidt CM**, McKillop IH, Cahill PA, Sitzmann JV: Increased MAPK Expression and Activity in Primary Human Hepatocellular Carcinoma, *Bioch Biophys Res Comm* 1997; 236(1): 54-58.
31. McKillop IH, **Schmidt CM**, Cahill PA, Sitzmann JV: Altered Expression of Mitogen-activated Protein Kinases in a Rat Model of Experimental Hepatocellular Carcinoma, *Hepatology* 1997; 26(6): 1484-1491.
32. **Schmidt CM**, McKillop IH, Cahill PA, Sitzmann JV: The Role of Adenylyl Cyclase Linked MAPK Signaling in the Regulation of Human Hepatocellular Carcinoma, *Surg Forum* 1998; X(477): 1-3.
33. **Schmidt CM**, McKillop IH, Cahill PA, Sitzmann JV: Altered Gq/G11 Guanine Nucleotide Regulatory Protein Expression in a Rat Model of Hepatocellular Carcinoma: Role in Mitogenesis. *Hepatology* 1999; 29(2): 371-378.
34. McKillop IH, Vyas N, **Schmidt CM**, Cahill PA, Sitzmann JV: Enhanced Gi-protein-mediated Mitogenesis following Chronic Ethanol Exposure in a Rat Model of Experimental Hepatocellular Carcinoma, *Hepatology* 1999; 29(2): 412-420.
35. **Schmidt CM**, McKillop IH, Cahill PA, Sitzmann JV: The Role of cAMP-MAPK Signalling in the Regulation of Human Hepatocellular Carcinoma Growth In Vitro, *Eur J Gastro Hep* 1999; 11(12): 1393-1399.
36. McKillop IH, **Schmidt CM**, Cahill PA, Sitzmann JV: Inhibitory Guanine Nucleotide Regulatory Protein Activation of Mitogen-activated Protein Kinase in Experimental Hepatocellular Carcinoma In Vitro. *Eur J Gastro Hep* 1999; 11(7): 761-768.
37. **Schmidt CM**, Wang Y, Wiesenauer C: Novel Combination of Cyclooxygenase-2 and MEK Inhibitors in Human Hepatocellular Carcinoma Provides a Synergistic Increase in Apoptosis, *J Gastrointest Surg* 2003; 7(8): 1024-1033.
38. Yip-Schneider MT, Wiesenauer CA, **Schmidt CM**: Inhibition of the Phosphatidylinositol 3'-kinase Signaling Pathway Increases the Responsiveness of Pancreatic Carcinoma Cells to Sulindac, *J Gastrointest Surg* 2003; 7(3): 354-363. (Top 5 most cited articles by Journal in 2003).
39. Yip-Schneider MT, **Schmidt CM**: MEK Inhibition of Pancreatic Carcinoma Cells by U0126 and its Effect in Combination with Sulindac, *Pancreas* 2003; 27(4): 337-344.
40. Wiesenauer CA, Yip-Schneider MT, Wang Y, **Schmidt CM**: Multiple Anticancer Effects of Blocking MEK-ERK Signaling in Hepatocellular Carcinoma, *J Am College of Surg* 2004; 198(3): 410-421.
41. Yip-Schneider MT, Nakshatri H, Sweeney CJ, Marshall MS, Wiebke EA, **Schmidt CM**: Parthenolide and Sulindac Cooperate to Mediate Growth Suppression and Inhibit the Nuclear Factor-kappa B Pathway in Pancreatic Carcinoma Cells, *Mol Cancer Ther* 2005; 4(4): 587-594.
42. Eppstein AC, Sandoval JA, Klein PJ, Woodruff HA, Grosfeld JL, Hickey RJ, Malkas LH, **Schmidt CM**: Differential Sensitivity of Chemoresistant Neuroblastoma Subtypes to MAPK-Targeted Treatment Correlates with ERK, p53 Expression and Signaling Response to U0126, *J Pediatr Surgery*, 2006; 41:252-259.

43. **Schmidt CM**, Klein PJ, Wiesenauer CA, Choi JN, Gage EA, Yip-Schneider MT, Wiebke EA, Wang Y, Omer C, Sebolt-Leopold JS: The Effects of a Novel MEK PD184161 on MEK-ERK Signaling and Growth in Human Liver Cancer, *Neoplasia*, 2006; Jan 8:1-8.
44. Sandoval J, **Schmidt CM**. Proteomic Analysis of Neuroblastoma Subtypes in Response to MAPK Inhibition: Profiling Multiple Targets of Cancer Kinase Signaling, 2006; *J Surg Res*, 134(1):61-7.
45. Ralstin MC, Gage EA, Yip-Schneider MT, Klein PJ, Wiebke EA, **Schmidt CM**: Parthenolide Cooperates with NS398 to Inhibit Growth of Human Hepatocellular Carcinoma Cells Through Effects on Apoptosis and G0/G1 Cell Cycle Arrest, *Mol Cancer Res*, 2006; 4(6): 387-399.
46. **Schmidt CM**, Crowell PL, Yip-Schneider MT, Savage JJ, Hertzler DA, Cummings WO: Cyclooxygenase-2-Expression Throughout Hamster and Human Pancreatic Neoplasia, *Neoplasia*, 2006; 8(6): 437- 445.
47. Holcomb B, Yip-Schneider M, **Schmidt CM**: The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy. *Pancreas*. 2008 Apr;36(3):225-35. Review. *featured on the cover* of *Pancreas* April 2008 Vol 36 Issue 3.
48. Vegeler R, Yip-Schneider MT, **Schmidt CM**: Effect of Targeting COX-2 and NF-kB with Celecoxib and a Novel NF-kB Inhibitor, LC-1, in a Hamster Model of Lung Adenocarcinoma. *J Surg Res*. 2007 Nov;143(1):169-76.
49. Yip-Schneider MT, Wu H, Ralstin M, Yiannoutsos C, Crooks PA, Neelakantan S, Noble S, Nakshatri H, Sweeney CJ, **Schmidt CM**: Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo, 2007; *Mol Cancer Ther*. 2007 Jun;6(6):1736-44. (Designated as a "Featured Article" of *Mol Cancer Ther Journal*).
50. **Schmidt CM**, Yip-Schneider MT, Lillemoe KD: PGE₂ in Pancreatic Cyst Fluid Helps Differentiate IPMN from MCN and Predict IPMN Dysplasia. *J Gastrointest Surg*. 2008 Feb;12(2):243-9.
51. Holcomb BH, **Schmidt CM**: Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies *J Gastrointest Surg*. 2008 Feb;12(2):288-96.
52. Wentz SC, Wu H, Yip-Schneider MT, Hennig M, Klein PJ, Sebolt-Leopold J, **Schmidt CM**. Targeting MEK is effective chemoprevention of hepatocellular carcinoma in TGF- α -transgenic mice. *J Gastrointest Surg*. 2008 Jan;12(1):30-7.
53. J Choi, F Albertin, CA Wiesenauer, MT Yip-Schneider, E Gage, PJ Klein, KD Lillemoe, **CM Schmidt**. Doxorubicin Effect on MEK-ERK Signaling Predicts its Efficacy in HCC. *J Surg Res*. 2008 Dec;150(2):219-26.
54. Yip-Schneider, MT, **Schmidt CM**. Effect of celecoxib and the novel anti-cancer agent dimethylamino-parthenolide in a developmental model of pancreatic cancer. *Pancreas*. 2008 Oct;37(3):e45-53.

55. Matos JM, Witzmann F, Cummings OW, **Schmidt CM**. A Pilot Study of Proteomic Profiles of Human Hepatocellular Carcinoma in the United States. *J Surg Res*. 2009 Aug;155(2):237-43. Epub 2008 Jul 16.
56. Hennig M, Yip-Schneider MT, Klein P, Wentz S, Matos JM, Doyle C, Choi J, Wu H, O'Mara A, Menze A, Noble S, McKillop IH, **Schmidt CM**. Ethanol Promotes TGF α -MEK-ERK Dependent Growth in Human Hepatocellular Carcinoma *Surg Res*. 2009 Jun 15;154(2):187-95. Epub 2008 Dec 13.
57. Wentz SC, Yip-Schneider MT, Gage EA, Saxena R, Badve S, **Schmidt CM**. Sulindac prevents carcinogen-induced intrahepatic cholangiocarcinoma formation in vivo. *J Surg Res*. 2008 Nov 7. [Epub ahead of print]
58. Ramachandran PV, Yip-Schneider MT, **Schmidt CM**. Natural and Synthetic α,β -Unsaturated Carbonyls for NF- κ B Inhibition: A Mini-review. *Future Medicinal Chemistry* 2009;1 (1):179-200.
59. Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, **Schmidt CM**. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells. *J Pharmacol Exp Ther*. 2009 Jun;329(3):1063-70. Epub 2009 Mar 3.
60. Dalbec KM, **Schmidt CM**, Wade TE, Wang S, Swartz-Basile DA, Pitt HA, Zyromski NJ. Adipokines and Cytokines in Human Pancreatic Juice: Unraveling the Local Pancreatic Inflammatory Milieu. *Dig Dis Sci*. 2009.
61. Hennig M, Yip-Schneider MT, Wentz S, Wu H, Hekmatyar S, Klein P, Bansal N, **Schmidt CM**. Targeting MAP kinase kinase (MEK) with the inhibitor PD0325901 decreases hepatocellular carcinoma growth in vitro and in mouse model systems. *Hepatology*. 2010 Apr;51(4):1218-25.
62. Haab BB, Porter A, Yue T, Li L, Scheiman J, Anderson MA, Barnes D, **Schmidt CM**, Feng Z, Simeone DM. Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms. *Ann Surg*. 2010 May;251(5):937-45.
63. Ramachandran PV, Pratihari D, Nair HNG, Walters M, Smith S, Yip-Schneider MT, Wu H, **Schmidt CM**, Tailored α -methylene- γ -butyrolactones and their effects on growth suppression in pancreatic carcinoma cells. *Bioorg Med Chem Lett*. 2010 Nov 15;20(22):6620-3. Epub 2010 Sep 21.
64. Li Z, Dong Z, Myer D, Yip-Schneider M, Liu J, Cui P, **Schmidt CM**, Zhang JT. Role of 14-3-3 σ in poor prognosis and in radiation and drug resistance of human pancreatic cancers. *BMC Cancer*. 2010 Nov 1;10:598.
65. Yang Y, Liu H, Li Z, Zhao Z, Yip-Schneider MT, Fan Q, **Schmidt CM**, Chiorean EG, Xie J, Cheng L, Chen JH, Zhang JT. Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic cancers. *Int J Biochem Mol Biol*. 2011 January 1; 2 (1): 89–98.
66. Sandrasegaran K, Akisik FM, Patel AA, Rydberg M, Cramer HM, Agaram NP, **Schmidt CM**. Diffusion-weighted imaging in characterization of cystic pancreatic lesions. *Clin Radiol*. 2011 May 19. [Epub ahead of print]
67. Doyle CJ, Agaram NP, Yip-Schneider MT, **Schmidt CM**. Transforming growth factor α levels in pancreatic fluid. *Pancreas*. 2011 Mar;40(2):260-4.

68. Yip-Schneider MT, Doyle C, McKillip IH, Wentz SC, Brandon-Warner E, Matos JM, Sandrasegaran K, Saxena R, Hennig ME, Wu H, Klein PJ, Froehlich JC, **Schmidt CM**. Alcohol induces liver neoplasia in a novel alcohol-preferring rat model. *Alcohol Clin Exp Res*. 2011 Jul 25. doi: 10.1111/j.1530-0277.2011.01568.x. [Epub ahead of print]
69. Wu J, Matthaei H, Maitra A, Dal Molin M, Wood LD, Eshleman JR, Goggins M, Canto MI, Schulick RD, Edil BH, Wolfgang CL, Klein AP, Diaz LA Jr, Allen PJ, **Schmidt CM**, Kinzler KW, Papadopoulos N, Hruban RH, Vogelstein B. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. *Science Transl Med*. 2011 Jul 20;3(92):92ra66.
70. Doyle CJ, Yancey K, Pitt HA, Wang M, Bemis K, Yip-Schneider MT, Sherman ST, Lillemoe KD, Goggins MD, **Schmidt CM**. The Proteome of Normal Pancreatic Juice. *Pancreas*. 2011 Nov 29. [Epub ahead of print]
71. Al-Rashdan A, **Schmidt CM**, Al-Haddad M, McHenry L, Leblanc JK, Sherman S, Dewitt J. Fluid analysis prior to surgical resection of suspected mucinous pancreatic cysts. A single centre experience. *J Gastrointest Oncol*. 2011 Dec;2(4):208-14.
72. Wu J, Jiao Y, Dal Molin M, Maitra A, de Wilde RF, Wood LD, Eshleman JR, Goggins MG, Wolfgang CL, Canto MI, Schulick RD, Edil BH, Choti MA, Adsay V, Klimstra DS, Offerhaus GJ, Klein AP, Kopelovich L, Carter H, Karchin R, Allen PJ, **Schmidt CM**, Naito Y, Diaz LA Jr, Kinzler KW, Papadopoulos N, Hruban RH, Vogelstein B. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. *Proc Natl Acad Sci U S A*. 2011 Dec 8
73. Mann BF, Goetz JA, House MG, **Schmidt CM**, Novotny MV. Glycomic and proteomic profiling of pancreatic cyst fluids identifies hyperfucosylated lactosamines on the N-linked glycans of overexpressed glycoproteins. *Mol Cell Proteomics*. 2012 Mar 5. [Epub ahead of print]
74. Holcomb BK, Yip-Schneider MT, Waters JA, Beane JD, Crooks PA, **Schmidt CM**. Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells. *J Gastrointest Surg*. 2012 Jul;16(7):1333-40.
75. Yip-Schneider MT, Wu H, Hruban RH, Lowy AM, Crooks PA, **Schmidt CM**. Efficacy of Dimethylaminoparthenolide and Sulindac in Combination with Gemcitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer. *Pancreas*. 2013 Jan;42(1):160-167.
76. Ramachandran PV, Nicponski DR, Drolet MP, Yip-Schneider MT, **Schmidt CM**. The first synthesis of a borylated α -methylene- γ -butyrolactone. *Future Med Chem*. 2013 Apr;5(6):633-9. doi: 10.4155/fmc.13.37.
77. Yip-Schneider MT, Wu H, Stantz K, Agaram N, Crooks PA, **Schmidt CM**. Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. *BMC Cancer*. 2013 Apr 17;13(1):194.
78. Mehrabi S, **Schmidt CM**, Waters JA, Beesley C, Krishnan A, Kesterson J, Dexter P, Al-Haddad MA, Tierney WM, Palakal M. An efficient pancreatic cyst identification methodology using natural language processing. *Stud Health Technol Inform*. 2013;192:822-6.

79. Chan IS, Guy CD, Machiado MV, Wank A, Kadiyala V, Michelotti G, Choi S, Swiderska-Syn M, Karaca G, Pereira TA, Yip-Schneider MT, **Schmidt CM**, Diehl AM. Alcohol Activates the Hedgehog Pathway and Induces Related Pro-carcinogenic Processes in the Alcohol-Preferring Rat Model of Hepatocarcinogenesis. *Alcohol Clin Exp Res*. 2013 Oct 24.
80. Ramachandran PV, Nicponski DR, Nair HN, Helppi MA, Gagare PD, **Schmidt CM**, Yip-Schneider MT. Synthetic α -(aminomethyl)- γ -butyrolactones and their anti-pancreatic cancer activities. *Bioorg Med Chem Lett*. 2013 Dec 15;23(24):6911-4.
81. **Schmidt CM**, Wu H, Dumas RP, Agaram N, Feliciano DV, Yip-Schneider MT. VEGF-A: A Novel and Highly Accurate Pancreatic Fluid Biomarker for Serous Pancreatic Cysts. *J Am Coll Surg*. 2014 Apr;218(4):608-17. doi: 10.1016/j.jamcollsurg.2013.12.019. Epub 2013 Dec 24.
82. Bettgowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Lubber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih IM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, **Schmidt CM**, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr.. Circulating tumor DNA for the detection and monitoring of human malignancies. *Sci Transl Med*. 2014 Feb 19;6(224):224ra24.
83. Waters JA, Matos J, Yip-Schneider M, Aguilar-Saavedra JR, Crean CD, Beane JD, Dumas RP, Suvannasankha A, **Schmidt CM**. Targeted NF- κ B suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts. *Surgery*. 2015 Oct;158(4):881-9. doi: 10.1016/j.surg.2015.04.043. Epub 2015 Jul 21.
84. Springer S, Wang Y, Molin MD, Masica DL, Jiao Y, Kinde I, Blackford A, Raman SP, Wolfgang CL, Tomita T, Niknafs N, Douville C, Ptak J, Dobbyn L, Allen PJ, Klimstra DS, Schattner MA, **Schmidt CM**, Yip-Schneider M, Cummings OW, Brand RE, Zeh HJ, Singhi AD, Scarpa A, Salvia R, Malleo G, Zamboni G, Falconi M, Jang JY, Kim SW, Kwon W, Hong SM, Song KB, Kim SC, Swan N, Murphy J, Geoghegan J, Brugge W, Fernandez-Del Castillo C, Mino-Kenudson M, Schulick R, Edil BH, Adsay V, Paulino J, van Hooft J, Yachida S, Nara S, Hiraoka N, Yamao K, Hijioka S, van der Merwe S, Goggins M, Canto MI, Ahuja N, Hirose K, Makary M, Weiss MJ, Cameron J, Pittman M, Eshleman JR, Diaz LA Jr, Papadopoulos N, Kinzler KW, Karchin R, Hruban RH, Vogelstein B, Lennon AM. A combination of molecular and clinical features improve the classification of pancreatic cysts: a multicenter retrospective study. *Gastroenterology*. 2015 Aug 4.
85. Ramachandran PV, Helppi MA, Lehmkuhler A, Marchia JM, **Schmidt CM**, Yip-Schneider MT. Factors influencing the cytotoxicity of α -methylene- γ -hydroxy esters against pancreatic cancer. *Bioorg Med Chem Lett*. 2015 Oct 1;25(19):4270-3.
86. Kadayifci A, Al-Haddad M, Atar M, Dewitt JM, Forcione DG, Sherman S, Casey BW, Fernandez-del Castillo C, **Schmidt CM**, Pittman MB, Brugge WR. The Value of KRAS Mutation Testing with CEA for the Diagnosis of Pancreatic Mucinous Cysts. *Endoscopy International* 2016 Jan 18; 04: E391-E396

87. Nguyen HV, Gore J, Zhong X, Savant SS, Deitz-McElyea S, Schmidt CM, House MG, Korc M. MicroRNA Expression in a Readily Accessible Common Hepatic Artery Lymph Node Predicts Time to Pancreatic Cancer Recurrence Postresection. *J Gastrointest Surg.* 2016 Oct;20(10):1699-706. doi: 10.1007/s11605-016-3208-x. Epub 2016 Jul 25.
88. Ivry SL, Sharib JM, Dominguez DA, Roy N, Hatcher SE, Yip-Schneider M, **Schmidt CM**, Brand RE, Park WG, Hebrok M, Kim G, O'Donoghue AJ, Kirkwood KS, Craik CS. Global protease activity profiling provides differential diagnosis of pancreatic cysts. *Clin Cancer Res.* 2017 Apr 19. pii: clincanres.2987.2016. doi: 10.1158/1078-0432.CCR-16-2987.
89. Carr RA, Yip-Schneider MT, Dolejs S, Hancock BA, Wu H, Radovich M, **Schmidt CM**. Pancreatic Cyst Fluid Vascular Endothelial Growth Factor A and Carcinoembryonic Antigen: A Highly Accurate Test for the Diagnosis of Serous Cystic Neoplasm. *J Am Coll Surg.* 2017 May 18. pii: S1072-7515(17)30452-0. doi: 10.1016/j.jamcollsurg.2017.05.003. [Epub ahead of print]
90. Cohen JD, Javed AA, Thoburn C, Wong F, Tie J, Gibbs P, **Schmidt CM**, Yip-Schneider MT, Allen PJ, Schattner M, Brand RE, Singhi AD, Petersen GM, Hong SM, Kim SC, Falconi M, Doglioni C, Weiss MJ, Ahuja N, He J, Makary MA, Maitra A, Hanash SM, Dal Molin M, Wang Y, Li L, Ptak J, Dobbyn L, Schaefer J, Silliman N, Popoli M, Goggins MG, Hruban RH, Wolfgang CL, Klein AP, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Lennon AM. A combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancer. *Proc Natl Acad Sci U S A.* 2017 Sep 19;114(38):10202-10207. doi: 10.1073/pnas.1704961114. Epub 2017 Sep 5.
91. Yip-Schneider MT, Carr RA, Wu H, **Schmidt CM**. Prostaglandin E2: a Pancreatic Fluid Biomarker of IPMN Dysplasia. *J Am Coll Surg.* 2017 Oct;225(4):481-487.
92. Carr RA, Yip-Schneider MT, Simpson RE, Dolejs S, Schneider JG, Wu H, Ceppa EP, Park W, **Schmidt CM**. Pancreatic cyst fluid glucose: rapid, inexpensive, and accurate diagnosis of mucinous pancreatic cysts. *Surgery.* 2018 Mar;163(3):600-605.
93. Sims EK, Bahnson HT, Nyalwidhe J, Haataja L, Davis AK, Speake C, DiMeglio LA, Blum J, Morris MA, Mirmira RG, Nadler J, Mastracci TL, Marcovina S, Qian WJ, Yi L, Swensen AC, Yip-Schneider M, **Schmidt CM**, Considine RV, Arvan P, Greenbaum CJ, Evans-Molina C; T1D Exchange Residual C-peptide Study Group. Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes. *Diabetes Care.* 2019 Feb;42(2):258-264.
94. Simpson RE, Yip-Schneider MT, Wu H, Fan H, Liu Z, Korc M, Zhang J, **Schmidt CM**. Circulating Thrombospondin-2 enhances prediction of malignant intraductal papillary mucinous neoplasm. *Am J Surg.* 2019 Mar;217(3):425-428.
95. Fahrman JF, Bantis LE, Capello M, Scelo G, Dennison JB, Patel N, Murage E, Vykoukal J, Kundnani DL, Foretova L, Fabianova E, Holcatova I, Janout V, Feng Z, Yip-Schneider MT, Zhang J, Brand R, Taguchi A, Maitra A, Brennan P, **Schmidt CM*** (dual senior author), Hanash S. A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. *JNCI J Natl Cancer Inst* (2019)111 (4):djj126: 1-8.
96. Yip-Schneider MT, Simpson R, Carr RA, Wu H, Fan H, Liu Z, Korc M, Zhang J, **Schmidt CM**. Circulating Leptin and Branched Chain Amino Acids-Correlation with Intraductal Papillary Mucinous Neoplasm Dysplastic Grade. *J Gastrointest Surg.* 2019 May;23(5):966-974.

97. Springer S, Masica DL, Dal Molin M, Douville C, Thoburn CJ, Afsari B, Li L, Cohen JD, Thompson E, Allen PJ, Klimstra DS, Schattner MA, **Schmidt CM**, Yip-Schneider M, Simpson RE, Fernandez-Del Castillo C, Mino-Kenudson M, Brugge W, Brand RE, Singhi AD, Scarpa A, Lawlor R, Salvia R, Zamboni G, Hong SM, Hwang DW, Jang JY, Kwon W, Swan N, Geoghegan J, Falconi M, Crippa S, Doglioni C, Paulino J, Schulick RD, Edil BH, Park W, Yachida S, Hijioka S, van Hooft J, He J, Weiss MJ, Burkhart R, Makary M, Canto MI, Goggins MG, Ptak J, Dobbyn L, Schaefer J, Sillman N, Popoli M, Klein AP, Tomasetti C, Karchin R, Papadopoulos N, Kinzler KW, Vogelstein B, Wolfgang CL, Hruban RH, Lennon AM. A multi-modality test to guide the management of patients with pancreatic cysts. *Sci Transl Med*. 2019 Jul 17;11(501).
98. Simpson RE, Yip-Schneider MT, Flick KF, Wu H, Colgate CL, **Schmidt CM**. Pancreatic Fluid Interleukin-1 β Complements Prostaglandin E2 and Serum Carbohydrate Antigen 19-9 in Prediction of Intraductal Papillary Mucinous Neoplasm Dysplasia. *Pancreas*. 2019 Sep;48(8):1026-1031.
99. Zhong X, Pons M, Poirier C, Jiang Y, Liu J, Sandusky GE, Shahda S, Nakeeb A, **Schmidt CM**, House MG, Ceppa EP, Zyromski NJ, Liu Y, Jiang G, Couch ME, Koniaris LG, Zimmers TA. The systemic activin response to pancreatic cancer—implications for effective cancer cachexia therapy. *J Cachexia Sarcopenia Muscle*. 2019 Oct;10(5):1083-1101.
100. Yip-Schneider MT, Soufi M, Carr RA, Flick KF, Wu H, Colgate CL, **Schmidt CM**. Performance of candidate urinary biomarkers for pancreatic cancer - Correlation with pancreatic cyst malignant progression? *Am J Surg*. 2020 Mar;219(3):492-495.
101. Yip-Schneider MT, Soufi M, Carr RA, Flick KF, Wu H, **Schmidt CM**. Discussion on: Performance of candidate urinary biomarkers for pancreatic cancer - Correlation with pancreatic cyst malignant progression? *Am J Surg*. 2020 Mar;219(3):496.
102. Simpson RE, Yip-Schneider M, Flick KF, Soufi M, Ceppa EP, Al-Haddad MA, Easler JJ, Sherman S, Dewitt JM, **Schmidt CM**. Secretin-induced Duodenal Aspirate of Pancreatic Juice (SIDA): Utility of Commercial Genetic Analysis. *Anticancer Res*. 2020 Aug;40(8):4215-4221.
103. Fahrman JF, **Schmidt CM**, Mao X, Irajizad E, Loftus M, Zhang J, Patel N, Vykoukal J, Dennison JB, Long JP, Do KA, Zhang J, Chabot JA, Kluger MD, Kastrinos F, Brais L, Babic A, Jajoo K, Lee LS, Clancy TE, Ng K, Bullock A, Genkinger J, Yip-Schneider MT, Maitra A, Wolpin BM, Hanash S. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. *Gastroenterology*. 2021 Mar;160(4):1373-1383.
104. Fujikura K, Hosoda W, Felsenstein M, Song Q, Reiter JG, Zheng L, Beleva Guthrie V, Rincon N, Dal Molin M, Dudley J, Cohen JD, Wang P, Fischer CG, Braxton AM, Noë M, Jongepier M, Fernández-Del Castillo C, Mino-Kenudson M, **Schmidt CM**, Yip-Schneider MT, Lawlor RT, Salvia R, Roberts NJ, Thompson ED, Karchin R, Lennon AM, Jiao Y, Wood LD. Multiregion whole-exome sequencing of intraductal papillary mucinous neoplasms reveals frequent somatic KLF4 mutations predominantly in low-grade regions. *Gut*. 2021 May;70(5):928-939.

RESEARCH: NON-REFEREED

105. Sims EK, Bahnson HT, Nyalwidhe J, Haataja L, Davis AK, Speake C, DiMeglio LA, Blum J, Morris MA, Mirmira RG, Nadler J, Mastracci TL, Marcovina S, Qian WJ, Yi L, Swensen AC, Yip-Schneider M, **Schmidt CM**, Considine RV, Arvan P, Greenbaum CJ, Evans-Molina C.

Response to Comment on Sims et al. Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes. *Diabetes Care* 2019;42:258-264. *Diabetes Care*. 2019 May;42(5):e85-e86.

SERVICE: REFEREED

106. Andersen RM, Lyttle CS, Kohrman CH, Levey GS, Neymarc K, **Schmidt CM**: National Study of Internal Medicine Manpower XVII: Changes in the Characteristics of Internal Medicine Residents and their Training Programs, *Annals of Internal Medicine* 1990; 113(3): 243-249.
107. Lyttle CS, Andersen RM, Neymarc K, **Schmidt CM**, Kohrman CH, Levey GS: National Study of Internal Medicine Manpower XVIII: Subspecialty Fellowships with a Special Look at Hematology and Oncology, *Annals of Internal Medicine* 1991; 114(1): 36-42.
108. **Schmidt CM**, Horton KM, Sitzmann JV, Jones B, Bayless T: Simple Radiographic Evaluation of Ileoanal Pouch Volume, *Dis Colon Rectum*, 1996; 39: 66-73.
109. Hou MC, Lin HC, Kuo BI, Lee FY, **Schmidt CM**, Lee SD: Clinical Implications of the White Nipple Sign and Its Role in the Diagnosis of Esophageal Variceal Hemorrhage, *Am J Gastro* 1996; 91(10): 2103-2109.
110. **Schmidt CM**, Lazenby AJ, Hendrickson RJ, Sitzmann JV: Preoperative Terminal Ileal and Colonic Resection Histopathology Predicts Risk of Pouchitis in Patients after Ileoanal Pull-through Procedure, *Annals of Surgery* 1998; 227(5) 654-665.
111. **Schmidt CM**, Talamini MA, Kaufman HS, Lillemoe KD, Learn PA, Bayless T: Laparoscopic Surgery for Crohn's Disease: Reasons for Conversion, *Annals of Surgery* 2001; 233(6): 733-739.
112. Kovach SJ, Hendrickson RJ, Cappadona CR, **Schmidt CM**, Groen K, Konaiaris LG, Sitzmann JV: Cryoablation of Unresectable Pancreatic Cancer, *Surgery* 2002; 131(4): 463-464.
113. **Schmidt CM**, Wiesenauer CA, Cummings OW, Yiannoutsos CT, Howard TJ, Wiebke EA, Goulet RJ, McHenry LH, Sherman S, Lehman GA, Cramer H, Madura JA: Preoperative Predictors of Malignancy in Pancreatic Intraductal Papillary Mucinous Neoplasms, *Arch Surg* 2003; 138(6): 610-617.
114. Stanton KJ, Sidner RA, Miller GA, Cummings OW, **Schmidt CM**, Howard TJ, Wiebke EA: Analysis of Ki-67 Antigen Expression, DNA Proliferative Fraction and Survival in Resected Cancer of the Pancreas, *Am J Surg* 2003, 186(5): 486-492.
115. Madura JA, Yum MN, Lehman GA, Sherman S, **Schmidt CM**: Mucin Secreting Cystic Lesions of the Pancreas: Treatment by Enucleation, *Am Surg* 2004; 70(2): 106-112.
116. **Schmidt CM**, Powell ES, Yiannoutsos CT, Howard TJ, Wiebke EA, Wiesenauer CA, Baumgardner JA, Cummings OW, Jacobson LE, Broadie TA, Canal DF, Goulet RJ jr, Curie EA, Cardenes H, Watkins JM, Loehrer PJ, Lillemoe KD, Madura JA: Pancreaticoduodenectomy: A 20-year Experience in 516 Patients, *Arch Surg* 2004; 139(7): 718-727.
117. Howard TJ, Moore SA, Matthews DE, Saxena R, **Schmidt CM**, Wiebke EA: Pancreatic Duct Strictures are a Common Cause of Recurrent Pancreatitis after Successful Management of Pancreatic Necrosis, *Annals of Surg* 2004; 136(4):909-916.

118. Krouse R, Mohler MJ, Wendel CS, Grant M, Baldwin CM, Rawl S, McCorkle R, Rosenfeld KE, Ko CY, **Schmidt CM**, Coons SJ: The VA Ostomy Health-Related Quality of Life Study: Objectives, Methods, and Patient Sample, *Current Medical Res and Opinions*, 2006; 22(4): 781-791.
119. Howard TJ, Krug JE, Yu J, Zyromski NJ, **Schmidt CM**, Jacobson LE, Madura JA, Wiebke EA, Lillemoe KD: A Margin-Negative R0 Resection Accomplished with Minimal Postoperative Complications is the Surgeon's Contribution to Long-term Survival in Pancreatic Cancer, 2006; *J Gastroint Surg*; 10(10): 1338-1346.
120. Pais SA, Attasaranya S, LeBlanc JK, Sherman S, **Schmidt CM**, DeWitt J: The Role of EUS in the Diagnosis of Intraductal Papillary Mucinous Tumors: Correlation with Surgical Histopathology, 2007; *Clin Gastroenterol Hepatol*;5(4):489-95.
121. Tann M, Sandrasegaran K, Jennings SG, Skandarajah A, McHenry L, **Schmidt CM**: Positron Emission Tomography and CT of Cystic Pancreatic Masses. *Clin Radiol*. 2007 Aug;62(8):745-51.
122. Krouse RS, Grant M, Wendel CS, Mohler MJ, Rawl SM, Baldwin CM, Coons SJ, McCorkle R, Ko CY, **Schmidt CM**. A Mixed-Methods Evaluation of Health-Related Quality of Life for Male Veterans with and without Intestinal Stomas. *Dis Colon Rectum* 2007 Dec; 50(12):2054-2066.
123. **Schmidt CM**, Glant J, Winter JM, Kennard J, Dixon J, Zhao Q, Howard TJ, Madura JA, Nakeeb A, Pitt HA, Cameron JL, Yeo CJ, Lillemoe KD. Total Pancreatectomy (R0 Resection) Improves Survival Over Sub-Total Pancreatectomy in Isolated Neck Margin Positive Pancreatic Adenocarcinoma. *Surgery*. 2007 Oct;142(4):572-8; discussion 578-80.
124. **Schmidt CM**, White PB, Waters JA, Yiannoutsos CT, Cummings OW, Baker M, Howard TJ, Zyromski NJ, Nakeeb A, DeWitt JM, Akisik FM, Sherman S, Pitt HA, Lillemoe KD. Intraductal Papillary Mucinous Neoplasms: Predictors of Malignant and Invasive Pathology. *Ann Surg*. 2007 Oct;246(4):644-
125. Mathur A, Pitt HA, Marine M, Saxena R, **Schmidt CM**, Howard TJ, Nakeeb A, Zyromski NJ, Lillemoe KD. Fatty pancreas: a factor in postoperative pancreatic fistula. *Ann Surg*. 2007 Dec;246(6):1058-64.
126. Zhu L, Shi G, **Schmidt CM**, Hruban RH, Konieczny SF: Acinar Cells Contribute to the Molecular Heterogeneity of Pancreatic Intraepithelial Neoplasia. *Am J Pathol*. 2007 Apr 26; [Epub ahead of print]
127. Shen C, Breen TE, Dobrolecki LE, **Schmidt CM**, Sledge GW, Miller KD, Hickey RJ. Comparison of Computational Algorithms for the Classification of Liver Cancer using SELDI Mass Spectrometry: A Case Study. *Cancer Informatics* 2007; 3: 339-349.
128. **Schmidt CM**, Waters JA, Lillemoe KD: CT vs. MRCP: Optimal Classification of IPMN Type and Extent. *J Gastrointest Surg*. 2008 Jan;12(1):101-9.
129. Mitchell KA, Rawl SM, **Schmidt CM**, Grant M, Ko CY, Baldwin CM, Wendel C, Krouse RS. Demographic, Clinical, and Quality of Life Variables Related to Embarrassment in Veterans Living With an Intestinal Stoma. *J Wound Ostomy Continence Nurs* 2007 September/October; 34(5):524-532.

130. **Schmidt CM**, Matos JM, Crowell PL, Howard TJ, Cummings OW, Wiebke EA, Madura JA, Loehrer PJ Sr: A Phase II Trial of Perillyl Alcohol in Patients with Resectable Pancreatic Cancer. *J Surg Res.* 2008 Jun 15;147(2):194-9.
131. Baker MS, Knuth JL, Dewitt J, Leblanc J, Cramer H, Howard TJ, **Schmidt CM**, Lillemoe KD, Pitt HA. Pancreatic cystic neuroendocrine tumors: preoperative diagnosis with endoscopic ultrasound and fine-needle immunocytology. *J Gastrointest Surg.* 2008 Mar;12(3):450-6.
132. **Schmidt CM**, Wiesenauer CA, Sitzmann JV. Long-term effects on diet after proctocolectomy for ulcerative colitis. *Am J Surg.* 2008 Mar;195(3):353-7; discussion 357.
133. Kooby DA, Gillespie T, Bentrem D, Nakeeb A, **Schmidt CM**, Merchant N, Parikh A, Martin RC III, Scoggins CR, Ahmad S, Kim H-J, Park J, Johnston F, Strouch R, Menze A, Strasborg S, Talamonti M, Staley CA, McMasters K, Byrd-Sellers L, Wood WC, Hawkins W. Left-sided pancreatectomy: A multicenter comparison of laparoscopic and open approaches. *Ann Surg.* 2008 Sep;248(3):438-46.
134. **Schmidt CM**, Matos JM, Bentrem DJ, Talamonti MS, Lillemoe KD, Bilimoria KY. Acinar cell carcinoma of the pancreas in the United States: prognostic factors and comparison to ductal adenocarcinoma. *J Gastrointest Surg.* 2008 Dec;12(12):2078-86.
135. Lavu H, Knuth JL, Baker MS, Zyromski ND, **Schmidt CM**, Nakeeb A, Howard TJ. Middle segment pancreatectomy is easily incorporated into a pancreatic surgeon's clinical practice. *HPB (Oxford).* 2008;10(6):491-7.
136. Pittman J, Rawl SM, **Schmidt CM**, Grant M, Ko CY, Wendel C, Krouse RS. Demographic and Clinical Factors Related to Ostomy Complications and Quality of Life in Veterans With an Ostomy. *J Wound Ostomy Continence Nurs.* 2008 Aug 21.
137. Dewitt J, Al-Haddad M, Fogel E, Sherman S, Leblanc JK, McHenry L, **Schmidt CM**. Endoscopic transduodenal drainage of an abscess arising after EUS-FNA of a duodenal GI stromal tumor. *Gastrointest Endosc.* 2009 Jul;70(1):185-8. Epub 2009 Jan 18.
138. Krouse RS, Grant M, Rawl SM, Mohler MJ, Baldwin CM, Coons SJ, McCorkle R, **Schmidt CM**, Ko CY. Coping and acceptance: the greatest challenge for veterans with intestinal stomas. *J Psychosom Res* 2009 Mar;66(3):227-233.
139. Jain S, McGory ML, Ko CY, Sverdlik A, Tomlinson JS, Wendel CS, Coons SJ, Rawl SM, **Schmidt CM**, Grant M, McCorkle R, Mohler MJ, Baldwin CM, Krouse RS. Comorbidities play a larger role in predicting quality of life compared to having an ostomy. *Am J Surg* 2007 Dec;194(6):774-779.
140. Baldwin C, Grant M, Wendel C, Rawl S, **Schmidt CM**, Ko C, Krouse R. Influence of Intestinal Stoma on Spiritual Quality of Life of U. S. Veterans. *J Holist Nurs.* 2008 Sep;26(3):185-94; discussion 195-6; quiz 197-9.
141. Merchant NB, Rymer J, Koehler EAS, Ayers GD, Castellanos J, Kooby DA, Weber SH, Cho CS, **Schmidt CM**, Nakeeb A, Matos JM, Scoggins CR, Martin RCG, Kim HJ, Ahmad SA, McClaine RC, Bednarski BK, Staley CA, Sharp K, Parikh AA. Adjuvant Chemoradiation Therapy For Pancreatic Adenocarcinoma: Who Really Benefits? *J Am Coll Surg.* 2009 May;208(5):829-38; discussion 838-41. Epub 2009 Mar 26.

142. Berger AC, Howard TJ, Kennedy EP, Sauter PK, Bower-Cherry M, Dutkevitch S, Hyslop T, **Schmidt CM**, Rosato EL, Lavu H, Nakeeb A, Pitt HA, Lillemoe KD, Yeo CJ. Does type of pancreaticojejunostomy after pancreaticoduodenectomy decrease rate of pancreatic fistula? A randomized, prospective, dual-institution trial. *J Am Coll Surg*. 2009 May;208(5):738-47; discussion 747-9.
143. **Schmidt CM**, Choi J, Powell ES, Yiannoutsos CT, Zyromsky NJ, Nakeeb A, Pitt HA, Wiebke EA, Madura JA, Lillemoe KD. Pancreatic Fistula Following Pancreaticoduodenectomy: Clinical Predictors and Patient Outcomes. *HPB Surgery*, vol. 2009, Article ID 404520, 8 pages, 2009.
144. Eehalt F, Saeger HD, **Schmidt CM**, Grützmann R. [Neuroendocrine Tumors of the Pancreas](#). *Oncologist*. 2009 May;14(5):456-67. Epub 2009 May 1. Review.
145. Matos JM, Grützmann R, Agaram NP, Hans-Detlev S, Kumar HR, Lillemoe KD, **Schmidt CM**. Solid pseudopapillary neoplasms of the pancreas: A multi-institutional study. *J Surg Res*. 2009 Nov;157(1):e137-42. Epub 2009 May 8.
146. DeWitt J, McGreevy M, **Schmidt CM**, Brugge WR. EUS-Guided Ethanol versus Saline Solution Lavage for Pancreatic Cysts: A Randomized, Double-Blinded Study. *Gastrointest Endosc*. 2009 Jul 3. [Epub ahead of print]
147. **Schmidt CM**, Matos JM, Turrini O, Agaram NP, Niedergethmann M, Saeger HD, Merchant N, Johnson CS, Lillemoe KD, Grützmann R. Pancreatic acinar cell carcinoma: a multi-institutional study. *J Gastrointest Surg*. 2009 Aug;13(8):1495-502. Epub 2009 Jun 3.
148. Turrini O, **Schmidt CM**, Moreno J, Parikh P, House M, Zyromski NJ, Nakeeb A, Howard TJ; Pitt HA; Lillemoe KD. Should high serum CA 19-9 levels preclude surgery in patients with resectable pancreatic head adenocarcinoma? *J Gastrointest Surg*. 2009 May 21. [Epub ahead of print]
149. Weber SM, Cho CS, Merchant N, Pinchot S, Rettammel R, Nakeeb A, Bentrem D, Parikh A, Mazo AE, Martin III RC, Scoggins CR, Ahmad S, Kim HJ, Hamilton N, Hawkins W, **Schmidt CM**, Kooby DA. Laparoscopic Left Pancreatectomy: Complication Risk Score Predicts Morbidity and Risk for Pancreatic Fistula. *Ann Surg Oncol* 2009;16(10):2825-33.
150. Parikh PY, Pitt HA, Kilbane M, Howard TJ, Nakeeb A, **Schmidt CM**, Lillemoe KD, Zyromski NJ. Pancreatic Necrosectomy: North American Mortality Is Much Lower Than Expected. *J Am Coll Surg*. 2009 Dec;209(6):712-9. Epub 2009 Oct 17.
151. Zeigler M, Al-Haddad M, **Schmidt CM**. Prepancreatic Portal Vein in a Patient with Intestinal Nonrotation: Report of a Case. *J Gastrointest Surg*. 2010 Jan 12. [Epub ahead of print].
152. Ball C, **Schmidt CM**, Lillemoe KD. A Bifid Neck of the Pancreas. *J Gastrointest Surg*. 2010 May 5.
153. Kooby DA, Hawkins WG, **Schmidt CM**, Weber SM, Bentrem DJ, Gillespie TW, Sellers JB, Merchant NB, Scoggins CR, Martin RC 3rd, Kim HJ, Ahmad S, Cho CS, Parikh AA, Chu CK, Hamilton NA, Doyle CJ, Pinchot S, Hayman A, McClaine R, Nakeeb A, Staley CA, McMasters KM, Lillemoe KD. A multicenter analysis of distal pancreatectomy for adenocarcinoma: is laparoscopic resection appropriate? *J Am Coll Surg*. 2010 May;210(5):779-85, 786-7.

154. **Schmidt CM**, Turrini O, Parikh P, House MG, Zyromski NJ, Nakeeb A, Howard TJ, Pitt HA, Lillemoe KD. Effect of Hospital Volume, Surgeon Experience, and Surgeon Volume on Patient Outcomes After Pancreaticoduodenectomy. *Arch Surg*. 2010 Jul;145(7):634-40.
155. Waters JA, Canal DF, Wiebke EA, Dumas RP, Beane JD, Aguilar-Saavedra JR, Ball C, House MG, Nakeeb A, Zyromski NJ, Pitt HA, Lillemoe KD, **Schmidt CM**. Robotic Distal Pancreatectomy: Cost-Effective? Surgery. 2010 Oct;148(4):814-23. Epub 2010 Aug 24.
156. Ball CG, Correa-Gallego C, Howard TJ, Zyromski NJ, House M, Pitt HA, Nakeeb A, **Schmidt CM**, Lillemoe KD. Radiation dose from CT in patients with necrotizing pancreatitis: How much is too much? *J Gastrointest Surg*. 2010 Oct;14(10):1529-35. Epub 2010 Sep 8.
157. Turrini O, Waters JA, Schnelldorfer T, Lillemoe KD, Yiannoutsos CT, Farnell MB, Sarr MG, **Schmidt CM**. Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy. *HPB (Oxford)*. 2010 Sep;12(7):447-55.
158. Turrini O, Wiebke EA, Delpero JR, Viret F, Lillemoe KD, **Schmidt CM**. Preservation of Replaced or Accessory Right Hepatic Artery during Pancreaticoduodenectomy for Pancreatic Adenocarcinoma: Impact on Margin Status and Survival. *J Gastrointest Surg*. 2010 Nov;14(11):1813-9. Epub 2010 Aug 10.
159. Horner DJ, Wendel CS, Coons SJ, Skeps RP, Rawl SM, Grant M, **Schmidt CM**, Ko CY, Krouse RS. Positive Correlation of Employment and Psychological Quality of Life for Veterans with Major Abdominal Surgery. *Am J Surg*. 2010 Nov;200(5):585-90.
160. Popek S, Grant M, Gemmill R, Wendel CS, Mohler MJ, Rawl SM, Baldwin CM, **Schmidt CM**, Krouse RS. Overcoming Challenges: Life with an Ostomy. *Am J Surg*. 2010 Nov;200(5):640-5.
161. Al-Haddad MA, Friedlin J, Kesterson J, Waters JA, Aguilar-Saavedra JR, **Schmidt CM**. Natural language processing for the development of a clinical registry: a validation study in IPMN. *HPB (Oxford)*. 2010 Dec;12(10):688-95.
162. Friedlin J, Overhage M, Al-Haddad MA, Waters JA, Aguilar-Saavedra JR, Kesterson J, **Schmidt CM**. Comparing methods for identifying pancreatic cancer patients using electronic data sources. *AMIA Annu Symp Proc*. 2010 Nov 13;2010:237-41.
163. Turrini O, **Schmidt CM**, Guiramand J, Aguilar-Saavedra JR, Aboudi S, Pitt HA, Lillemoe KD, Delpero JR. Side-branch IPMN of the Pancreatic Head/Uncinate: Resection or Enucleation? *HPB (Oxford)*. 2011 Feb;13(2):126-31. doi: 10.1111/j.1477-2574.2010.00256.x.
164. Ziegler KM, Nakeeb A, Pitt HA, **Schmidt CM**, Bishop SN, Moreno J, Matos JM, Zyromski NJ, House MG, Madura JA, Howard TJ, Lillemoe KD. Pancreatic Surgery: Evolution at a High Volume Center. *Surgery*. 2010 Oct;148(4):702-9; discussion 709-10. Epub 2010 Aug 24.
165. Chauhan A, Pitt HA, Nakeeb A, Howard TJ, Zyromski NJ, **Schmidt CM**, Ball CG, Lillemoe KD, House MG. Postoperative Morbidity Results in Decreased Survival after Resection for Hilar Cholangiocarcinoma. *HPB (Oxford)*. 2011 Feb;13(2):139-47.
166. Al-Haddad M, **Schmidt CM**, Sandrasegaran K, Dewitt J. Diagnosis and treatment of cystic pancreatic tumors. *Clin Gastroenterol Hepatol*. 2011 Aug;9(8):635-48. Epub 2011 Mar 11. Review.

167. Beane JD, Nakeeb A, Pitt HA, Ziegler KM, **Schmidt CM**, Zyromski NJ, Howard TJ, Lillemoe KD. Splenic Preserving Distal Pancreatectomy: Does Vessel Preservation Matter? *J Am Coll Surg*. 2011 Apr;212(4):651-7; discussion 657-8.
168. **Schmidt CM**. Introduction: SSAT/AGA/ASGE State-of-the-Art Conference: necrotizing pancreatitis: novel minimally invasive strategies. *J Gastrointest Surg*. 2011 Jul;15(7):1086-8. Epub 2011 Apr 12.
169. Waters JA, Schnelldorfer T, Aguilar-Saavedra JR, Chen JH, Yiannoutsos CT, Lillemoe KD, Farnell MB, Sarr MG, **Schmidt CM**. Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American Joint Committee on Cancer Stage. *J Am Coll Surg*. 2011 Aug;213(2):275-83. Epub 2011 May 20.
170. Minter RM, Angelos P, Coimbra R, Dale P, de Vera ME, Hardacre J, Hawkins W, Kirkwood K, Matthews JB, McLoughlin J, Peralta E, Schmidt M, Zhou W, Schwarze ML. Ethical management of conflict of interest: proposed standards for academic surgical societies. *J Am Coll Surg*. 2011 Nov;213(5):677-82. Epub 2011 Aug 31.
171. Cho CS, Kooby DA, **Schmidt CM**, Nakeeb A, Bentrem DJ, Merchant NB, Parikh AA, Martin RC 2nd, Scoggins CR, Ahmad SA, Kim HJ, Hamilton N, Hawkins WG, Weber SM. Laparoscopic versus open left pancreatectomy: can preoperative factors indicate the safer technique? *Ann Surg*. 2011 May;253(5):975-80. Erratum in: *Ann Surg*. 2011 Aug;254(2):391
172. Glant JA, Waters JA, House MG, Zyromski NJ, Nakeeb A, Pitt HA, Lillemoe KD, **Schmidt CM**. Does the interval from imaging to operation affect the rate of unanticipated metastasis encountered during operation for pancreatic adenocarcinoma? *Surgery*. 2011 Oct;150(4):607-16.
173. Beane JD, House MG, Coté GA, DeWitt JM, Al-Haddad M, LeBlanc JK, McHenry L, Sherman S, **Schmidt CM**, Zyromski NJ, Nakeeb A, Pitt HA, Lillemoe KD. Outcomes after preoperative endoscopic ultrasonography and biopsy in patients undergoing distal pancreatectomy. *Surgery*. 2011 Oct;150(4):844-53.
174. Miller JR, Meyer JE, Waters JA, Al-Haddad M, Dewitt J, Sherman S, Lillemoe KD, **Schmidt CM**. Outcome of the pancreatic remnant following segmental pancreatectomy for non-invasive intraductal papillary mucinous neoplasm. *HPB (Oxford)*. 2011 Nov;13(11):759-66. doi: 10.1111/j.1477-2574.2011.00354.x. Epub 2011 Sep 9.
175. Cauley CE, Waters JA, Dumas RP, Meyer JE, Al-Haddad MA, Dewitt JM, Lillemoe KD, **Schmidt CM**. Outcomes of Primary Surveillance for Intraductal Papillary Mucinous Neoplasm. *J Gastrointest Surg*. 2012 Feb;16(2):258-67 [Epub ahead of print]
176. Cauley CE, Pitt HA, Ziegler KM, Nakeeb A, **Schmidt CM**, Zyromski NJ, House MG, Lillemoe KD. Pancreatic Enucleation: Improved Outcomes Compared to Resection. *J Gastrointest Surg*. 2012 Apr 24.
177. Tanaka M, Fernández-Del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, Kimura W, Levy P, Pitman MB, **Schmidt CM**, Shimizu M, Wolfgang CL, Yamaguchi K, Yamao K. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. *Pancreatology*. 2012 May;12(3):183-97.

178. Ceppa EP, Pitt HA, House MG, Kilbane EM, Nakeeb A, **Schmidt CM**, Zyromski NJ, Lillemoe KD. Reducing surgical site infections in hepatopancreatobiliary surgery. *HPB (Oxford)*. 2013 May;15(5):384-91.
179. Sturm EC, Roch AM, Shaffer KM, Schmidt CM 2nd, Lee SJ, Zyromski NJ, Pitt HA, Dewitt JM, Al-Haddad MA, Waters JA, **Schmidt CM**. Obesity increases malignant risk in patients with branch-duct IPMN. *Surgery*. 2013 Oct;154(4):803-9.e
180. Abdeljawad K, Vemulapalli KC, **Schmidt CM**, DeWitt J, Sherman S, Imperiale TF, Al-Haddad M. Prevalence of malignancy in patients with pure main pancreatic duct IPMN. *Gastrointest Endosc*. 2013 Oct 2. pii: S0016-5107(13)02309-2.
181. Tirkes T, Sandrasegaran K, Sanyal R, Sherman S, **Schmidt CM**, Cote GA, Akisik F. Secretin-enhanced MR Cholangiopancreatography: Spectrum of Findings. *Radiographics*. 2013 Nov-Dec;33(7):1889-906.
182. Al-Haddad M, Dewitt J, Sherman S, **Schmidt CM**, Leblanc JK, McHenry L, Coté G, El Chafic AH, Luz L, Stuart JS, Johnson CS, Klochan C, Imperiale TF. Performance Characteristics of Molecular (DNA) Analysis for the Diagnosis of Mucinous Pancreatic Cysts. *Gastrointest Endosc*. 2014 Jan;79(1):79-87.
183. NJoku VC, Howard T, Shen C, **Schmidt CM**, Pitt HA, Nakeeb A, Lillemoe K, Zyromski N. Pyogenic liver abscess following pancreaticoduodenectomy: Risk factors, treatment, and long term outcome. *J Gastrointest Surg*. 2014 Feb 8. [Epub ahead of print]
184. Pitman MB, Centeno BA, Ali SZ, Genevay M, Stelow E, Mino-Kenudson M, Fernandez-Del Castillo C, **Schmidt CM**, Brugge W, Layfield L. Standardized Terminology and Nomenclature for Pancreatobiliary Cytology: The Papanicolaou Society of Cytopathology Guidelines. *Diagn Cytopathol*. 2014 Feb 19.
185. Barron MR, Roch AM, Waters JA, Parikh JA, DeWitt JM, Al-Haddad MA, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, Pitt HA, **Schmidt CM**. Does Preoperative Imaging Accurately Predict Main Duct Involvement in Intraductal Papillary Mucinous Neoplasm. *J Gastrointest Surg*. 2014 Mar;18(3):447-56.
186. Van Buren G, Bloomston M, Hughes S, Winter J, Behrman SW, Zyromski NJ, Vollmer C, Velanovich V, Riall T, Muscarella P, Trevino J, Nakeeb A, **Schmidt CM**, Behrns K, Ellison EC, Barakat O, Perry K, Drebin J, House M, Abdel-Misih S, Silberfein EJ, Golden S, Brown K, Hodges SE, McElhany A, Issazadeh M, Jo E, Mo Q, and Fisher WE. A Randomized Prospective Multicenter Trial of Pancreaticoduodenectomy with and without Routine Intraperitoneal Drainage. *Ann Surg*. 2014 Apr;259(4):605-12.
187. DeWitt J, **Schmidt CM** et al. Alterations in Cross-Sectional Imaging and Cyst Fluid Genetics Following EUS Guided Pancreatic Cyst Ablation with Ethanol and Paclitaxel. *Endoscopy*. 2014 Jun;46(6):457-64.
188. Roch AM, DeWitt JM, Al-Haddad MA, Schmidt CM 2nd, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**. Non-operative management of suspected main duct involved IPMN may be indicated in select patients. *J Am Coll Surg*. 2014 Mar 19

189. Kurtycz D, Tabatabai ZL, Michaels C, Young N, **Schmidt CM**, Farrell J, Gopal D, Simeone D, Merchant NB, Field A, Pitman MB. Postbrushing and fine-needle aspiration biopsy follow-up and treatment options for patients with pancreatobiliary lesions: the Papanicolaou Society of Cytopathology guidelines. *Diagn Cytopathol*. 2014 Apr;42(4):363-71.
190. Kurtycz DF, Field A, Tabatabai L, Michaels C, Young N, **Schmidt CM**, Farrell J, Gopal D, Simeone D, Merchant NB, Pitman MB. Post-brushing and fine-needle aspiration biopsy follow-up and treatment options for patients with pancreatobiliary lesions: The Papanicolaou Society of Cytopathology Guidelines. *Cytojournal*. 2014 Jun 2;11(Suppl 1):5. (*note this is separate publication, but nearly same material as #161*)
191. Adler D, **Schmidt CM**, Al-Haddad M, Barthel JS, Ljung BM, Merchant NB, Romagnuolo J, Shaaban AM, Simeone D, Pitman MB, Layfield LJ. Clinical evaluation, imaging studies, indications for cytologic study and preprocedural requirements for duct brushing studies and pancreatic fine-needle aspiration: The Papanicolaou Society of Cytopathology Guidelines. *Cytojournal*. 2014 Jun 2;11(Suppl 1):1.
192. Roch AM, Ceppa EP, DeWitt JM, Al-Haddad MA, House MG, Nakeeb A, **Schmidt CM**. International consensus guideline parameters carry unequal weight and are not cumulative in intraductal papillary mucinous neoplasm malignant risk prediction. *HPB (Oxford)*. 2014 Oct;16(10):929-35.
193. Roch AM, Ceppa EP, Al-Haddad MA, DeWitt JM, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**. Natural history of mixed type IPMN: Parameters predictive of progression. *Ann Surg*. 2014 Oct;260(4):680-90.
194. Roch AM, Parikh JA, Al-Haddad MA, DeWitt JM, Ceppa EP, House MG, Nakeeb A, **Schmidt CM**. Abnormal Serum Pancreatic Enzymes, but not Pancreatitis, are Associated with an Increased Risk of Malignancy in Patients with Intraductal Papillary Mucinous Neoplasms. *Surgery*. 2014 Oct;156(4):923-30.
195. Beane JD, House MG, Miller A, Nakeeb A, **Schmidt CM**, Zyromski NJ, Ceppa E, Feliciano DV, Pitt HA. Optimal management of delayed gastric emptying following pancreatectomy: an analysis of 1089 patients resected between 2007-2012. *Surgery*. 2014 Oct;156(4):939-48.
196. Roch AM, Singh H, House MG, Ceppa E, Zyromski NJ, Nakeeb A, **Schmidt CM**. Extended distal pancreatectomy for pancreatic adenocarcinoma with splenic vein thrombosis and/or adjacent organ invasion. *Am J Surg*. 2015 Mar;209(3):564-9.
197. Butler JR, Rogers T, Kanshiro K, Eckart G, Martens GR, Ceppa EP, House MG, Nakeeb A, **Schmidt CM**, Zyromski NJ. Is antisecretory therapy after pancreatoduodenectomy necessary? Meta-analysis and contemporary practices of pancreatic surgeons. *J Gastrointest Surg*. 2015 Apr;19(4):604-12.
198. Ceppa EP, McCurdy RM, Becerra DC, Kilbane EM, Zyromski NJ, Nakeeb A, **Schmidt CM**, Lillemoie KD, Pitt HA, House MG. Does Pancreatic Stump Closure Method Influence Distal Pancreatectomy Outcomes. *J Gastrointest Surg*. 2015 Apr 23.

199. Roch AM, Mehrabi S, Krishnan A, Schmidt HE, Kesterson J, Beesley C, Dexter PR, Palakal M, **Schmidt CM**. Automated pancreatic cyst screening using natural language processing: a new tool in pancreatic cancer early detection. *HPB (Oxford)*. 2015 May;17(5):447-53.
200. Roch AM, Barron MR, Tann M, Sandrasegar K, Hannaford KN, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**. Does PET with CT Have Clinical Utility in the Management of Patients with Intraductal Papillary Mucinous Neoplasm? *J Am Coll Surg*. 2015 Jul;221(1):48-56.
201. Ceppa EP, Pitt HA, Nakeeb A, **Schmidt CM**, Zyromski NJ, House MG, Kilbane EM, George-Minkner AN, Brand B, Lillemoe KD. Reducing Readmissions after Pancreatectomy: Limiting Complications and Coordinating the Care Continuum. *J Am Coll Surg*. 2015 Sep;221(3):708-16.
202. Ceppa EP, Roch AM, Cioffi JL, Sharma N, Easler JJ, DeWitt JM, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**. Invasive mixed-type IPMN: Superior prognosis compared to invasive main-duct IPMN. *Surgery*. 2015 Oct;158(4):881-9. doi: 10.1016/j.surg.2015.04.043. Epub 2015 Jul 21.
203. Mehrabi S, Krishnan A, Sohn S, Roch AM, Schmidt H, Kesterson J, Beesley C, Dexter PR, **Schmidt CM**, Liu H, Palakal MJ. Identifying patients with pancreatic cyst and family history of pancreatic cancer using NLP methods. *Stud Health Technol Inform*. 2015;216:604-8.
204. Mehrabi S, Krishnan A, Sohn S, Roch AM, Schmidt H, Kesterson J, Beesley C, Dexter PR, **Schmidt CM**, Liu H, Palakal MJ. DEEPEN: A negation detection system for clinical text incorporating dependency relation into NegEx Corresponding. *JBIBI* 2015 in press
205. Cioffi JL, McDuffie LA, Roch AM, Zyromski NJ, Ceppa EP, **Schmidt CM**, Nakeeb A, House MG. Pancreaticojejunostomy stricture after pancreatoduodenectomy: outcomes after operative revision. *J Gastrointest Surg*. 2015 Nov 9.
206. Butler JR, Fohtung TM, Sandrasegaran K, Ceppa EP, House MG, Nakeeb A, **Schmidt CM**, Zyromski NJ. The natural history of pancreatic lipoma: Does it need observation. *Pancreatology*. 2015 Nov 27.
207. Roch AM, House MG, Cioffi J, Ceppa EP, Zyromski NJ, Nakeeb A, **Schmidt CM**. Significance of portal vein invasion and extent of invasion in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma. *J Gastrointest Surg*. 2016 Jan 14
208. Riditid W, DeWitt JM, **Schmidt CM**, Roch A, Stuart JS, Sherman S, Al-Haddad MA. Management of branched duct intraductal papillary mucinous neoplasms: a large single center study to assess predictors of malignancy and recurrence on long term follow-up. *Gastrointest Endosc*. 2016 Feb 18.
209. Roch AM, Rosati CM, Cioffi JL, Ceppa EP, DeWitt JM, Al-Haddad MA, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**. Intraductal Papillary Mucinous Neoplasm of the pancreas, one manifestation of a more systemic disease? *Am J Surg*. 2016 Mar;211(3):512-8.
210. Carr RA, Chung CW, Schmidt CM 2nd, Jester A, Kilbane ME, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**, Ceppa EP. Impact of Fellow Versus Resident Assistance on Outcomes Following Pancreatoduodenectomy. *J Gastrointest Surg*. 2017 Feb 13.

211. Carr RA, Roch AM, Shaffer K, Aboudi S, Schmidt CM 2nd, DeWitt J, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**. Smoking and IPMN malignant progression. *Am J Surg*. 2017 Mar;213(3):494-497.
212. Roch AM, Bigelow K, Schmidt CM 2nd, Carr RA, Jester AL, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**. Management of Undifferentiated Solitary Mucinous Cystic Lesion of the Pancreas: A Clinical Dilemma. *J Am Coll Surg*. 2017 Apr;224(4):717-723.
213. Baptiste D, Fecher AM, Dolejs SC, Yoder J, **Schmidt CM**, Couch ME, Ceppa DP. Gender Differences in Academic Surgery, Work-Life Balance, and Satisfaction. *J Surg Res*. 2017 Oct;218:99-107.
214. Roch A, Carr R, Nakeeb A, **Schmidt CM**, Ceppa E, House M, Easler J, Maatman T, Zyromski N. Evolving treatment of necrotizing pancreatitis. *Am J Surg*. 2017 Nov 14. pii: S0002-9610(17)31096-6.
215. Van Buren G 2nd, Bloomston M, Schmidt CR, Behrman SW, Zyromski NJ, Ball CG, Morgan KA, Hughes SJ, Karanicolas PJ, Allendorf JD, Vollmer CM Jr, Ly Q, Brown KM, Velanovich V, Winter JM, McElhany AL, Muscarella P 2nd, **Schmidt CM**, House MG, Dixon E, Dillhoff ME, Trevino JG, Hallet J, Coburn NSG, Nakeeb A, Behrns KE, Sasson AR, Ceppa EP, Abdel-Misih SRZ, Riall TS, Silberfein EJ, Ellison EC, Adams DB, Hsu C, Tran Cao HS, Mohammed S, Villafaña-Ferriol N, Barakat O, Massarweh NN, Chai C, Mendez-Reyes JE, Fang A, Jo E, Mo Q, Fisher WE. A Prospective Randomized Multicenter Trial of Distal Pancreatectomy With and Without Routine Intraoperative Drainage. *Ann Surg*. 2017 Sep;266(3):421-431.
216. Carr RA, Roch AM, Zhong X, Ceppa EP, Zyromski NJ, Nakeeb A, **Schmidt CM**, House MG. Prospective Evaluation of Associations between Cancer-Related Pain and Perineural Invasion in Patients with Resectable Pancreatic Adenocarcinoma. *J Gastrointest Surg*. 2017 Oct;21(10):1658-1665.
217. Carr R, Kiel B, Roch A, Ceppa E, House M, Zyromski N, Nakeeb A, **Schmidt CM**. Cancer history: a predictor of IPMN subtype and dysplastic status? *Am J Surg*. 2017 Nov 13. pii: S0002-9610(17)31094-2.
218. Schwartz PB, Roch AM, Han JS, Vaicius AV, Lancaster WP, Kilbane EM, House MG, Zyromski NJ, **Schmidt CM**, Nakeeb A, Ceppa EP. Indication for en bloc pancreatectomy with colectomy: when is it safe? *Surg Endosc*. 2018 Jan;32(1):428-435.
219. Bauman MD, Becerra DG, Kilbane EM, Zyromski NJ, **Schmidt CM**, Pitt HA, Nakeeb A, House MG, Ceppa EP. Laparoscopic distal pancreatectomy for pancreatic cancer is safe and effective. *Surg Endosc*. 2018 Jan;32(1):53-61.
220. Roch AM, Maatman T, Carr RA, Easler JJ, **Schmidt CM**, House MG, Nakeeb A, Ceppa EP, Zyromski NJ. Evolving treatment of necrotizing pancreatitis. *Am J Surg*. 2018 Mar;215(3):526-529.
221. Carr RA, Kiel BA, Roch AM, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**. Cancer history: A predictor of IPMN subtype and dysplastic status? *Am J Surg*. 2018 Mar;215(3):522-525.

222. El Chafic A, El Hajj II, DeWitt J, **Schmidt CM**, Siddiqui A, Sherman S, Aggarwal A, Al-Haddad M. Does cyst growth predict malignancy in branch duct intraductal papillary mucinous neoplasms? Results of a large multicenter experience. *Dig Liver Dis.* 2018 Sep;50(9):961-968.
223. Kelley KE, Fajardo AD, Strange NM, Harmon CA, Pawlecki K, Sieber M, Walke N, Fadel WF, Wooden WA, Sadowski J, Birdas TJ, Stevens LH, Rozycki GS, **Schmidt CM**. Impact of a Novel Preoperative Patient-centered Surgical Wellness Program. *Ann Surg.* 2018 Oct;268(4):650-656.
224. Simpson RE, Cockerill NJ, Yip-Schneider MT, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, Al-Haddad MA, **Schmidt CM**. DNA profile components predict malignant outcomes in select cases of intraductal papillary mucinous neoplasm with negative cytology. *Surgery.* 2018 Oct;164(4):712-718.
225. Mohammed Ilyas MI, Haggstrom DA, Maggard-Gibbons MA, Wendel CS, Rawl S, **Schmidt CM**, Ko CY, Krouse RS. Patients With Temporary Ostomies: Veterans Administration Hospitals Multi-institutional Retrospective Study. *J Wound Ostomy Continence Nurs.* 2018 Nov/Dec;45(6):510-515.
226. Simpson RE, Ceppa EP, Wu HH, Akisik F, House MG, Zyromski NJ, Nakeeb A, Al-Haddad MA, DeWitt JM, Sherman S, **Schmidt CM**. The Dilemma of the Dilated Main Pancreatic Duct in the Distal Pancreatic Remnant After Proximal Pancreatectomy for IPMN. *J Gastrointest Surg.* 2019 Jan 2.
227. Roch AM, Schneider J, Carr RA, Lancaster WP, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**, Ceppa EP. Are BRCA1 and BRCA2 gene mutation patients under-screened for pancreatic adenocarcinoma? *J Surg Oncol.* 2019 Jan 12.
228. Roch AM, Maatman TK, Carr RA, Colgate CL, Ceppa EP, House MG, Lopes J, Nakeeb A, **Schmidt CM**, Zyromski NJ. Venous Thromboembolism in Necrotizing Pancreatitis: an Underappreciated Risk. *J Gastrointest Surg.* 2019 Feb 7.
229. Carr RA, Bletsis P, Schmidt CM II, Roch AM, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**, Ceppa EP. Cystic pancreatic neuroendocrine tumors: A more favorable lesion? *Pancreatology.* 2019 Mar;19(2):372-376.
230. Butler JR, Kays JK, House MG, Ceppa EP, Nakeeb A, **Schmidt CM**, Zyromski NJ. Outcomes of pancreatoduodenectomy in the cirrhotic patient: risk stratification and meta-analysis. *HPB (Oxford).* 2019 Mar;21(3):301-309.
231. Simpson RE, Fennerty ML, Colgate CL, Kilbane EM, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**. Post-Pancreatoduodenectomy Outcomes and Epidural Analgesia: A 5-Year Single Institution Experience. *J Am Coll Surg.* 2019 Apr;228(4):453-462.
232. Soufi M, Yip-Schneider MT, Carr RA, Roch AM, Wu HH, **Schmidt CM**. Multifocal High-Grade Pancreatic Precursor Lesions: A Case Series and Management Recommendations. *J Pancreat Cancer.* 2019 Apr 29;5(1):8-11.
233. Birdas TJ, Rozycki GF, Dunnington GL, Stevens L, Liali V, **Schmidt CM**. "Show Me the Data": A Recipe for Quality Improvement Success in an Academic Surgical Department *J Am Coll Surg.* 2019 Apr;228(4):368-373.

234. Roch AM, Schneider J, Carr RA, Lancaster WP, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**, Ceppa EP. Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma? *J Surg Oncol*. 2019 May;119(6):777-783.
235. Simpson RE, Cockerill NJ, Yip-Schneider MT, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, Al-Haddad MA, **Schmidt CM**. Clinical criteria for integrated molecular pathology in intraductal papillary mucinous neoplasm: less is more. *HPB (Oxford)*. 2019 May;21(5):574-581.
236. Schwartz PB, Easler JJ, Lancaster WP, House MG, Zyromski NJ, **Schmidt CM**, Nakeeb A, Ceppa EP. Sphincter of Oddi Dysfunction After Gastric Bypass: Surgical or Endoscopic Therapy? *J Surg Res*. 2019 Jun;238:41-47.
237. Simpson RE, Wang CY, House MG, Zyromski NJ, **Schmidt CM**, Nakeeb A, Ceppa EP. Travel distance affects rates and reasons for inpatient visits after pancreatectomy. *HPB (Oxford)*. 2019 Jul;21(7):818-826.
238. Maatman TK, Mahajan S, Roch AM, Lewellen KA, Heimberger MA, Colgate CL, Ceppa EP, House MG, Nakeeb A, **Schmidt CM**, Zyromski NJ. High Rates of Readmission in Necrotizing Pancreatitis: Natural History or Opportunity for Improvement *J Gastrointest Surg*. 2019 Sep;23(9):1834-1839.
239. Maatman TK, Weber DJ, Timsina LR, Qureshi B, Ceppa EP, Nakeeb A, Schmidt CM, Zyromski NJ, Koniaris LG, House MG. Antibiotic irrigation during pancreatoduodenectomy to prevent infection and pancreatic fistula: A randomized controlled clinical trial. *Surgery*. 2019 Oct;166(4):469-475.
240. Maatman TK, Weber DJ, Qureshi B, Ceppa EP, Nakeeb A, **Schmidt CM**, Zyromski NJ, House MG. Does the Microbiology of Bactibilia Drive Postoperative Complications After Pancreatoduodenectomy? *J Gastrointest Surg*. 2019 Nov 19.
241. Roch AM, Carr RA, Watkins JL, Lehman G, House MG, Nakeeb A, **Schmidt CM**, Ceppa EP, Zyromski NJ. Percutaneous Gastrostomy in Necrotizing Pancreatitis: Friend or Foe? *J Gastrointest Surg*. 2019 Dec 2
242. Maatman TK, Butler JR, Quigley SN, Loncharich AJ, Crafts T, Ceppa EP, Nakeeb A, **Schmidt CM**, Zyromski NJ, House MG. Leukocytosis after distal pancreatectomy and splenectomy as a marker of major complication. *Am J Surg*. 2019 Dec 6.
243. Trudeau MT , Maggino L, Ecker BL, Vollmer CM, et. al. Schmidt CM, Pancreatic Head Resection after Roux-en-Y Gastric Bypass Study Group. Pancreatic Head Resection Following Roux-en-Y Gastric Bypass: Operative Considerations and Outcomes. *J Gastrointest Surg*. 2020 Jan;24(1):76-87. doi: 10.1007/s11605-019-04366-y. Epub 2019 Sep 4.
244. Maatman TK, Roch AM, Ceppa EP, House MG, Nakeeb A, **Schmidt CM**, Cournoyer RM, Wehlage KM, Zyromski NJ. Damage Control Pancreatic Débridement: Salvaging the Most Severely Ill. *JOP*. 2019; 20(1):37-43.
245. Maatman TK, Mahajan S, Roch AM, Ceppa EP, House MG, Nakeeb A, **Schmidt CM**, Zyromski NJ. Disconnected pancreatic duct syndrome predicts failure of percutaneous therapy in necrotizing pancreatitis. *Pancreatology*. 2020 Jan 28

246. Simpson RE, Carpenter KL, Wang CY, Schmidt CM II, Kilbane EM, Colgate CL, House MG, Zyromski NJ, **Schmidt CM**, Nakeeb A, Ceppa EP. Is resident assistance equivalent to fellows during hepatectomy? *Surg Endosc.* 2020 Jan 28.
247. Lewellen KA, Maatman TK, Heimberger MA, Ceppa EP, House MG, Nakeeb A, **Schmidt CM**, Zyromski NJ. Pancreatic Adenocarcinoma Causing Necrotizing Pancreatitis: Not as Rare as You Think? *J Surg Res.* 2020 Feb 1;250:53-58.
248. Flick KF, Simpson RE, Soufi M, Fennerty ML, Yip-Schneider MT, Colgate CL, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**. Comparison of skin closure techniques in patients undergoing open pancreaticoduodenectomy: A single center experience. *Am J Surg.* 2020 Feb 17.
249. Maatman TK, Roch AM, Lewellen KA, Heimberger MA, Ceppa EP, House MG, Nakeeb A, **Schmidt CM**, Zyromski NJ. Disconnected Pancreatic Duct Syndrome: Spectrum of Operative Management. *J Surg Res.* 2020 Mar;247:297-303.4
250. Maatman TK, Westfall-Snyder JA, Nicolas ME, Yee EJ, Ceppa EP, House MG, Nakeeb A, **Schmidt CM**, Zyromski NJ. The morbidity of *C. difficile* in necrotizing pancreatitis. *Am J Surg.* 2020 Mar;219(3):509-512.
251. Maatman TK, Nicolas ME, Westfall-Snyder JA, Ceppa EP, House MG, Nakeeb A, **Schmidt CM**, Zyromski NJ. Discussion on: The morbidity of *C. difficile* in necrotizing pancreatitis. *Am J Surg.* 2020 Mar;219(3):513-514
252. Simpson RE, Fennerty ML, Flick KF, Colgate CL, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**. Two open Whipples a day: Excessive or efficient. *Am J Surg.* 2020 Mar;219(3):390-393.
253. Simpson RE, Fennerty ML, Flick KF, Colgate CL, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**. Discussion on: Two open Whipples a day: Excessive or efficient. *Am J Surg.* 2020 Mar;219(3):394-395.
254. Steward JE, Kitley WR, **Schmidt CM**, Sundaram CP. Urologic Surgery and COVID-19: How the Pandemic Is Changing the Way We Operate. *J Endourol.* 2020 May;34(5):541-549.
255. Maatman TK; Heimberger MA; Lewellen KA; Roch AMD; Colgate CL; Nakeeb A; Ceppa EP; **Schmidt CM**; Zyromski NJ. Visceral Artery Pseudoaneurysm in Necrotizing Pancreatitis: Incidence and Outcomes. *Can J Surg.* 2020 May 21;63(3):E272-E277.
256. Steward JE, Kitley WR, **Schmidt CM**, Sundaram CP. Urologic Surgery and COVID-19: How the Pandemic Is Changing the Way We Operate. *J Endourol.* 2020 May;34(5):541-549.
257. Simpson RE, Flick KF, Gromski MA, Al-Haddad MA, Easler JJ, Sherman S, Fogel EL, **Schmidt CM**, DeWitt JM. Utility of DNA Profiling From Main Pancreatic Duct Fluid by Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography to Screen for Malignant Potential. *Pancreas.* 2020 May/Jun;49(5):714-722.
258. Maatman TK, Nicolas ME, Roch AM, Lewellen KA, Al-Azzawi HH, Ceppa EP, House MG, Nakeeb A, **Schmidt CM**, Zyromski NJ. Colon Involvement in Necrotizing Pancreatitis: Incidence, Risk Factors, and Outcomes. *Ann Surg.* 2020 Jul 7.

259. Dirks RC, Burney HN, Anjanappa M, Sandusky GE, Hao Y, Liu Y, **Schmidt MC**, Nakshatri H. Breast Heterogeneity: Obstacles to Developing Universal Biomarkers of Breast Cancer Initiation and Progression. *J Am Coll Surg.* 2020 Jul;231(1):85-96.
260. Maatman TK, McGreevy KA, Sood AJ, Ceppa EP, House MG, Nakeeb A, **Schmidt CM**, Nguyen TK, Zyromski NJ. Improved Outpatient Communication Decreases Unplanned Readmission in Necrotizing Pancreatitis. *J Surg Res.* 2020 Sep;253:139-146.
261. Flick KF, Yip-Schneider MT, Sublette CM, Simpson RE, Colgate CL, Wu H, Soufi M, Dewitt JM, Mosley AL, Ceppa EP, Zhang J, **Schmidt CM**. A Quantitative Global Proteomics Approach Identifies Candidate Urinary Biomarkers That Correlate With Intraductal Papillary Mucinous Neoplasm Dysplasia. *Pancreas.* 2020 Sep;49(8):1044-1051.
262. Flick KF, Al-Temimi MH, Maatman TK, Sublette CM, Swensson JK, Nakeeb A, Ceppa EP, Nguyen TK, **Schmidt CM**, Zyromski NJ, Tann MA, House MG. Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After Pancreatoduodenectomy. *J Gastrointest Surg.* 2020 Sep;24(9):2008-2014.
263. Maatman TK, Ceppa EP, Fogel EL, Easler JJ, Gromski MA, House MG, Nakeeb A, **Schmidt CM**, Sherman S, Zyromski NJ. Biliary Stricture after Necrotizing Pancreatitis: An Underappreciated Challenge. *Ann Surg.* 2020 Oct 19.
264. Maatman TK, Roch AM, Ceppa EP, Easler JJ, Gromski MA, House MG, Nakeeb A, **Schmidt CM**, Sherman S, Zyromski NJ. The continuum of complications in survivors of necrotizing pancreatitis. *Surgery.* 2020 Dec;168(6):1032-1040.
265. Soufi M, Yip-Schneider MT, Carr R, Roch A, Akisik F, **Schmidt CM**. Intraductal Papillary Mucinous Neoplasm originating from the accessory (Santorini) duct: A rare entity. *Am Surgeon* 2020 Dec 19.
266. Maatman TK, McGuire SP, Lewellen KA, McGreevy KA, Ceppa EP, House MG, Nakeeb A, Nguyen TK, **Schmidt CM**, Zyromski NJ. Prospective Analysis of the Mechanisms Underlying Ineffective Deep Vein Thrombosis Prophylaxis in Necrotizing Pancreatitis. *J Am Coll Surg.* 2021 Jan;232(1):91-100.
267. Maatman TK, Loncharich AJ, Flick KF, Simpson RE, Ceppa EP, Nakeeb A, Nguyen TK, **Schmidt CM**, Zyromski NJ, House MG. Transient Biliary Fistula After Pancreatoduodenectomy Increases Risk of Biliary Anastomotic Stricture. *J Gastrointest Surg.* 2021 Jan;25(1):169-177.
268. Flick KF, Sublette CM, Yip-Schneider MT, Maatman TK, Colgate CL, Soufi M, Kelley KE, **Schmidt CM**. Insurance Type and Marital Status Impact Hospital Length of Stay After Pancreatoduodenectomy. *J Surg Res.* 2021 Jan;257:587-592.
269. Maatman TK, Westfall-Snyder JA, Ceppa EP, House MG, Nakeeb A, Nguyen TK, **Schmidt CM**, Zyromski NJ. Necrotizing Pancreatitis from Hypertriglyceridemia: More Severe Disease? *Dig Dis Sci.* 2021 Jan 19.
270. Evrimler S, Swensson JK, Soufi M, Tirkes T, **Schmidt CM**, Akisik F. Wirsungocoele: evaluation by MRCP and clinical significance. *Abdom Radiol (NY).* 2021 Feb;46(2):616-622.

271. Banter LR, Maatman TK, McGuire SP, Ceppa EP, House MG, Nakeeb A, Nguyen TK, **Schmidt CM**, Zyromski NJ. Duodenal complications in necrotizing pancreatitis: Challenges of an overlooked complication. *Am J Surg.* 2021 Mar;221(3):589-593.
272. Yip-Schneider MT, Wu H, **Schmidt CM**. Novel expression of vascular endothelial growth factor isoforms in the pancreas and pancreatic cystic lesions. *Biochimie.* 2021 Feb;181:234-239.
273. Dbeibo L, Kuebler K, Keen A, George A, Kelley K, Sadowski J, Basham L, Beeson T, **Schmidt CM**, Beeler C, Webb D. Assessment of a universal preprocedural screening program for coronavirus disease 2019 (COVID-19). *Infect Control Hosp Epidemiol.* 2021 Feb 2:1-3.
274. Flick KF, Soufi M, Yip-Schneider MT, Simpson RE, Colgate CL, Nguyen TK, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**. Routine Gastric Decompression after Pancreatoduodenectomy: Treating the Surgeon? *J Gastrointest Surg.* 2021 Mar 26.
275. Novel Preoperative Patient-centered Surgical Wellness Program Impacts Length of Stay Following Pancreatectomy. Soufi M, Deperalta DK, Simpson R, Flick K, Yip-Schneider MT, Schmidt CM 2nd, Kilbane M, Colgate C, Kelley KE, Wooden W, Ceppa EP, House M, Zyromski N, Nakeeb A, **Schmidt CM**. *Anticancer Res.* 2021 Apr;41(4):1895-1901.
276. Narasimhan A, Zhong X, Au EP, Ceppa EP, Nakeeb A, House MG, Zyromski NJ, **Schmidt CM**, Schloss KNH, Schloss DEI, Liu Y, Jiang G, Hancock BA, Radovich M, Kays JK, Shahda S, Couch ME, Koniaris LG, Zimmers TA. Profiling of Adipose and Skeletal Muscle in Human Pancreatic Cancer Cachexia Reveals Distinct Gene Profiles with Convergent Pathways. *Cancers (Basel).* 2021 Apr 20;13(8):1975.
277. Flick KF, **Schmidt CM**, Colgate CL, Yip-Schneider MT, Sublette CM, Maatman TK, Soufi M, Ceppa EP, House MG, Zyromski NJ, Nakeeb A. Preoperative Nomogram Predicts Non-home Discharge in Patients Undergoing Pancreatoduodenectomy. *J Gastrointest Surg.* 2021 May;25(5):1253-1260.
278. Soufi M, Al-Temimi M, Nguyen TK, House MG, Zyromski NJ, **Schmidt CM**, Nakeeb A, Ceppa EP. Friend or foe? Feeding tube placement at the time of pancreatoduodenectomy: propensity score case-matched analysis. *Surg Endosc.* 2021 Jun 24.
279. McGuire SP, Maatman TK, Keller SL, Ceppa EP, House MG, Nakeeb A, Nguyen TK, **Schmidt CM**, Zyromski NJ. Early postoperative serum hyperamylasemia: Harbinger of morbidity hiding in plain sight? *Surgery.* 2021 Aug 21
280. Yee EJ, Al-Temimi MH, Flick KF, Kilbane EM, Nguyen TK, Zyromski NJ, **Schmidt CM**, Nakeeb A, House MG, Ceppa EP. Use of primary surgical drains in synchronous resection for colorectal liver metastases: a NSQIP analysis of current practice paradigm. *Surg Endosc.* 2021 Aug;35(8):4275-4284.
281. Maatman TK, McGuire SP, Flick KF, Madison MK, Al-Haddad MA, Bick BL, Ceppa EP, DeWitt JM, Easler JJ, Fogel EL, Gromski MA, House MG, Lehman GA, Nakeeb A, **Schmidt CM**, Sherman S, Watkins JL, Zyromski NJ. Outcomes in Endoscopic and Operative Transgastric Pancreatic Debridement. *Ann Surg.* 2021 Sep 1;274(3):516-523.

282. Yip-Schneider MT, Wu H, Allison HR, Easler JJ, Sherman S, Al-Haddad MA, Dewitt JM, **Schmidt CM**. Biomarker Risk Score Algorithm and Preoperative Stratification of Patients with Pancreatic Cystic Lesions. *J Am Coll Surg*. 2021 Sep;233(3):426-434.
283. Tirkes T, Patel AA, Tahir B, Kim RC, **Schmidt CM**, Akisik FM. Abdom Radiol (NY). Pancreatic cystic neoplasms and post-inflammatory cysts: interobserver agreement and diagnostic performance of MRI with MRCP. 2021 Sep;46(9):4245-4253.
284. Real World Utilization of Nurse-Driven Urinary Catheter Removal Protocol in Patients with Epidural Pain Catheters. Dbeibo L, Yeap YL, Porter H, Beeson T, **Schmidt CM**, House MG, Glossenger A, Kelley K, Birdax TJ, Beeler C. *Am J Infect Control*. 2021 Sep 19
285. Evrimler S, Yip-Schneider MT, Swensson J, Soufi M, Muraru R, Tirkes T, **Schmidt CM**, Akisik F. Magnetic resonance imaging-derived fat fraction predicts risk of malignancy in intraductal papillary mucinous neoplasm. *Abdom Radiol (NY)*. 2021 Oct;46(10):4779-4786.
286. **Hernandez et al: "Diminished Immune Surveillance During Histological Progression of Intraductal Papillary Mucinous Neoplasms: An opportunity for cancer interception", submitted Clin Cancer Res*
287. *Sean P. McGuire, Thomas K. Maatman, Eugene P. Ceppa, Michael G. House, Attila Nakeeb, Trang K. Nguyen, C. Max Schmidt, Nicholas J. Zyromski. Contemporary Intervention in Necrotizing Pancreatitis: Improved Understanding Changing Practice. submitted JACS*

SERVICE: NON-REFEREED

Editorials, Invited Commentary

288. **Schmidt CM**. Extended Lymphadenectomy for Pancreatic Head Cancer: Less is More, *American Journal of Oncology Review*, 2006;5(5):302-306
289. **Schmidt CM**, Lillemoe KD. IPMN – Controversies in an “Epidemic,” *J. Surg Oncology*, 2006; 94(2): 91-93.
290. **Schmidt CM**: “Pancreatic Cysts: A Window of Opportunity for Early Detection of Pancreatic Cancer” a commentary on Chapter “Cystic neoplasms of the pancreas – SCN, MCN, IPMN” by Hackert T, Fritz S, Büchler MW. *International Practices in Pancreatic Surgery 2013* (Mantke, Lippert, Buchler, Sarr).
291. **Schmidt CM**: Is Surgical Intervention for Cystic Neoplasms of the Pancreas Being Underutilized? *J Gastrointest Surg*. 2014 Jan;18(1):184-6.
292. **Schmidt CM**: Pancreatic Cancer Prevention: Avoiding the Innocent Bystander Effect. *IBJ* April 2014.
293. Yip-Schneider M, **Schmidt CM**. Vascular endothelial growth factor: in reply to Giorgakis and colleagues. *J Am Coll Surg*. 2014 Sep;219(3):591-2.

Web Publications

ADDENDUM: PUBLISHED ABSTRACTS

1. Trippi, Schmidt CM, Enos, Valentine, Tavel: *Doppler Assessment of Left Ventricular Inflow during Exercise Induced Ischemia*, American Heart Association 60th Scientific Session November 1987.
2. Schmidt CM, Ryan, Cooper, Weiser, Michelassi, Block: *The Use of Radiolabeled Immunoconjugates in the Detection of Recurrent and Metastatic Colorectal Cancer*, Forty-Sixth Annual Sr. Scientific Session, The Pritzker School of Medicine, University of Chicago, May 1992.
3. Block, Michelassi, Schmidt CM: *The Clinical Trials of Radiolabeled Immunoconjugates for the Detection of Colorectal, Ovarian and Prostate Carcinoma*, Forty-First Annual Meeting of the Society of Pelvic Surgeons, November 1992; 35.
4. Schmidt CM, Block, Michelassi, Ryan, Cooper: *Indium 111 Labeled B72.3 Murine Monoclonal Antibody as a Diagnostic Imaging Agent in the Management of Patients with Colorectal Adenocarcinoma*, Annual Report of Cancer Research at the University of Chicago, 1992-93.
5. Schmidt CM, Ryan, Cooper, Weiser, Block: *Detection of Recurrent and Metastatic Colorectal Cancer with Immune Scintigraphy-Comparison with CT*, Central Chapter Society of Nuclear Medicine, March 1992: 59.
6. Schmidt CM, Ryan, Cooper, Weiser, Block: *Immune Scintigraphy: Promising Role in Detection of Recurrent and Metastatic Colon Cancer*, Association of University Radiologists Annual Meeting, May 1992.
7. Schmidt CM, Sitzmann JV, Horton, Jones, Bayless TM: *Simple Radiographic Evaluation of Ileal-Anal Pouch Volume Correlates with Bowel Function*, Baltimore Academy of Surgery, Sprint Meeting, May 5, 1994.
8. Schmidt CM, Sitzmann JV, Horton, Jones, Bayless TM: *Novel Radiographic Evaluation of Ileal-Anal Pouch Volume Correlates with Bowel Function*, The Society for Surgery of the Alimentary Tract, May 16, 1994; (#637)100.
9. McKillop IH, Schmidt CM, Cahill PA, Sitzmann JV: *Role of Inhibitory Guanine Nucleotide Regulatory Proteins (GI-Proteins) in the Development and Progression of Hepatocellular Carcinoma (HCC)*, Student Research Days Proceedings, Georgetown University, October 1, 1996: 46.
10. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV: *Differential Guanine Nucleotide Protein Expression in Human Hepatocellular Carcinoma: Possible Role in Growth Signaling Through the MAPK Pathway*, Student Research Days Proceedings, Georgetown University, October 1, 1996: 62.
11. Schmidt CM, Cahill PA, McKillop IH, Redmond EM, Sitzmann JV: *Increased Expression of Guanine Nucleotide Regulatory Proteins Gqa/G11 in Hepatocellular Carcinoma*, FASEB 1996; 10(3):A300.
12. McKillop IH, Schmidt CM, Cahill PA, Sitzmann JV: *Ethanol Upregulates Gia Protein Expression in an Experimental Hepatoma Cell Line: Possible Role in the Progression of HCC Growth*, FASEB 1996; 10(6): A1283.
13. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV: *Increased Expression of Mitogen Activated Protein Kinase Pathway in Rat and Human Hepatocellular Carcinoma*, FASEB 1996; 10(6):A1429.
14. McKillop IH, Schmidt CM, Cahill PA, Sitzmann JV: *Mitogen Activated Protein Kinase (MAPK) Expression in Experimental Hepatocellular Carcinoma (HCC)*, Molec Bio of Cell 1996; 7:512a.
15. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV: *Increased Expression of Guanine Nucleotide Regulatory Protein (G-Protein) G11 in Hepatocellular Carcinoma (HCC)*, Hepatology 1996; 24(4): 575a.
16. McKillop IH, Johnson R, Sabharwal P, Schmidt CM, Cahill PA, Sitzmann JV: *Hepatic Insulin-like Growth Factor-I (IGF-I) Receptor and mRNA Expression in Experimental Hepatocellular Carcinoma (HCC)*, FASEB 1997.

17. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV: *Increased MAPK Expression and Activity in Primary Human Hepatocellular Carcinoma*, Washington Academy of Surgery Proceedings, February 1997.
18. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV: *Alterations in Guanine Nucleotide Regulatory Proteins in Human Hepatocellular Carcinoma*, AACR Meeting, April 1997.
19. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV: *Functionally Significant GI-Protein Linked MAPK Pathway in Primary Human Hepatocellular Carcinoma*, Hepatology 1997; 26(4): 263A.
20. McKillop IH, Schmidt CM, Cahill PA, Sitzmann JV: *Selective Changes in G-Protein Expression and GI-Protein Linked Mitogenesis in Experimental Hepatocellular Carcinoma Following Chronic Ethanol Exposure*, Hepatology 1997; 26(4): 264A.
21. Schmidt CM, Lazenby AJ, Hendrickson RJ, Sitzmann JV, *Preoperative Colonic Ileal Histopathology Predicts Risks of Pouchitis after Ileo-anal Pull Through Operation*, Southern Surgical Association, 1997; 5:11-12.
22. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV: *Alterations in Guanine Nucleotide Regulatory Protein Expression and Activity in Human Hepatocellular Carcinoma*, Washington Academy of Surgery Proceedings 1998; 11.
23. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV: *Inhibitory Guanine Nucleotide Proteins Regulate Human Hepatocellular Carcinoma Growth via a MAPK Pathway*, Student Research Days Proceedings, Georgetown University 1998: 37.
24. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV: *Functionally Significant Gq α -linked MAPK Pathway in Experimental Hepatocellular Carcinoma*, FASEB J 1998; 12(4): A455.
25. McKillop IH, Schmidt CM, Cahill PA, Sitzmann JV: *G-Protein Activation of Mitogen Activated Protein Kinases in Hepatocellular Carcinoma*, FASEB J 1998; 12(4):A124.
26. Tio TL, Salcedo J, Roy PK, Sitzmann JV, Al Kawas F, Hendrickson RJ, Schmidt CM, Cusso XF, Bandres D: *Does EUS Help the Surgeon in Staging Pancreatic and Ampullary Cancers?* Gastro 1998.
27. Hendrickson RJ, Schmidt CM, Cappadona CR, Tio LT, Sitzmann JV: *Intraoperative Ultrasound Improves Diagnostic and Therapeutic Strategies During Pancreatic Surgery*, Gastro 1998.
28. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV: *Inhibitory Guanine Nucleotide Proteins Regulate Human Hepatocellular Carcinoma Growth via a MAPK Pathway*, Gastro 1998.
29. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV: *Alpha Subunit of Inhibitory Guanine Nucleotide Proteins Regulates Human Hepatocellular Carcinoma Growth via a MAPK Pathway*, SEBM Proceedings, March 1998
30. Hendrickson RJ, Cappadona CR, Schmidt CM, Sitzmann JV: *Intraoperative Ultrasound Improves Diagnostic and Therapeutic Strategies During Surgery for Cholangiocarcinoma*, Hepatology 1998: 28(4): 308A.
31. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV: *G-Protein Stimulated Mitogenesis in Human Hepatocellular Carcinoma*, Hepatology 1998: 28(4): 414A.
32. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV: *The Role of Adenylyl Cyclase Linked MAPK Signaling in the Regulation of Human Hepatocellular Carcinoma*, Surg Forum 1998: X477-1-3.
33. McKillop IH, Theodorakis NG, Schmidt CM, Sitzmann JV: *Decreased Cell Mitogenesis Following Inhibition of Gi-Protein-MAPK Signaling in HCC*, AACR 2000.
34. Schmidt CM, Talamini MA, Kaufman HK, Moesinger RJ, Bayless TM: *Safety for Laparoscopic Surgery for Crohn's Disease Depends Upon Prudence in Deciding When to Convert to an Open Procedure*, SSAT May 2000.
35. Schmidt CM, Talamini MA, Kaufman HK, Lillemoe K, Learn PA, Bayless TM: *Laparoscopic Surgery for Crohn's Disease: Reasons for Conversion*, Southern Surgeons 2000: #8.
36. Wiesenauer C, Yip-Schneider M, Schmidt CM: *Chemotherapy with MEK Inhibitors, PD098059 and U0126 in Human HCC: Multiple Mechanisms of Tumor Kill in vitro*, Gastro 2002: M821.
37. Yip-Schneider M, Schmidt CM: *Inhibition of Akt Signal Transduction Pathway Complements the Response of Pancreatic Carcinoma Cells to Sulindac*, Gastro 2002: 123: 15.
38. Wiesenauer C, Schmidt CM, Howard TJ, Wiebke EA, Goulet R, Curry EA, Madura JA: *Preoperative Predictors of Malignancy in Pancreatic Intraductal Papillary Mucinous Neoplasms (IPMN)*, Western Surgical Association 2002.

39. Yip-Schneider M, Sweeney C, Marshall M, Nakshatri H, Schmidt CM: *Nuclear Factor-Kappa B Inhibition Augments Growth Suppression by Sulindac in Pancreatic Cancer Cells*, Proceedings of the AACR 2002, 44: #6365:1458.
40. Schmidt CM, Wang Y, Wiesenauer CA, Yip-Schneider M, Wu M: *Novel Combination of a COX-2 Inhibitor, NS398 and MEK Inhibitor, U0126, In Human Hepatocellular Carcinoma Provides Synergistic Increase in Apoptosis*, SSAT at DDW 2003, #732:A150.
41. McHenry L, Fletcher JW, Tann M, DeWitt JM, LeBlanc JK, Howard TJ, Schmidt CM, Fogel EL, Sherman S, Lehman GA: *Cystic Tumors of the Pancreas: Evaluation with 18-Fluorodeoxyglucose Positron Emission Tomography (PET) and Endoscopic Ultrasound-Guided Fine Needle Aspiration, EUS-FNA*, DDW 2003; #W120: A896.
42. Madura JA, Yum MN, Lehman GA, Schmidt CM: *Mucin Secreting Cystic Lesions of the Pancreas: Treatment by Enucleation*, Midwest Surgical Association 2003.
43. Tann MA, Fletcher JW, McHenry L, DeWitt JM, LeBlanc JK, Howard TJ, Schmidt CM, Fogel EL, Sherman S, Lehman GA: *FDG-PET/CT in the Evaluation of Cystic Pancreatic Tumors: Comparison with EUS/FNA*, Society of Nuclear Medicine January 2003.
44. Wiesenauer CA, Schmidt CM: *An Escape Mechanism Used by Hepatocellular Carcinoma to Resist MEK Inhibitor Chemotherapeutics*, JK Berman Meeting Proceedings, June 2003
45. Wiesenauer CA, Schmidt CM, Madura JA: *Preoperative Predictors of Malignancy in Pancreatic IPMN's*, Proceedings of the Indiana American College of Surgeons 2003.
46. Schmidt CM, Howard TJ, Wiebke EA, Madura JA: *Pancreaticoduodenectomy: A Twenty Year Experience in 516 Patients*, Western Surgical Meeting 2003.
47. Howard TJ, Moore SA, Matthews DE, Schmidt CM, Wiebke EA: *Pancreatic Duct Obstruction is a Common Cause of Recurrent Pancreatitis after Successful Management of Pancreatic Necrosis*, Central Surgical 2004.
48. Choi J, Albertin F, Wiesenauer CA, Yip-Schneider MT, Gage E, Klein PJ, Wang P, Lillemoe KD, Schmidt CM: *Doxorubicin's Effect on MEK-ERK Signaling Predicts its Efficacy in HCC*, Accepted SUS 2004
49. Gage EA, Wiesenauer CA, Choi JN, Klein PJ, Yip-Schneider MT, Wang Y, Albertin F, Omer C, Sebolt-Leopold JS, Schmidt CM: *Characterization of a Novel MEK Inhibitor (PD181461) Which Inhibits Human Hepatocellular Carcinoma Growth in Vitro and in Vivo*, AACR 2004.
50. Yip-Schneider MT, Schmidt CM, Crowell PL, Savage JJ, Hertzler II DA, Cummings WO, *The Role of Cyclooxygenase-2 in Hamster and Human Pancreatic Tumorigenesis*, AACR 2004
51. Klein PJ, Wiesenauer CA, Choi JN, Schmidt CM: *The Role of Protein Phosphatase 1 in Human Hepatocellular Carcinoma*, AASLD/DDW 2004.
52. Gage EA, Ralstin MC, Patel A, Yip-Schneider MT, Lillemoe KD, Schmidt CM: *NF-kB and Cyclooxygenase-2 Inhibitors Provide Synergistic Inhibition of Hepatocellular Carcinoma Cellular Proliferation Possibly Through Modulation of IKBa*, SSAT/DDW 2004.
53. Klein PJ, Wiesenauer CA, Choi J, Schmidt CM: *Human Hepatocellular Carcinoma Cells Exhibit Resistance to MEK Inhibition by U0126*, International Hepato-Pancreatico-Biliary Association 2004
54. Schmidt CM, Powell ES, Wiebke EA, Howard TJ, Yiannoutsos CT, Nakeeb A, Lillemoe KD, Madura JA: *Predictors of Pancreaticoenteric Anastomotic Leak or Fistula and Effect on Patient Outcomes Following Pancreaticoduodenectomy*, International Hepato-Pancreatico-Biliary Association 2004
55. Larson DM, Sidner RA, Schmidt CM, Miller GA, Howard TJ, Cummings OW, Wiebke EA: *Analysis of Angiogenesis as Determined by Factor VIII Expression, Lymphovascular invasion and Survival in Resected Pancreas Cancer*, International Hepato-Pancreatico-Biliary Association 2004
56. Wiesenauer CA, Schmidt CM: *Preoperative Predictors of Malignancy in Pancreatic IPMNs-the IU Experience*, JK Berman Proceedings 2004.
57. Gage EA, Schmidt CM: *NF-kB and Cyclooxygenase-2 Inhibitors Provide Synergistic Inhibition of Hepatocellular Carcinoma Cellular Proliferation Possibly Through Modulation of IKBa*, JK Berman Proceedings 2004.
58. Choi J, Schmidt CM: *Predictors of Pancreaticoenteric Anastomotic Leak or Fistula and Effect on Patient Outcomes Following Pancreaticoduodenectomy*, JK Berman Proceedings 2004.

59. Larson DM, Sidner RA, Schmidt CM, Miller GA, Howard TJ, Cummings OW, Wiebke EA: *Analysis of Angiogenesis as Determined by Factor VIII Expression, Lymphovascular Invasion and Survival in Resected Pancreas Cancer*, LustGarten/AACR Pancreatic Cancer Research Conference 2004.
60. Henning M, Klein PJ, Menze A, Matos J, Campbell J, Fausto N, McKillop IH, Sitzmann JV, Schmidt CM: *Chronic Ethanol Exposure Promotes MEK-ERK Dependent Growth in Human Haptocellular Carcinoma (HCC)*, Digestive Disease Week Meeting, 2005.
61. Klein PJ, Zeni AM, McCune KR, Wait AD, Matos JM, Menze AJ, Wiesenauer CA, Wiebke EA, Lai P, Feitelson MA, Schmidt CM: *Human Hepatocellular Carcinoma Exhibits Resistance to Small Molecule MEK Inhibition that is Independent of P53, HBx and P-glycoprotein Expression*, AACR Annual Meeting, 2005.
62. Yip-Schneider M, Wu H, Ralstin M, Crooks P, Nakshatri H, Sweeney C, Schmidt CM: *Suppression of Human Pancreatic Tumor Growth in vivo by Sulindac and a Novel Analog of Parthenolide with Improved Bioavailability*, AACR Annual Meeting, 2005.
63. Eppstein AC, Sandoval JA, Klein PJ, Woodruff HA, Grosfeld JL, Hickey RJ, Malkas LH, Schmidt CM: *Differences in MAP Kinase Signaling Responses to MEK Inhibition in Three Distinct Neuroblastoma Cell Types*, AACR Annual Meeting, 2005.
64. Eppstein AC, Sandoval JA, Klein PJ, Woodruff HA, Grosfeld JL, Hickey RJ, Malkas LH, Schmidt CM: *Differential Signaling Response of Neuroblastoma to MEK Activity Inhibitor Treatment Predicts Resistance to MAP Kinase Based Treatment Strategies*, American Pediatric Surgical Association Annual Meeting, 2005.
65. Ralstin MC, Gage EA, Yip-Schneider MT, Klein PJ, Wiebke EA, Lillemoe KD, Schmidt CM: *NF-KappaB and COX-2 Inhibitors Provide Complementary Growth Inhibition in Human Hepatocellular Carcinoma through Apoptosis and Cyclind1 Mediated G0/G1 Arrest*, Poster of Distinction, Digestive Disease Week, McCormick Place, Chicago, IL, May 14-19, 2005.
66. Akisik F, Schmidt CM: *Role of Secretin Enhanced MRCP in Post-Whipple Surgical Patients*, Annual Biliary Meeting, 2005.
67. Akiski F, Schmidt CM: *High Resolution in Vitro Proton MR Spectroscopy of Pancreatic Fluid: Preliminary Results*, Annual Biliary Meeting, 2005.
68. Henning M, Klein PJ, Matos J, Norris A, Noble S, Doyle C, McKillop IH, Wiebke EA, Schmidt CM: *Ethanol-TGF- α -MEK Growth Signaling May Promote Alcohol Associated Human Hepatocellular Carcinoma*, Gastroenterology, 2005; 128(4-Supplement 2): A-780.
69. Sandoval JA, Eppstein AC, Hoelz DJ, Klein PJ, Linebarger JH, Turner KE, Rescorla FJ, Hickey RJ, Malkas LH, Schmidt CM: *Proteomic Analysis of Neuroblastoma Subtypes in Response to MAPK Inhibition: Profiling Multiple Targets of Cancer Kinase Signaling* American Cancer Society/SUS Annual Meeting, 2005.
70. Symms M, Rawl S, Schmidt CM, Hickey S, Bangle N, Grant M, Ko C, Baldwin C, Wendel C, Krouse R: *Influence of an Intestinal Ostomy on Sexual Function and Intimate Relationships*
71. Akisik MF, Schmidt CM, et al: *Role of Secretin Enhanced MRCP in Post Whipple.....* Accepted RSNA
72. Akisik MF, Schmidt CM, et al: *High Resolution In Vitro Proton MR Spec on Panc Fluid ...* accepted MRI Meeting
73. Mitchell KA, Raw SM, Schmidt CM, Grant M, Ko C, Baldwin CM, Wendel C, Hickey S, Bangel N, Krouse RS: *Embarrassment Linked to Quality of Life Outcome for Veterans with Intestinal Ostomies*, Midwest Nursing Research Society, 2006
74. Mitchell KA, Rawl SM, Schmidt CM, Grant M, Ko C, Baldwin CM, Wendel C, Hickey S, Bangel N, Krouse RS: *Affect of Embarrassment on Veteran's with Intestinal Ostomies*, Research Day Saint Francis Medical Center College of Nursing, Peoria IL, November 21, 2005.
75. Wentz S, Schmidt CM: *Sulindac Decreases N-nitrosobis (2-oxypropyl)amine-induced cholangiocarcinoma in hamsters (Schmidt CM – Mentor)*, AACR Annual Meeting, 2006.
76. Pais, SA, Attasaranya S, Leblanc JK, McHenry L, Stuart S, Schmidt CM, Dewitt J: *Utility of Presenting Symptoms and Endoscopic Ultrasound Morphology Characteristics in the Diagnosis of Intraductal Papillary Mucinous Tumors: Correlation with Histopathology in 74 Patients*, Annual DDW/SSAT, Los Angeles, CA, May 20-24-2006

77. Howard TJ, Krug JE, Yu J, Schmidt CM, Jacobson LE, Madura JA, Wiebke EA, Lillemoe KD: *A Margin Negative R0 Resection Accomplished with Minimal Blood Loss is the Surgeons Contribution to Long-Term Survival in Pancreatic Cancer*, Annual DDW/SSAT, Los Angeles, CA, May 20-24, 2006.
78. Mitchell KA, Rawl SM, Schmidt CM, Grant M, Ko C, Baldwin CM, Wendel C, Hickey S, Banel N, Krouse RS: *Quality of Life Outcomes for Veterans with Intestinal Ostomies to be Presented at the 30th Annual MNRS Research Conference, Milwaukee, WI, March 31-April 3, 2006.*
79. Holcomb B, Yip-Schneider MT, Ralstin M, Dixon J, Mahomed J, Sweeney C, Nakshatri H, Crooks P, Schmidt CM: *NF-kB Targeting in Pancreatic Cancer Promotes the Antiproliferative Effects of Gemcitabine*, DDW/SSAT, Los Angeles CA, May 20-24, 2006.
80. Henning M, Schmidt CM et al: *Targeting MEK with PD325901 Inhibits Hepatocellular Carcinoma Growth in TGF-+ Transgenic Mice*” Poster of Distinction, SSAT Annual Meeting, Los Angeles CA, May 20-24, 2006.
81. Howard T, Krug JE, Yu J, Schmidt CM, Jacobson LE, Maduar JA, Wiebke EA, Lillemoe KD: *A R0 Resection Accomplished with Minimal Blood Loss is the Surgeons Contribution to Long-Term Survival in Pancreatic Cancer*, SSAT, Los Angeles CA, May 20-24, 2006.
82. Grant M, Baldwin C, McCorkle R, Rawl S, Schmidt CM, Ko C, Wendel C, Krouse R: *Applying the Mixed Method Approach to a Multisite Study of Patients with Ostomies*, 2006, ONS Annual Meeting, 2006
83. Krouse RS, Wendel C, Mohler MJ, Rawl S, Grant M, Baldwin C, Coons SJ, McCorkle R, Ko C, Schmidt CM: *Health-Related Quality of Life in Veterans with Colorectal Cancer*, Association of VA Surgeons 20th Annual Surgical Symposium, Cincinnati, OH May 7-9, 2006.
84. Vegeler R Schmidt CM, Yip-Schneider M,: *“Effect of LC-1, A Novel Nuclear Factor-Kappa B(NF-kB) Inhibitor, and Celecoxib, A COX-2 Inhibitor, in a N-Nitrosobis(2-oxopropyl)amine (BOP) Model of Lung Cancer”*, Academic Surgery Congress, 2007
85. Abhishek M, Pitt HA, Marine M, Saxena R, Schmidt CM, Howard TJ, Lillemoe KD: *“Fatty Pancreas: A Factor in Postoperative Pancreatic Fistula,”* IHPBA, Scotland UK, 2006
86. Krouse RS, Schmidt CM, et al: *Intimacy Issues for Veterans with Colorectal Cancer and Ostomies*, APOS Symposium, 2006.
87. Schmidt CM, et al: *“Total Pancreatectomy (R0 Resection) Improves Survival Over Sub-Total Pancreatectomy in Isolated Neck Margin Positive Pancreatic Adenocarcinoma,”* Central Surgical Association, Chicago, IL, March 8-10, 2007.
88. DeWitt J, McGreevy K, Schmidt CM, Collier K, Brugge WR: *“Ethanol Pancreatic Injection of Cysts (EPIC): Preliminary Results of a Prospective Multicenter, Randomized Double Blinded Study,”* Gastrointest Endosc, 2007.
89. White PB, Waters JA, Baker M, Cummings WO, Howard TJ, DeWitt J, Pitt HA, Zyromski NJ, Nakeeb A, Akisik F, Lillemoe KD, Grosfeld JL, Schmidt CM: *“Intraductal Papillary Mucinous Neoplasms (IPMN): Factors Predicting Malignancy,”* ASA Annual Meeting, 2007.
90. Yip-Schneider MT, Ralstin M, Wu Huangbing, Njoku V, Holcomb BC, Schmidt CM: *“The Role of Celecoxib and LC-1 in the Treatment of Pancreatic Cancer,”* AACR, April, 2007.
91. Waters JA, Pinchot JW, White PB, Pitt HA, Sandrasegaran K, Akisik F, Howard TJ, Nakeeb A, Zyromski NJ, Lillemoe KD, Schmidt CM: *“CT vs. MRCP: Optimal Classification of IPMN Type and Extent”*, AHPBA, 2007
92. Holcomb B, Yip-Schneider MT, Dixon J, Kennar J, Mahomed J, Wiebke EA, Sebolt-Leopold J, Schmidt CM: *“Tumor Genetics and Signaling Response to Gemcitabine Correlate with Treatment Effect of Gemcitabine-based Molecular Targeting Strategies”* AHPBA, 2007.
93. Baker MS, DeWitt JM, Kognkam P, Leblanc JK, Cramer HM, Howard TJ, Schmidt CM, Lillemoe KD, Pitt HA, *“Cystic Pancreatic Neuroendocrine Tumors: A Rare Entity?”* American Hepato-Pancreato-Biliary Association Annual Meeting, Las Vegas, NV, April 19-22, 2007.
94. Zyromski NJ, Nakeeb A, Schmidt CM, Pitt HA, Lillemoe KD, Howard TJ: *“ Unusual Early and Late Complications of Pancreaticoduodenectomy: Recognition is Paramount to Diagnosis,”* Poster

- Session, American Hepato-Pancreato-Biliary Association Annual Meeting, Las Vegas, NV, April 19-22, 2007.
95. Schmidt CM, Yip-Schneider MT, Ralstin MC, Dutkevitch S, Wentz SC, DeWitt JM, Howard TJ, McHenry L, Lillemoe KD: “*PGE₂ in Pancreatic Cyst Fluid Differentiates IPMN from Mucinous Cystadenoma and May predict Degree of IPMN Dysplasia*,” Washington DC, SSAT Annual Meeting, May 19-23, 2007.
 96. Wentz SC, Wu H, Hennig H, Yip-Schneider MT, Schmidt CM: “*MEK Targeting is Effective Chemoprevention of HCC in TGF-alpha Transgenic Mice*,” Washington DC, SSAT Annual Meeting, May 19-23, 2007.
 97. Howard TJ, Cohen SM, Zyromski NJ, Nakeeb A, Schmidt CM, Pitt HA, Lillemoe KD: “*Persistent Pancreatic Fistula Following Necrosectomy: Long-Term Patency of Pancreaticojejunostomy is Superior to Fistulojejunostomy*,” Washington DC, SSAT Annual Meeting, May 19-23, 2007.
 98. Hekmatyar SK, Schmidt CM, Babsky A, Wu H, Wentz S, Hennig ME, Miller MA, Sebolt-Leopold, JS, Bansal N: “*Monitoring of Liver Tumor Response to Treatment by MRI*,” Joint Annual Meeting ISMRM-ESMRMB, Berlin, Germany, May 19-25, 2007.
 99. Schmidt CM, Wiesenauer CA, Sitzmann JV: “*Long Term Effects on Diet after Proctocolectomy for Ulcerative Colitis*,” Midwest Surgical Association, August, 2007.
 100. Schmidt CM, Klein PJ, Wentz SC, Hennig M, Yip-Schneider MT, Matos-Bramblia JM, Froehlich JC, “*Novel Model of Alcohol-induced Hepatocellular Carcinoma (HCC)*,” RSA Annual Meeting, Chicago, IL, July 2007.
 101. Yancey K, Pitt HA, Wang M, Yip-Schneider MT, Sherman S, Lillemoe KD, Goggins M, Schmidt CM. “*Proteome of Normal Pancreatic Juice*”. American Pancreatic Association, 2007 (Accepted 8-2007).
 102. Y Zhukov, TJ Howard, A Nakeeb, HA Pitt, KD Lillemoe, L McHenry, EL Fogel, CM Schmidt, NJ Zyromski. “*Resistant Organisms Predict Poor Outcome in Necrotizing Pancreatitis: A Plea to do no Harm*”. American Pancreatic Association, 2007 (Accepted 8-2007).
 103. Lavu H, Knuth JL, Baker MS, Zyromski NJ, Schmidt CM, Nakeeb A, Howard TJ. “*Middle pancreatectomy is a technique readily incorporated into a pancreatic surgeons clinical practice*”. AHPBA, 2008.
 104. Brugge WR, Collier K, McGreevy K, Schmidt CM, DeWitt JD. “*Ethanol pancreatic injection of cysts: Results of a prospective, multicenter, randomized, double blinded study*”. ASGE 2007 Supplement; S192:209.
 105. Y Zhukov, TJ Howard, L McHenry, EL Fogel, A Nakeeb, HA Pitt, KD Lillemoe, CM Schmidt, NJ Zyromski. Yeast infection in patients with necrotizing pancreatitis may cause a rise in morbidity and mortality. SSAT/DDW, 2008 pending acceptance.
 106. Pittman J, Rawl S, Grant M, Ko C, Schmidt CM, Wendel C, Krouse R. Demographic and Clinical Factors related to Ostomy Complications and Quality of Life in Veterans with an Ostomy. WOCN Society 40th Annual Conference (June 21-25th, 2008).
 107. Matos JM, Witzmann FA, Schmidt CM. Proteomic profiles of human hepatocellular carcinoma and adjacent non-malignant liver. ASC (February 2008).
 108. Matos JM, Schmidt CM, Howard TJ, Cummings OW, Wiebke EA, Madura JA, Loehrer PJ, Crowell PL. A pilot study of perillyl alcohol in pancreatic cancer. ASC (February 2008).
 109. Cardenes H, Chiorean G, Perkins S, Schmidt CM, DeWitt J, Schmidt CM, Crowell P, Yip-Schneider MT, Zyromski NJ, Cramer H, Howard TJ. Neoadjuvant Gemcitabine, Erlotinib and hypofractionated radiation therapy for potentially resectable pancreatic cancer: A Pilot Study. ASCO 2008.
 110. Kooby, Gillespie, Bentrem, Nakeeb, Schmidt, Merchant, Parikh, Martin, Scoggins, Ahmad, Kim, Park, Staley, Byrd-Sellers, Wood, Hawkins. Multicenter Analysis of 667 Left Pancreatectomies: Should the Laparoscopic Approach Become Standard? American Surgical (Nov 2008).
 111. A Nakeeb, A Prather, HA Pitt, A Mathur, CM Schmidt, NJ Zyromski, JA Madura, TJ Howard, KD Lillemoe. Distal Pancreatectomy in the modern era: Evolution of a procedure. Pancreas Club 2008.

112. Schmidt CM, Matos JM, Bentrem DJ, Talamonti MS, Lillemoe KD, Bilimoria KY. Predictors of Survival in 865 Patients with Acinar Cell Carcinoma of the Pancreas: Survival after Surgery compared to Ductal Adenocarcinoma. SSAT 2008.
113. Matos JM, Schmidt CM, Niedergethmann M, Saeger HD, Merchant N, Lillemoe KD, Grützmann R. Pancreatic Acinar Cell Carcinoma: a Multi-institutional study. SSAT 2008.
114. Kennedy EP, Yeo CY, White PB, Howard T, Sauter P, Lillemoe KD, Schmidt. Clinical Significance and Natural History of Microinvasive Pancreatic Adenocarcinomas Associated with Resected Intraductal Papillary Mucinous Neoplasms: A Multi-Institutional Experience. SSAT 2008.
115. Lopes JM, Zyromski NJ, Zhukov, Attila N, Pitt HA, Lillemoe KD, Schmidt CM, Howard TJ. Pancreatitis DVT incidence. SSAT 2008.
116. Doyle CJ, Yip-Schneider MT, Schmidt CM. Pancreatic fluid TGF- α expression in intraductal papillary mucinous neoplasms and other cystic lesions of the pancreas. ASC 2009.
117. Matos, Grutzmann, Schmidt. Solid Pseudopapillary Neoplasms: a multi-institutional experience. ASC 2009.
118. Schmidt CM, Dobrolecki L, Agarwal A, Tector JA, Yip-Schneider MT, Matos JM, Hickey RJ. SELDI-TOF mass spectroscopy of serum predicts hepatocellular carcinoma in patients prior to liver transplantation. SSAT/DDW 2009
119. Turrini O, Schmidt CM, Moreno J, Parikh P, House M, Zyromski NJ, Nakeeb A, Howard TJ; Pitt HA; Lillemoe KD. Should high serum CA 19-9 levels preclude surgery in patients with resectable pancreatic head adenocarcinoma? SSAT/DDW 2009.
120. Al-Azzawi, Hayder H.1; Bermes, Angela M.1; Kuhlenschmidt, Heidi1; Howard, Thomas J.1; Wiebke, Eric A.1; Pitt, Henry A.1; Nakeeb, Attila1; Schmidt, C. Max1; Lillemoe, Keith D.1; Zyromski, Nicholas J.1 Colectomy in necrotizing pancreatitis portends a complex clinical course. Submitted for SSAT 2009.
121. Weber SM, Schmidt CM et al. Laparoscopic versus open left pancreatectomy: can preoperative factors indicate the safer technique? Accepted SSO 2009.
122. Cho CS, Kooby DA, Schmidt M, Nakeeb A, Bentrem D, Merchant N, Parikh AA, Martin RC III, Scoggins CR, Ahmad S, Kim HJ, Hamilton N, Hawkins W, Weber SM. Laparoscopic versus open left pancreatectomy: can preoperative factors indicate the safer technique? Accepted ACoS 2009.
123. Al-Haddad M, Schmidt CM et al. The Role of Pancreatic Cyst Fluid DNA Analysis in Patients' Management: Are we there yet? ASCGE/DDW Chicago, IL, June 3, 2009.
124. Cho CS, Kooby DA, Schmidt M, Nakeeb A, Bentrem D, Merchant N, Parikh AA, Martin RC III, Scoggins CR, Ahmad S, Kim HJ, Hamilton N, Hawkins W, Weber SM.. Laparoscopic versus open left pancreatectomy: can preoperative factors indicate the safer technique? Accepted Pancreas Club 2009.
125. Sandrasegaran K, Akisik FM, Rydberg M, Patel AA, Cramer HM, Agaram NP, Schmidt CM. The usefulness of diffusion-weighted imaging in characterization of cystic pancreatic lesions. RSNA 2009.
126. Akisik MF, Aisen AM, Sandrasegaran K, Schmidt CM, Jennings SG, Sherman S, Rydberg M. Growth rates and behavior over time of pathologically proven pancreatic side branch IPMN. RSNA 2009.
127. Kleyman S, Cardenes H, Howard T, Yu M, Burns M, Schmidt CM, Loehrer PJ, Helft P, Nakeeb A, Lillemoe KD, Chiorean EG. Is Adjuvant Gemcitabine-based Chemoradiation (GRT) Superior to Gemcitabine Alone for Resected Pancreatic Adenocarcinoma? The Indiana University Experience. ASCO 2010.
128. Pitt HA Kilbane EM, Nakeeb A, Howard TJ, Schmidt CM, Maluccio MM, Zyromski NJ, House MG, Lillemoe KD. Reducing surgical site infections in hepato-pancreato-biliary surgery. ACS-NSQIP 2010.
129. Saavedra JRA, Waters JA, Beane JD, Schmidt CM. The Role of Robotic-assisted Approach to Distal Pancreatectomy. ASC 2010

130. Doyle C, Aboudi S, Matos JM, Grützmann R, Turrini O, Agaram NP, Lillemoe KD, Schmidt CM. Adenosquamous carcinoma of the pancreas: a multi-institutional study. ASC 2010.
131. Doyle C, Wu H, Matos JM, Yip-Schneider MT, Schmidt CM. HAD Rat: A Model for Ethanol-Induced Hepatocellular Carcinoma. ASC 2010.
132. Waters JA, Yip-Schneider MT, Wentz S, Wu H, Schmidt CM. Increased Hepatocellular Dysplasia in Alcohol Preferring P Rat model. ASC 2010.
133. Ziegler KM, Nakeeb A, Pitt HA, Schmidt CM, Bishop SN, Moreno J, Matos JM, Zyromski NJ, House MG, Madura JA, Howard TJ, Lillemoe KD. Pancreatic Surgery: Evolution at a High Volume Center. CSA 2010.
134. Waters JA, Canal DF, Wiebke EA, Dumas RP, Beane JD, Aguilar-Saavedra JR, Ball C, House MG, Nakeeb A, Lillemoe KD, Schmidt CM. Robotic Distal Pancreatectomy: Cost-effective?. CSA 2010.
135. Turrini O, Waters JA, Yiannoutsis C, Schnelldorfer T, Lillemoe KD, Farnell MB, Sarr MG, Schmidt CM. Invasive IPMN: Adjuvant therapy and treatment of recurrence. IHPBA 2010
136. Al-Haddad, M, Friedlin, J, Kesterson, J, Waters, JA, Aguilar-Saavedra, JR, Schmidt, CM. Natural language processing for the development of a clinical registry: a validation study in IPMN. IHPBA 2010.
137. Turrini O, Schmidt CM, Guiramand J, Aguilar-Saavedra JR, Aboudi S, Pitt HA, Lillemoe KD, Delperro JR. Side-branch IPMN of the pancreatic head/uncinate: resection or enucleation? IHPBA 2010
138. Al-Haddad MA, DeWitt JM, Sherman S, Schmidt CM, Juliar BE, Stuart JS, LeBlanc JK. Diagnostic accuracy of pancreatic cyst fluid tumor markers obtained by EUS-guided sampling. AGA-DDW 2010.
139. Turrini O, Wiebke EA, Delperro JR, Viret F, Lillemoe KD, Schmidt CM. Preservation of Replaced or Accessory Right Hepatic Artery during Pancreaticoduodenectomy for Pancreatic Adenocarcinoma: Impact on Margin Status and Survival. SSAT-DDW, 2010.
140. Ball CG, Correa-Gallego C, Howard TJ, Zyromski NJ, House M, Pitt HA, Nakeeb A, Schmidt CM, Lillemoe KD. Radiation dose from CT in patients with necrotizing pancreatitis: How much is too much? SSAT-DDW, 2010.
141. Parikh P, Waters JA, Pitt HA, Aguilar-Saavedra JR, Cardenes H, Chiorean EG, Helft PR, Schmidt CM, Nakeeb A, Lillemoe KD. Ampullary carcinoma: Adjuvant chemoradiation improves survival in node-positive patients. SSAT-DDW, 2010.
142. JA Waters, JR Aguilar-Saavedra, M House, NJ Zyromski, A Nakeeb, TJ Howard, HA Pitt, KD Lillemoe, C M Schmidt. Survival of Invasive Intraductal Papillary Mucinous Neoplasm (IPMN) and Pancreatic Adenocarcinoma Following Resection: A Multi-institutional Comparison According to AJCC Stage. ACoS, 2010.
143. Henry A. Pitt MD, E. Molly Kilbane RN, BSN, Attila Nakeeb MD, Thomas J. Howard MD, C. Max Schmidt MD, Mary M. Maluccio MD, Nicholas J. Zyromski MD, Michael G. House MD, Keith D. Lillemoe MD. Reducing Surgical Site Infections in Hepato-Pancreato-Biliary Surgery. ACoS 2010.
144. Horner DJ, Wendel CS, Coons SJ, Rawl SM, Grant M, Schmidt CM, Ko CY, Krouse RS. Positive Correlation of Employment and Psychological Quality of life for Veterans with Major Abdominal Surgery. AVAS 2010.
145. PB White, H Wu, M Yip-Schneider, CM Schmidt, KM Ziegler, HA Pitt, DA Swartz-Basile, NJ Zyromski. High-Fat Diet Hastens Mortality from Pancreatic Adenocarcinoma in Kras/Cre/p53 Mice. APA 2010.
146. Beane JD, Nakeeb A, Pitt HA, Ziegler KM, Schmidt CM, Zyromski NJ, Howard TJ, Lillemoe KD. Splenic Preserving Distal Pancreatectomy: With or Without Vessel Preservation? Southern Surgical Association, 2010.
147. Friedlin J, Schmidt CM et al. Comparing Methods for Identifying Pancreatic Cancer Patients Using Electronic Data Sources. AMIA Nov 15, 2010.

148. S. Aboudi, J. A. Waters, J. R. Aguilar-Saavedra, C. M. Schmidt. Routine Closed Suction Drainage Of Pancreatic Resection In The Setting Of A Soft Pancreas: Is It Necessary? Academic Surgical Congress 2011.
149. El Chafic, II El Hajj, J DeWitt, S Sherman, TF Imperiale, J LeBlanc, L McHenry, CM Schmidt, M. Al-Haddad. Comparison of Preoperative Cytopathology, Tumor Markers and Molecular Analysis for the Diagnosis of Mucinous Pancreatic Cysts in Patients Undergoing Surgical Resection. ACG 2010 (received the presidential award for best poster).
150. Meyer JE, Miller JR, Waters JA, Al-Haddad M, DeWitt J, Sherman S, Lillemoe KD, Schmidt CM Outcome of Pancreatic Remnant Following Segmental Pancreatectomy for Non-Invasive Intraductal Papillary Mucinous Neoplasm (IPMN) American Hepato-Pancreato-Biliary Association, 2011.
151. JA Glant, JA Waters, MG House, NJ Zyromski, AJ Nakeeb, HA Pitt, KD Lillemoe, CM Schmidt. Does the Interval from Imaging to Operation affect the Rate of Occult Metastases Encountered During Operation for Pancreatic Adenocarcinoma? Central Surgical Association 2011.
152. Al-Haddad M, Schmidt CM et al. Preoperative Endoscopic Tissue Sampling of Intraductal Papillary Mucinous Neoplasms (IPMNs) with Mural Nodules (MNs). DDW 2011
153. Ball C.G., Correa-Gallego JC, Howard TJ, Zyromski N, House MG, Pitt HA, Nakeeb A, **Schmidt CM** & Lillemoe KD. Damage control principles for hemorrhaging patients undergoing operative debridement for necrotizing pancreatitis. In: HPB: Abstracts of the 9th Congress of the European-African Hepato-Pancreato-Biliary Association, Cape Town, South Africa, 2011.
154. Eugene P. Ceppa, Michael G. House, Henry A. Pitt, E. Molly Kilbane, Sandra Janitz, Attila Nakeeb, Thomas J. Howard, C. Max Schmidt, Mary A. Maluccio, Nicholas J. Zyromski, Keith D. Lillemoe. Reducing Surgical Site Infections in Hepato-Pancreato-biliary Surgery. AHPBA 2012.
155. Cauley CE, Waters J, Dumas R, Meyer J, Al-Haddad M, DeWitt J, Sherman S, Lillemoe KD, Schmidt CM. Outcomes of Primary Surveillance for Intraductal Papillary Mucinous Neoplasm. SSAT/DDW Plenary, May 10, 2011. Received Best of DDW Award Designation
156. Eugene P. Ceppa, Robert M. McCurdy, Molly Kilbane, Attila Nakeeb, Thomas J. Howard, C. Max Schmidt, Nicholas J. Zyromski, Keith D. Lillemoe, Henry A. Pitt, and Michael G. House. Does Pancreatic Stump Closure Method Influence Distal Pancreatectomy Fistula Rate. SSAT 2012.
157. Wesley Leung, MD¹, Gregory A. Coté, MD, MS¹, Damien Tan, MD¹, Joshua A. Waters, MD², C. Max Schmidt, MD, PhD², Stuart Sherman, MD¹, Glen A. Lehman, MD¹, Evan Fogel, MD¹, James Watkins, MD¹, Lee McHenry, MD¹, Michael G. House, MD² Self-expandable metallic stents do not impact on the frequency of complications related to preoperative biliary drainage or subsequent pancreatoduodenectomy. SSAT 2012
158. Schmidt CM. IPMN: Guides to management: past, present, future. IHPBA Proceedings 2012.
159. Saavedra J, Schmidt CM. Molecular Targeted NF-kB Suppression Inhibits Gemcitabine Resistance in Human Pancreatic Tumor Cells In vitro and In vivo. IHPBA Proceedings 2012.
160. DeWitt JM, Al-Haddad M, Sherman S, LeBlanc J, Schmidt CM, Finkelstein S. Alterations in Cross-sectional Imaging and Cyst Fluid Genetics Following Endoscopic Ultrasound Guided Pancreatic Cyst Ablation with Ethanol and Paclitaxel. ACG Proceedings, 2012
161. Lee SJ, Waters JA, Schmidt CM, Pitt HA, Zyromski NJ. Does acute pancreatitis change the natural history of IPMN? *Pancreatology* 13(2013)
162. Shaffer K, Schmidt CM et al. IPMN type but not grade of dysplasia is associated with smoking. AHPBA Proceedings, 2013.
163. Sturm E, Schmidt CM et al. Obesity increases malignant risk in patients with branch-duct IPMN. CSA Proceedings, 2013.
164. Catalano M, Schmidt CM et al. Interim results from an outcome based retrospective analysis of integrated molecular profiling of pancreatic cystic lesions. AGA Proceedings, 2013
165. Pitt HA, Schmidt CM et al. Reducing Readmissions Following Pancreatectomy: Coordination of the Care Continuum. SSAT Proceedings, 2013
166. Barron M, Schmidt CM et al. Does Preoperative Imaging Accurately Predict Main Duct Involvement in Intraductal Papillary Mucinous Neoplasm. SSAT Proceedings, Pancreas Club Proceedings, 2013

167. Ceppa E, Schmidt CM et al. Impact of Pancreatoduodenectomy Complications on Adjuvant Therapy and Long-Term Outcomes for Pancreatic Adenocarcinoma. SSAT Proceedings, Pancreas Club Proceedings, 2013
168. Chafic AE, Roch A, Schmidt CM, Al-Haddad MA, et al. Predictors of Malignancy in Branch Duct IPMN: How accurate are the 2012 International Consensus Guidelines? ACG Proceedings, 2013.
169. Aggarwal A, Valsangkar N, Roch A, Chafic AE, DeWitt JM, Sherman S, LeBlanc J, McHenry L, Cote G, Imperiale TF, Schmidt CM, Al-Haddad MA. Recurrence after Surgical Resection of Branch Duct Intraductal Papillary Mucinous Neoplasms (BD-IPMNs). ACG Proceedings, 2013.
170. Catalano M, Al-Haddad MA, Schmidt CM, Haddad N, Malhotra N, Mertz H, Siddiqui A, Kowalski T, Patel S, Martinez N, Lybik M, Mallat D, Karasik M, Golioto M, Linder J, Corcoran B, Ellsworth E, Jackson S, Finkelstein SD. Clinical validity of integrated molecular profiling in diagnosing pancreatic lesions: Results (N=492) of an outcomes based registry. ACG Proceedings, 2013.
171. Al-Haddad MA, Schmidt CM, Catalano M, Haddad N, Malhotra N, Mertz H, Siddiqui A, Kowalski T, Patel S, Okoh E, Lybik M, Mallat D, Karasik M, Swales C, Linder J, Corcoran B, Ellsworth E, Jackson S, Finkelstein SD. The performance of second-line integrated molecular profiling compared to common, first-line testing risk features in diagnosing and predicting benign and malignant pancreatic lesions: Interim results from an outcome based registry in 422 patients. ACG Proceedings, 2013.
172. Roch A, Ceppa EP, DeWitt JD, Al-Haddad MA, Schmidt CM. Non-operative management of main pancreatic duct involved intraductal papillary mucinous neoplasm may be indicated in select patients. WSA Proceedings 2013.
173. Schmidt CM, Wu H, Dumas RP, Agaram N, Feliciano DV, Yip-Schneider MT. VEGF-A, A Novel and Highly Accurate Pancreatic Fluid Biomarker for Serous Pancreatic Cysts. SSA Proceedings, 2013.
174. Une prise en charge non chirurgicale des TIPMP du canal principal peut être raisonnablement offerte à des patients sélectionnés AM Roch, MR Barron, JA Waters, CM Schmidt (Indianapolis, USA) 115th meeting of the French Surgical Association, Paris, October 2nd 2013
175. Roch AM, Doyle CJ, Wang M, Bemis K, Yip-Schneider MT, Schmidt CM. Characterization of the Serum Proteome in patients with Malignant Intraductal Papillary Mucinous Neoplasm. ASC Proceedings 2014.
176. Schmidt H, Kilbane EM, Turner AP, House MG, Zyromski NJ, Nakeeb A, Schmidt CM, Ceppa EP. Socioeconomic Status and Surgical Outcomes after Total Pancreatectomy. AHPBA Proceedings 2014.
177. Roch A, Ceppa EP, DeWitt JD, Al-Haddad MA, Schmidt CM. International consensus guideline parameters carry unequal weight and are not cumulative in intraductal papillary mucinous neoplasm malignant risk prediction. AHPBA Proceedings 2014.
178. Ceppa E, Pitt H, Nakeeb A, Schmidt CM, Zyromski N, House M, Brand B, Weidert D, Lillemoe KD. Reducing readmissions following pancreatectomy: coordination of the care continuum. AHPBA Proceedings 2014.
179. Roch A, Schmidt CM et al. Abnormal Serum Pancreatic Enzymes, but not Pancreatitis, are Associated with an Increased Risk of Malignancy in Patients with Intraductal Papillary Mucinous Neoplasms. CSA Proceedings 2014.
180. Beane JD, House MG, Miller A, Nakeeb A, Schmidt CM, Ceppa E, Zyromski N, Feliciano DV, Pitt HA. Optimal management of delayed gastric emptying following pancreatectomy: an analysis of 1089 patients resected between 2007-2012. CSA Proceedings 2014
181. Roch A, Mehrabi S, Krishnan A, Schmidt H, Kesterson J, Beesley C, Dexter P, Tierney W, Palakal M, Schmidt CM. Automated pancreatic cyst screening using natural language processing: a new tool in pancreatic cancer early detection. IHPBA Proceedings 2014
182. Roch A, Ceppa EP, DeWitt JD, Al-Haddad MA, Feliciano D, Schmidt CM. The Natural History of Main Duct Involved, Mixed-Type Intraductal Papillary Mucinous Neoplasm: Parameters Predictive of Progression. ASA Proceedings 2014

183. Roch A, Ceppa EP, DeWitt JD, Al-Haddad MA, Schmidt CM. Intraductal Papillary Mucinous Neoplasm of the pancreas, one manifestation of a more systemic disease? Pancreas Club Proceedings 2014
184. McMillan RT et al Schmidt CM. The value of drains as a fistula mitigation strategy for pancreatoduodenectomy: something for everyone? Results of a randomized prospective multi-institutional study. Pancreas Club Proceedings 2014
185. Fisher W et al Schmidt CM. A randomized prospective multicenter trial of pancreaticoduodenectomy with and without routine intraperitoneal drainage. SSAT and Pancreas Club Proceedings 2014
186. Butler, Schmidt CM, Zyromski et al. Is Antacid Therapy after Pancreaticoduodenectomy Necessary? Contemporary Global Practice of Pancreatic Surgeons. SSAT Proceedings 2014.
187. Schmidt HE, Schmidt CM, Ceppa E et al. Socioeconomic Status and Surgical Outcomes after Regional Pancreatectomy. SSAT Proceedings 2014.
188. Roch A, Schmidt CM et al. Extended distal pancreatectomy for pancreatic adenocarcinoma with splenic vein thrombosis and/or adjacent organ invasion. MSA Proceedings 2014.
189. Roch A. Schmidt CM et al. Invasive mixed-type IPMN: Superior prognosis compared to invasive main-duct IPMN. CSA Proceedings 2015.
190. Waters, JA, Schmidt CM et al. Targeted NF- κ B suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts. CSA Proceedings 2015.
191. Welsh M, Schmidt CM ete al. Impact of margin status on survival in main duct involved IPMN. AHPBA Proceedings 2015.
192. Roch A. Schmidt CM et al. Significance of portal vein invasion and extent of invasion in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma. SSAT Proceedings 2015.
193. Wiriaporn R, Al-Haddad M, Schmidt CM et al. Management of branched duct intraductal papillary mucinous neoplasms: a large single center study to assess predictors of malignancy and recurrence on long term follow-up. ASGE Proceedings 2015
194. Mehrabi S, Schmidt CM et al. Identification of Patients with Family History of Pancreatic Cancer - Investigation of an NLP system Portability Med Info Proceedings 2015
195. Roch A. Schmidt CM et al. IPMN of the pancreas, one manifestation of a more systemic disease. MidWest Surgical Proceedings 2015.
196. Cioffi JL, Lee SJ, Waters JA, Schmidt CM, Nakeeb A, House MG, Ceppa EP, Zyromsky NJ. Should acute pancreatitis be an indication to resect IPMN? Pancreas Club Proceedings 2015.
197. Roch A, Ceppa EP, Tee MC, Marshall G, Morris-Stiff G, Alesidi A, Walsh M, Farnell M, Schmidt CM. Multi-institutional study on the natural history of large-sized (>3cm) branch-duct IPMN. WSA Proceedings 2015.
198. Butler J, Schmidt CM, Tector JA, et al. Silencing porcine carbohydrate genes significantly reduces human-anti-pig cytotoxicity profiles: an alternative to direct complement regulation. WSA Proceedings 2015
199. Springer S, Wang Y, Molin MD, Masica DL, Jiao Y, Kinde I, Blackford A, Raman SP, Wolfgang CL, Tomita T, Niknafs N, Douville C, Ptak J, Dobbyn L, Allen PJ, Klimstra DS, Schattner MA, Schmidt MC, Yip-Schneider M, Cummings OW, Brand RE, Zeh HJ, Singhi AD, Scarpa A, Salvia R, Malleo G, Zamboni G, Falconi M, Jang JY, Kim SW, Kwon W, Hong SM, Song KB, Kim SC, Swan N, Murphy J, Geoghegan J, Brugge W, Fernandez-Del Castillo C, Mino-Kenudson M, Schulick R, Edil BH, Adsay V, Paulino J, van Hooft J, Yachida S, Nara S, Hiraoka N, Yamao K, Hijioka S, van der Merwe S, Goggins M, Canto MI, Ahuja N, Hirose K, Makary M, Weiss MJ, Cameron J, Pittman M, Eshleman JR, Diaz LA Jr, Papadopoulos N, Kinzler KW, Karchin R, Hruban RH, Vogelstein B, Lennon AM: A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts. American Pancreatic Association (APA) Proceedings 2015.
200. McElyea SD, Nguyen HV, Gore J, Zhong X, Savant SS, Bayt D, Schmidt CM, House MG, and Korc M. MicroRNA-10b Expression in a Readily Accessible Common Hepatic Artery Lymph Node Correlates with Pancreatic Cancer Recurrence Post Resection. IUSCC Cancer Research Day 2016.

201. Carr RA, Chung C, Schmidt C, Jester A, Roch AM, Kilbane EM, House MG, Zyromski NJ, Nakeeb A, Schmidt CM, Ceppa EP. Impact of Fellow vs. Resident Assistance on Outcomes Following Pancreaticoduodenectomy. Resident Research Day 2016.
202. Jester A, Ceppa E, Nakeeb A, Schmidt CM, House MG, Zyromski NJ. Transgastric necrosectomy for the management of walled-off pancreatic necrosis: long-term outcomes at a high-volume pancreatic center. IHPBA 2016
203. Zimmers TA.....Schmidt CM....Koniaris L. Molecular and phenotypic profiling of pancreatic cancer cachexia in novel murine models and patients. AACR 2016
204. Shahda S,Schmidt CM....O'Neil B. Neoadjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer. AACR 2016
205. Bauman MD, Becerra DG, Kilbane EM, Zyromski NJ, **Schmidt CM**, Pitt HA, Nakeeb A, House MG, Ceppa EP. Laparoscopic distal pancreatectomy for pancreatic cancer is safe and effective. SAGES 2016.
206. Carr R, Roch A, Jester A, Ceppa EP, Zyromski NJ, Nakeeb A, **Schmidt CM**, House MG. Preoperative pain in pancreas cancer: a predictor of perineural invasion? Resident Research Day 2016.
207. Carr R, Roch A, Jester A, Ceppa EP, Zyromski NJ, Nakeeb A, **Schmidt CM**, House MG. Preoperative pain in pancreas cancer: a predictor of perineural invasion? SSAT 2016.
208. Jester A, Chung C, Becerra D, Roch A, Carr R, House MG, Zyromski NJ, **Schmidt CM**, Nakeeb A, Ceppa EP. The impact of hepaticojejunostomy anastomotic leaks after pancreatoduodenectomy: an uncommon complication but a devastating source of morbidity and mortality. SSAT 2016.
209. Roch A, Ceppa EP, Tee MC, Marshall G, Morris-Stiff G, Alesidi A, Walsh M, Farnell M, Schmidt CM. Multi-institutional study on the natural history of large-sized (>3cm) branch-duct IPMN. Pancreas Club 2015.
210. Roch AM, House MG, Cioffi J, Ceppa EP, Zyromski NJ, Nakeeb A, Schmidt CM. Significance of portal vein invasion and extent of invasion in patients undergoing pancreatoduodenectomy for pancreatic adenocarcinoma. Pancreas Club 2016.
211. Jester A, Ceppa E, Nakeeb A, Schmidt CM, House MG, Zyromski NJ. Transgastric necrosectomy for the management of walled-off pancreatic necrosis: long-term outcomes at a high-volume pancreatic center. Pancreas Club 2016
212. Springer S, Molin MD, Wang Y, Douville C, Masica DL, Blackford A, Wolfgang CL, Amini N, Allen PJ, Klimstra DS, Schattner MA, Schmidt MC, Yip-Schneider M, Cummings OW, Brugge WR, Brand RE, Zeh HJ, Singhi AD, Scarpa A, Salvia R, Malleo G, Zamboni G, Falconi M, Jang JY, Kim SW, Kwon W, Hong SM, Song KB, Kim SC, Swan N, Murphy J, Geoghegan J, Brugge W, Fernandez-Del Castillo C, Mino-Kenudson M, Schulick R, Edil BH, Adsay V, Paulino J, van Hooft J, Yachida S, Nara S, Hiraoka N, Yamao K, Hijioka S, van der Merwe S, Goggins M, Canto MI, Ahuja N, Hirose K, Makary M, Weiss MJ, Cameron J, Pittman M, Eshleman JR, Diaz LA Jr, Papadopoulos N, Hruban RH, Lennon AM: 597 Molecular Markers Help Define Cyst Type in the Pancreas: an International, Multicenter Study of Over 300 Cysts. Digestive Disease Week Proceedings 2016.
213. Roch AM, Carr RA, Watkins JL, Lehman GA, House MG, Nakeeb A, **Schmidt CM**, Ceppa EP, Zyromski NJ. Percutaneous gastrostomy in necrotizing pancreatitis: friend or foe? WSA 2016
214. Carr RA, Yip-Schneider MT, Dolejs SC, Schmidt CM. Pancreatic cyst fluid vascular endothelial growth factor: highly accurate in combination with carcinoembryonic antigen for serous cystic neoplasm diagnosis. WSA 2016
215. Roch AM, Carr RA, Lancaster WP, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**. Mucinous cystic neoplasm and branch duct IPMN of the pancreas: should we still treat them differently? SSA 2016
216. Schwartz PB, Roch AM, Lancaster WP, Kilbane EM, House MG, Zyromski NJ, **Schmidt CM**, Nakeeb A, Ceppa EP. Indication for en bloc pancreatectomy with colectomy: when is it safe? SAGES 2017

217. Van Buren II G,**Schmidt CM**...et al. A randomized prospective multicenter trial on distal pancreatectomy with and without routine intraperitoneal drainage. ASA 2017
218. Baptiste D, Fecher AM, Yoder J , **Schmidt CM** , Couch ME , Ceppa DP. Gender Differences in Academic Surgery Work-Life Balance and Satisfaction. ACS 2017
219. AM Roch, ME Johnston, J Schneider, JL Hunter, WP Lancaster, MG House, NJ Zyromski, A Nakeeb, **CM Schmidt**, EP Ceppa. Are BRCA2 gene mutation patients inappropriately under-screened for pancreatic adenocarcinoma? AHPBA Proceedings 2017
220. Bletsis P, Carr RA, Roch AM, Mazhar S, Schmidt CM-II, Lancaster WP, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**, Ceppa EP. Cystic pancreatic neuroendocrine tumors: a more favorable lesion? AHPBA Proceedings 2017.
221. W Lancaster, A Roch, E Ceppa, C Schmidt, M House, A Nakeeb, W Fisher, G Van Buren II, N Villafane-Ferriol, M Dillhoff, **CM Schmidt**, N Zyromski. Pathologic assessment of vascular involvement in pancreatectomy with vascular resection: room for improvement. AHPBA Proceedings 2017
222. R Carr, B Kiel, A Roch, E Ceppa, M House, N Zyromski, A Nakeeb, **CM Schmidt**. Association of pancreatic insufficiency with intraductal papillary mucinous neoplasm dysplasia. AHPBA Proceedings 2017.
223. C Schmidt II, AM Roch, RA Carr, P Bletsis, WP Lancaster, MG House, NJ Zyromski, A Nakeeb, EP Ceppa, **CM Schmidt**. Association of intraductal papillary mucinous neoplasm and pancreatic neuroendocrine tumors: myth or reality? AHPBA Proceedings 2017.
224. M Yip-Schneider, R Carr, H Wu, **CM Schmidt**. Prostaglandin E2: a pancreatic fluid biomarker of IPMN dysplasia. AHPBA Proceedings 2017.
225. K Ramanathan, RA Carr, AM Roch, WP Lancaster, EP Ceppa, MG House, NJ Zyromski, A Nakeeb, **CM Schmidt**. Splenic involvement in pancreatic adenocarcinoma may carry significant clinical impact. AHPBA Proceedings 2017.
226. Carr RA, Yip-Schneider MT, Dolejs S, Hancock BA, Wu H, Radovich M, **Schmidt CM**. Pancreatic cyst fluid VEGF-A and CEA: a highly accurate test for the diagnosis of serous cystic neoplasm. Panc Club Proceedings 2017
227. Roch AM, Johnston ME-II, Schneider J, Hunter JL, Lancaster WP, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**, Ceppa EP. Are BRCA2 gene mutation patients inappropriately under-screened for pancreatic adenocarcinoma? Panc Club Proceedings 2017
228. Roch AM, Bigelow K, Schmidt CM-II, Carr RA, Jester AL, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**. Management of the undifferentiated solitary mucinous cystic lesion of the pancreas: a clinical dilemma. Panc Club Proceedings 2017
229. Roch AM, Carr RA, Lopes J, Ceppa EP, Yoder J, House MG, Nakeeb A, **Schmidt CM**, Zyromski NJ. Venous thromboembolism in necrotizing pancreatitis: an underappreciated risk. Panc Club Proceedings 2017
230. Roch AM, Carr RA, **Schmidt CM**, House MG, Nakeeb A, Ceppa EP, Easler JJ, Zyromski NJ. Evolving treatment of necrotizing pancreatitis. Panc Club Proceedings 2017.
231. Roch AM, Carr RA, Watkins JL, Lehman G, House MG, Nakeeb A, **Schmidt CM**, Ceppa EP, Zyromski NJ. Percutaneous gastrostomy in necrotizing pancreatitis: friend or foe. Panc Club Proceedings 2017.
232. Bletsis P, Carr RA, Roch AM, Mazhar S, Schmidt CM-II, Lancaster WP, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**, Ceppa EP. Cystic pancreatic neuroendocrine tumors: a more favorable lesion? Panc Club Proceedings 2017.
233. Lancaster WP, Maatman T, **Schmidt CM**, Ceppa EP, Zyromski NJ, Nakeeb A, House MG. Impact of surgical margin clearance on patterns of recurrence for pancreatic adenocarcinoma. Panc Club Proceedings 2017.
234. Roch AM, Maatman T, Carr RA, **Schmidt CM**, House MG, Nakeeb A, Ceppa EP, Easler JJ, Zyromski NJ. Evolving Treatment of Necrotizing Pancreatitis. MSA Proceedings 2017

235. Carr RA, Roch AM, et al **Schmidt CM**. Cancer History: A Predictor of IPMN Subtype and Dysplastic Status? Top 5 Poster of Distinction. MSA Proceedings 2017
236. Carr RA, Yip-Schneider, et al **Schmidt CM**. Pancreatic Cyst Fluid Glucose: Rapid, Inexpensive, and Accurate Diagnosis of Mucinous Pancreatic Cysts. Oral Plenary Presentation. CSA/MSA Proceedings 2017
237. Yip-Schneider MT, Carr RA, Wu H, Fan H, Liu Z, Korc M, **Schmidt CM***, Zhang J. Circulating Leptin: Potential Predictor of IPMN Malignant Risk. WSA Proceedings 2017 (*co-senior author)
238. Maatman TK, Roch A, House M, Nakeeb A, Ceppa E, **Schmidt CM**, Wehlage K, Cournoyer R, Zyromski N. Damage control pancreatic debridement: salvaging the most severely ill. ASC Proceedings 2018
239. Simpson RE, Cockerill NJ, Yip-Schneider MT, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, Al-Haddad MA, **Schmidt CM**. DNA profile components predict malignant outcomes in select cases of intraductal papillary mucinous neoplasm with negative cytology. CSA Proceedings 2018
240. Butler J, Kays J, House MG, Nakeeb A, **Schmidt CM**, Ceppa EP, Zyromski NJ. Pancreaticoduodenectomy in the cirrhotic patient: predictors of outcome. AHPBA Proceedings 2018
241. Simpson R, Cockerill N, Yip-Schneider MT, Ceppa E, House MG, Zyromski NJ, Nakeeb A, Al-Haddad M, **Schmidt CM**. Clinical criteria for integrated molecular pathology in IPMN: less is more. AHPBA Proceedings 2018.
242. Carr RA, Roch AM, Zhong X, Motamed M, Ceppa EP, Zyromski NJ, **Schmidt CM**, Nakeeb A, House MG. Randomized controlled trial of intraoperative chemical splanchnicectomy for patients with resected pancreatobiliary malignancies. IHPBA Proceedings 2018
243. Kelley KE, Fajardo AD, Strange NM, Harmon CA, Pawlecki K, Sieber M, Walke N, Fadel WF, Wooden WA, Sadowski J, Birdas TJ, Stevens LH, Rozycki GS, **Schmidt CM**. Impact of a Novel Preoperative Patient-centered Surgical Wellness Program. ASA Proceedings 2018.
244. Solis LM et al. Schmidt CM et al. Characterization of Immune Profiling of Pancreatic IPMN using Multiplex Immunofluorescence and Image Analysis Approaches. AACR Proceedings 2018.
245. Springer S, Masica DL, Dal Molin M, Douville C, Thoburn CJ, Afsari B, Li L, Cohen JD, Thompson E, Allen PJ, Klimstra DS, Schattner MA, **Schmidt CM**, Yip-Schneider M, Simpson RE, Fernandez-Del Castillo C, Mino-Kenudson M, Brugge W, Brand RE, Singhi AD, Scarpa A, Lawlor R, Salvia R, Zamboni G, Hong SM, Hwang DW, Jang JY, Kwon W, Swan N, Geoghegan J, Falconi M, Crippa S, Doglioni C, Paulino J, Schulick RD, Edil BH, Park W, Yachida S, Hijioaka S, van Hooft J, He J, Weiss MJ, Burkhart R, Makary M, Canto MI, Goggins MG, Ptak J, Dobbyn L, Schaefer J, Sillman N, Popoli M, Klein AP, Tomasetti C, Karchin R, Papadopoulos N, Kinzler KW, Vogelstein B, Wolfgang CL, Hruban RH, Lennon AM. A multi-modality test to guide the management of patients with pancreatic cysts. DDW Proceedings 2018
246. Simpson RE, Ceppa EP, Wu HH, Akisik F, House MG, Zyromski NJ, Nakeeb A, Al-Haddad MA, DeWitt JM, Sherman S, **Schmidt CM**. The Dilemma of the Dilated Main Pancreatic Duct in the Distal Pancreatic Remnant After Proximal Pancreatectomy for IPMN. DDW Proceedings 2018
247. Ponugoti P, et al. **Schmidt CM** et al. Gain and Loss of KRAS Mutations in Pancreatic Cyst Fluid During Prolonged Surveillance: a Natural History Study. DDW Proceedings 2018
248. Maatman T, et al. **Schmidt CM** et al. Necrosis Morphology does not Predict Success of Percutaneous Drain in Necrotizing Pancreatitis. DDW Proceedings 2018
249. Maatman T, et al. **Schmidt CM** et al. Leukocytosis after Distal Pancreatectomy and Splenectomy (DPS); a Marker of Major Complications? DDW Proceedings 2018
250. Simpson R, et al. **Schmidt CM** et al. Impact of Trainee Assistance on Outcomes Following Hepatectomy. DDW Proceedings 2018
251. Simpson RE, Yip-Schneider MT, Wu H, Fan H, Liu Z, Korc M, Zhang J, **Schmidt CM**. Circulating Thrombospondin-2 enhances prediction of malignant intraductal papillary mucinous neoplasm. MSA Proceedings 2018.
252. Flick K, et al **Schmidt CM**. Pancreatic fluid interleukin-1B compliments prostaglandin E2 and serum CA19-9 in production of IPMN dysplasia. WSA Proceedings 2018.

253. Simpson RE, Fennerty ML, Colgate CL, Kilbane EM, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**. Post-Pancreatoduodenectomy Outcomes and Epidural Analgesia: A 5-Year Single Institution Experience. SSA Proceedings 2018
254. Birdas TJ, Rozycki GF, Dunnington GL, Stevens L, Liali V, **Schmidt CM**. "Show Me the Data": A Recipe for Quality Improvement Success in an Academic Surgical Department. SSA Proceedings 2018
255. Maatman T, et al Schmidt CM et al Zyromski NJ. Disconnected Pancreatic Duct Syndrome: Spectrum of Operative Management. ASC Proceedings 2019.
256. Maatman T, et al Schmidt CM et al Zyromski NJ. Pancreatic Cancer Causing Necrotizing Pancreatitis: Not as Rare as you Think?. ASC Proceedings 2019.
257. Shahda S, et al. **Schmidt CM** et al. Neoadjuvant Therapy Duration and Outcome of Patients with Resectable PDAC. ASCO Proceedings 2019
258. Sims EK et al, **Schmidt CM** et al Pro-insulin Secretion is a Persistent Feature of Type I Diabetes (T1D). Servier-IGIS Symposium Proceedings 2019
259. Roch A, et al. **Schmidt CM** et al. Can Mortality of Operative Pancreatic Debridement be Predicted Accurately? ACOS, Indiana Chapter Proceedings 2019
260. Maatman, et al. **Schmidt CM** et al. Does the Microbiology of Bactibilia Drive Postoperative Complications after Pancreatoduodenectomy. AHPBA Proceedings 2019.
261. Maatman, et al. **Schmidt CM** et al. Natural History of Disconnected Pancreatic Duct Syndrome and Necrotizing Pancreatitis: Which Operation and When? AHPBA Proceedings 2019.
262. Roch, et al. **Schmidt CM** et al. Drug Resistance in Infected Pancreatic Necrosis: Cause for Alarm. AHPBA Proceedings 2019.
263. Flick et al. **Schmidt CM**. "I will take glue with my stitches" A Comparison of skin Closure Techniques in Pancreaticoduodenectomy. AHPBA Proceedings 2019.
264. A Prospective Randomized Controlled Trial of Pancreatoduodenectomy with and without Post-anastomotic Intraperitoneal Antibiotic Irrigation. Maatman et al **Schmidt CM** et al House M. Trial Saline vs Irrigation. CSA Proceedings 2019
265. Colon Involvement in Necrotizing Pancreatitis: Incidence, Risk Factors, and Outcomes. SSAT/DDW Proceedings 2019
266. Simpson R, et al **Schmidt CM**. Low risk, low reward: a critical look at secretin-induced duodenal aspirate of pancreatic juice (SIDA) SSAT/DDW Proceedings 2019
267. Simpson R, et al **Schmidt CM** et al DeWitt J. DNA profiling of main pancreatic duct fluid: a worthwhile endeavor. SSAT/DDW Proceedings 2019
268. House MG, et al **Schmidt CM**. Station 8 abstract. SSAT/DDW Proceedings 2019
269. Roch et al **Schmidt CM** et al Zyromski NJ. the role and dangers of TPN after pancreatoduodenectomy. Poster SSAT/DDW Proceedings 2019
270. Flick K, et al, **Schmidt CM** et al, House MG. Less is more when it comes to hepatobiliary scintigraphy for gall bladder dyskinesia: milkshakes save hundreds of dollars. SSAT/DDW Proceedings 2019
271. Vollmer C, Trudeau M, et al **Schmidt CM**, et al. Pancreatoduodenectomy following Roux-en-y gastric bypass: operative considerations and outcomes. SSAT/DDW Proceedings 2019
272. DePeralta D, Soufi M et al **Schmidt CM**. Novel preoperative patient-centered surgical wellness program impacts length of stay following pancreatectomy. SSAT/DDW Proceedings 2019
273. Rahal M, et al, **Schmidt CM** et al Al-Haddad M. Serial EUS-guided FNA in pancreatic cystic neoplasms: a natural history study of Kras analysis in cyst fluid ASGE/DDW Proceedings 2019
274. Rahal M, et al, **Schmidt CM** et al Al-Haddad M. Performance characteristics of DNA analysis in the evaluation of mucinous pancreatic cysts. ASGE/DDW Proceedings 2019
275. Flick K, et al **Schmidt CM**. Pancreatic fluid interleukin-1B compliments prostaglandin E2 and serum CA19-9 in production of IPMN dysplasia. Panc Club Proceedings 2019
276. Flick et al. **Schmidt CM**. "I will take glue with my stitches" A Comparison of skin Closure Techniques in Pancreaticoduodenectomy. Panc Club Proceedings 2019

277. Simpson RE, Fennerty ML, Flick KF, Colgate CL, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**. Two open Whipples a day: Excessive or efficient. MSA Proceedings 2019
278. Yip-Schneider MT, Soufi M, Carr RA, Flick KF, Wu H, Colgate CL, **Schmidt CM**. Performance of candidate urinary biomarkers for pancreatic cancer - Correlation with pancreatic cyst malignant progression? MSA Proceedings 2019
279. Maatman TK, Westfall-Snyder JA, Nicolas ME, Yee EJ, Ceppa EP, House MG, Nakeeb A, **Schmidt CM**, Zyromski NJ, The Morbidity of C. Difficile in Necrotizing Pancreatitis. MSA Proceedings 2019
280. Flick KF, Yip-Schneider MT, Sublette CM, Simpson RE, Colgate CL, Wu H, Soufi M, Dewitt JM, Mosley AL, Ceppa EP, Zhang J, **Schmidt CM**. A Quantitative Global Proteomics Approach Identifies Candidate Urinary Biomarkers That Correlate with Intraductal Papillary Mucinous Neoplasm Dysplasia. WSA Proceedings 2019
281. Dirks RC, Burney HN, Anjanappa M, Sandusky GE, Hao Y, Liu Y, **Schmidt MC**, Nakshatri H. Breast Heterogeneity: Obstacles to Developing Universal Biomarkers of Breast Cancer Initiation and Progression. WSA Proceedings 2019
282. Flick K, Sublette CM, Colgate CL, Yip-Schneider MT, Soufi M, Ceppa EP, Zyromski NJ, Nakeeb A, House MG, **Schmidt CM**: Impact of Social Determinants on Length of Stay Following Pancreaticoduodenectomy. Academic Surgical Congress Proceedings, February 2020
283. Flick KF, **Schmidt CM**, Colgate CL, Yip-Schneider MT, Sublette CM, Maatman TK, Soufi M, Ceppa EP, House MG, Zyromski NJ, Nakeeb A. Preoperative Nomogram Predicts Non-home Discharge in Patients Undergoing Pancreatoduodenectomy. AHPBA Proceedings 2020.
257. Roch, A; Ceppa EP; **Schmidt CM** et al. Patients with deleterious germline mutations: a heterogeneous population for pancreatic cancer screening? AHPBA Proceedings 2020-Steve Sotsky Award Recipient
258. Maatman TK, Westfall-Snyder JA, Ceppa EP, House MG, Nakeeb A, Nguyen TK, **Schmidt CM**, Zyromski NJ. Necrotizing Pancreatitis from Hypertriglyceridemia: More Severe Disease? AHPBA Proceedings 2020
284. Maatman TK, Ceppa EP, Fogel EL, Easler JJ, Gromski MA, House MG, Nakeeb A, **Schmidt CM**, Sherman S, Zyromski NJ. Biliary Stricture after Necrotizing Pancreatitis: An Underappreciated Challenge. SSAT Proceedings 2020.
285. Maatman TK, Loncharich AJ, Flick KF, Simpson RE, Ceppa EP, Nakeeb A, Nguyen TK, **Schmidt CM**, Zyromski NJ, House MG. Transient Biliary Fistula After Pancreatoduodenectomy Increases Risk of Biliary Anastomotic Stricture. SSAT Proceedings 2020.
286. Yee EJ, Al-Temimi MH, Flick KF, Kilbane EM, Nguyen TK, Zyromski NJ, **Schmidt CM**, Nakeeb A, House MG, Ceppa EP. Use of primary surgical drains in synchronous resection for colorectal liver metastases: a NSQIP analysis of current practice paradigm. SSAT Proceedings 2020.
287. Soufi M, Al-Temimi M, Nguyen TK, House MG, Zyromski NJ, **Schmidt CM**, Nakeeb A, Ceppa EP. Friend or foe? Feeding tube placement at the time of pancreatoduodenectomy: propensity score case-matched analysis. SSAT Proceedings 2020
288. Maatman TK, McGuire SP, Lewellen KA, McGreevy KA, Ceppa EP, House MG, Nakeeb A, Nguyen TK, **Schmidt CM**, Zyromski NJ. Prospective Analysis of the Mechanisms Underlying Ineffective Deep Vein Thrombosis Prophylaxis in Necrotizing Pancreatitis. Pancreas Club Proceedings 2020
289. Flick KF, Al-Temimi MH, Maatman TK, Sublette CM, Swensson JK, Nakeeb A, Ceppa EP, Nguyen TK, **Schmidt CM**, Zyromski NJ, Tann MA, House MG. Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After Pancreatoduodenectomy. Pancreas Club Proceedings 2020.
290. Maatman TK, Loncharich AJ, Flick KF, Simpson RE, Ceppa EP, Nakeeb A, Nguyen TK, **Schmidt CM**, Zyromski NJ, House MG. Transient Biliary Fistula After Pancreatoduodenectomy Increases Risk of Biliary Anastomotic Stricture. Panc Club Proceedings 2020.
291. Maatman TK, Westfall-Snyder JA, Ceppa EP, House MG, Nakeeb A, Nguyen TK, **Schmidt CM**, Zyromski NJ. Necrotizing Pancreatitis from Hypertriglyceridemia: More Severe Disease? Pancreas Club Proceedings 2020

292. Maatman TK, Westfall-Snyder JA, Nicolas ME, Yee EJ, Ceppa EP, House MG, Nakeeb A, **Schmidt CM**, Zyromski NJ, The Morbidity of C. Difficile in Necrotizing Pancreatitis. Pancreas Club Proceedings 2019
293. Maatman TK, McGreevy KA, Sood AJ, Ceppa EP, House MG, Nakeeb A, **Schmidt CM**, Nguyen TK, Zyromski NJ. Improved Outpatient Communication Decreases Unplanned Readmission in Necrotizing Pancreatitis. Pancreas Club Proceedings 2020
294. Flick K, Sublette CM, Colgate CL, Yip-Schneider MT, Soufi M, Ceppa EP, Zyromski NJ, Nakeeb A, House MG, Schmidt CM: Impact of Social Determinants on Length of Stay Following Pancreaticoduodenectomy. Pancreas Club Proceedings 2020
295. Maatman TK, McGuire SP, Lewellen KA, McGreevy KA, Ceppa EP, House MG, Nakeeb A, Nguyen TK, **Schmidt CM**, Zyromski NJ. Prospective Analysis of the Mechanisms Underlying Ineffective Deep Vein Thrombosis Prophylaxis in Necrotizing Pancreatitis. ACoS Proceedings 2020
296. Flick K, **Schmidt CM** et al. Impact of mental health on surgical outcomes in pancreatectomy: an unrecognized social determinant of health. ACoS Proceedings 2020
297. Flick KF, Soufi M, Yip-Schneider MT, Simpson RE, Colgate CL, Nguyen TK, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**. Routine Gastric Decompression after Pancreatoduodenectomy: Treating the Surgeon? ACOS Proceedings 2020
298. Birdas T, Kelley K, **Schmidt CM** et al. Using a modified Delphi method to engage providers in ERAS deployment. ACoS Proceedings 2020
299. McGuire SP, Maatman TK, Keller SL, Ceppa EP, House MG, Nakeeb A, Nguyen TK, **Schmidt CM**, Zyromski NJ. Early postoperative serum hyperamylasemia: Harbinger of morbidity hiding in plain sight? ASC Proceedings 2021
300. Maatman TK, McGuire SP, Flick KF, Madison MK, Al-Haddad MA, Bick BL, Ceppa EP, DeWitt JM, Easler JJ, Fogel EL, Gromski MA, House MG, Lehman GA, Nakeeb A, **Schmidt CM**, Sherman S, Watkins JL, Zyromski NJ. Outcomes in Endoscopic and Operative Transgastric Pancreatic Debridement. ASA Proceedings 2021
301. Nguyen T, Kledzik M, Helft P, Ceppa E, Nakeeb A, Schmidt CM, Zyromski NJ, House M. Genetic Profiling of Goblet Cell Carcinoid of the Appendix Compared to Appendiceal Adenocarcinoma. CSA Proceedings 2021.
302. Soufi M, Ceppa DP, Flick KF, Blackwell MM, Muraruc R, Nguyen T, Schmidt CM, Nakeeb A, House MG, Ceppa EP. Investigating the Incidence, Impact and Severity of Pulmonary Complications After Hepatectomy: A Single Institutional Experience. CSA Proceedings 2021
303. McGuire S, Zyromski N et al **Schmidt CM**. Obesity Worsens Local and Systemic Complications of Necrotizing Pancreatitis and Prolongs Disease Course. SSAT Proceedings 2021.
304. Allen S, Zyromski N et al **Schmidt CM**. Pancreatic Tail Volumetrics: A Novel Approach for Surgical Decision-Making in Disconnected Pancreatic Duct Syndrome. SSAT Proceedings 2021.
305. Kone L, Pollini T, Brugge W, Fernandez-del Castillo C, Winter J, Yeo CJ, Hackert T, Buchler MW, Roggin K, Schmidt CM, Yip- Schneider MT, Salvia R, Bassi C, Chlipala G, and Maker AV: A novel microfluidic-based assay to determine high-risk pancreatic cysts for surgery utilizing pancreatic cyst fluid: An international multicenter study. AHPBA (August) Proceedings 2021
306. Allen S, Soufi M, Allison H, Nguyen T, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, **Schmidt CM**. Proximal versus distal resection in adenocarcinoma of the pancreatic neck: does it matter. AHPBA (August) Proceedings 2021
307. Bajpai S, Zyromski NJ, McGuire S, et al **Schmidt CM**. Renal Failure in Necrotizing Pancreatitis: incidence, risk, and increased mortality. AHPBA (August) Proceedings 2021
308. Zyromski NJ, McGuire S, et al **Schmidt CM**. Splanchnic Venous Thrombosis in Necrotizing Pancreatitis: Common, Heterogenous, and Deadly. AHPBA (August) Proceedings 2021
309. Sans M, Stephens B, Rajapakshe K, Yip-Schneider MT, Schmidt CM, Hurd M, Fahrman J, Hanash S, Guerrero P, Maitra A: Investigating Molecular Underpinnings of Neoplastic Progression in Pancreatic Cysts using Spatial Transcriptomics. APA Proceedings 2021

310. Soufi M, Ceppa EP et al **Schmidt CM**. Diuresis does make a difference in Major Hepatectomy. WSA Proceedings 2021.
311. Kim RC, Roch AM, Ceppa EP, Nakeeb A, **Schmidt CM**, Zyromski NJ, House MG, Nguyen TK. Effect of the SARS-CoV-2 pandemic on the experience and outcomes of patients who underwent resection for pancreatic cancer at a high-volume tertiary care center. ACoS Proceedings 2021
312. Sean P. McGuire, Thomas K. Maatman, Eugene P. Ceppa, Michael G. House, Attila Nakeeb, Trang K. Nguyen, **Schmidt CM**, Nicholas J. Zyromski. Contemporary Intervention in Necrotizing Pancreatitis: Improved Understanding Changing Practice. ACoS Proceedings 2021
313. Sean P. McGuire, Thomas K. Maatman, et al. Eugene P. Ceppa, Michael G. House, Attila Nakeeb, Trang K. Nguyen, **Schmidt CM**, Nicholas J. Zyromski. Primary vs. Salvage Operative Pancreatic Debridement: Discrete Interventions for Unique Populations. ACoS Proceedings 2021
314. Roch AM, Allen S, Kim R, et al Ceppa EP, Nakeeb A, Schmidt CM, Zyromski NJ, Nguyen TK, House MG. Updated TNM Classification for Pancreatic Cancer: More Practical, But Room For Improvement. IHPBA Proceedings 2022
315. McGuire S, Zyromski NJ. Operative Pancreas Debridement in 2021: Who and When. IHPBA Proceedings 2022
316. Rachel C. Kim, MD, Alexandra M. Roch, MD, Sean McGuire, MD, Eugene P. Ceppa, MD, Trang K. Nguyen, MD, Nicholas J. Zyromski, MD, Attila Nakeeb, MD, Michael G. House, MD, C. Max Schmidt, MD, PhD, MBA. Pancreatic fistula after pancreatectomy – what else can we consider other than drain amylase in the early postoperative period? IHPBA Proceedings 2022